fluorodeoxyglucose f18 profile

Fluorodeoxyglucose F18 (FDG) is a radioactive glucose analog used in Positron Emission Tomography (PET) scans to visualize glucose metabolism in living tissues. It is synthesized by reacting a fluorine-18 atom with a precursor molecule via nucleophilic substitution. FDG is taken up by cells via the glucose transporter and is then phosphorylated by hexokinase, trapping it within the cell. FDG is not metabolized further, allowing its accumulation in tissues with high glucose uptake. FDG PET imaging is commonly used to diagnose and monitor cancer, heart disease, and neurological disorders. It is an important research tool for studying glucose metabolism and for understanding disease processes at the cellular level.'

Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

magnesium tanshinoate B: an acitve compound purified from Danshen [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	68614
CHEMBL ID	1808698
CHEBI ID	49136
CHEBI ID	49134
MeSH ID	M0029360
PubMed CID	6918234
CHEMBL ID	39993
MeSH ID	M0029360

Synonym
2-deoxy-2-((18)f)fluoro-aldehydo-d-glucose
CHEBI:49136 ,
fluorodeoxyglucose f18
18f fluorodeoxyglucose
63503-12-8
2-deoxy-2-(18f)fluoro-d-glucose
fdg f-18
fludeoxyglucose, f-18
fdg-pet
18-fdg
18f-fluorodeoxyglucose
(18f)-fluorodeoxyglucose
fluorine (18f) fludeoxyglucose
18-f fdg
s8fdg
fluglucoscan
(18f)fluoro-2-deoxyglucose
(18f)-fdg
2-deoxy-2-fluoro-d-glucose, f-18
CHEMBL1808698
d-glucose, 2-deoxy-2-(fluoro-18f)-
2-deoxy-2(f-18)fluoro-2-d-glucose
unii-0z5b2cjx4d
2-deoxy-2-fluoro-18f-d-glucose
2-(18f)fluoro-2-deoxy-d-glucose
(18f)-2-fluoro-2-deoxy-d-glucose
18f-flurodeoxyglucose
2-deoxy-2-(fluoro-18f)-d-glucose
fluorine-18 fluorodeoxyglucose
fludeoxyglucose f 18 [usan]
2-deoxy-2-(18f)fluoroglucose
0z5b2cjx4d ,
fludeoxyglucose (18f) [who-dd]
fludeoxyglucose f 18 [mi]
fludeoxyglucose f 18 [vandf]
fludeoxyglucose (18f) [jan]
fludeoxyglucose f 18 [usp impurity]
fludeoxyglucose ((1)f) [inn]
fludeoxyglucose f-18 [orange book]
fludeoxyglucose f(sup 18) [mi]
DTXSID40212908
DB09502
(2r,3s,4r,5r)-2-(18f)fluoranyl-3,4,5,6-tetrahydroxyhexanal
fluorine-18 2-fluoro-2-deoxy-d-glucose
chebi:49134
2-f18-fluoro-2-deoxy-d-glucose
dtxcid801324219
fludeoxyglucosef 18
fludeoxyglucose f 18 injection
2-f18-fluoro-2-deoxyglucose
fludeoxyglucose f 18 (usp impurity)
fludeoxyglucosef18
fludeoxyglucose f-18 injection
magnesium tanshinoate b
magnesium salvianolate b
lithospermic acid b magnesium salt
CHEMBL39993
8v4r1e4c5y ,
154334-65-3
magnesium lithospermate b [inci]
magnesium tanshinoate b [who-dd]
magnesium, ((1r)-1-(carboxy-.kappa.o)-2-(3,4-dihydroxyphenyl)ethyl (2s,3s)-4-((1e)-3-((1r)-1-(carboxy-.kappa.o)-2-(3,4-dihydroxyphenyl)ethoxy)-3-(oxo-.kappa.o)-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylato(2-)-.kappa.o3
magnesium;(2r)-2-[(e)-3-[(2s,3s)-3-[(1r)-1-carboxylato-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoate
Q27271065

Excerpt	Reference	Relevance
" Similarly synthesized nonradioactive FDG and Na 18F were not toxic under comparable experimental conditions."	( Transient toxicity of 2-deoxy-2-[18F]fluoro-D-glucose in mammalian cells: concise communication. Adelstein, SJ; Fowler, JG; Kassis, AI; Shiue, CY; Wolf, AP, 1983)	0.27
" We did a phase I study to identify the dose-limiting toxic effects of imatinib in patients with advanced soft tissue sarcomas including GISTs."	( Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Dimitrijevic, S; Donato di Paola, E; Judson, I; Martens, M; Nielsen, OS; Sciot, R; Silberman, S; Stroobants, S; Van Glabbeke, M; van Oosterom, AT; Verweij, J; Webb, A, 2001)	0.31
" Toxic effects and haematological, biochemical, and radiological measurements were assessed during 8 weeks of follow-up."	( Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Dimitrijevic, S; Donato di Paola, E; Judson, I; Martens, M; Nielsen, OS; Sciot, R; Silberman, S; Stroobants, S; Van Glabbeke, M; van Oosterom, AT; Verweij, J; Webb, A, 2001)	0.31
"Five patients on 500 mg imatinib twice daily had dose-limiting toxic effects (severe nausea, vomiting, oedema, or rash)."	( Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Dimitrijevic, S; Donato di Paola, E; Judson, I; Martens, M; Nielsen, OS; Sciot, R; Silberman, S; Stroobants, S; Van Glabbeke, M; van Oosterom, AT; Verweij, J; Webb, A, 2001)	0.31
" It is concluded that cardiac FDG imaging during clamping is safe and provides excellent image quality, including in patients with diabetes mellitus."	( Feasibility, safety and image quality of cardiac FDG studies during hyperinsulinaemic-euglycaemic clamping. Bax, JJ; Boersma, E; Elhendy, A; Poldermans, D; van Lingen, A; Visser, CA; Visser, FC, 2002)	0.31
"Cardiac FDG single photon emission computed tomography after Acipimox is a simple and safe approach that renders comparable image quality to that obtained during hyperinsulinemic euglycemic clamping."	( Safety and feasibility of cardiac FDG SPECT following oral administration of Acipimox, a nicotinic acid derivative: Comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients. Bax, JJ; Boersma, E; Elhendy, A; Poldermans, D; Sloof, GW; Van Lingen, A; Visser, CA; Visser, FC, )	0.13
" Maximum toxicities were monitored and classified according to the Common Terminology Criteria for Adverse Events (ver."	( Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Avril, N; Jacobs, SA; Joyce, J; McCook, B; Torok, F; Vidnovic, N, 2005)	0.33
"Our experience suggests that 90Y ibritumomab tiuxetan treatment is safe for use in patients with prior myeloablative therapy when the general inclusion criteria are fulfilled."	( Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Avril, N; Jacobs, SA; Joyce, J; McCook, B; Torok, F; Vidnovic, N, 2005)	0.33
" Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible."	( PET scintigraphy of etoposide-induced pulmonary toxicity. Biesma, DH; Grutters, JC; Post, MC; Verzijlbergen, JF, 2007)	0.34
"3%) experienced a grade 3/grade 4 adverse event judged related to pertuzumab; none exhibited grade 3/grade 4 cardiac toxicity."	( Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Dang, TP; Davies, AM; de Vries, DJ; Eberhard, DA; Garland, LL; Herbst, RS; Johnson, BE; Lutzker, SG; Lyons, B; Melenevsky, Y; Mendelson, D; Miller, VA; Natale, RB; Schiller, JH; Van den Abbeele, AD, 2007)	0.34
" Therefore, at the current rate of 50-100 simulations annually, the addition of PET studies to SBRT simulations is safe for our staff."	( Radiation safety issues with positron-emission/computed tomography simulation for stereotactic body radiation therapy. Blackstock, AW; Hampton, CJ; Hinson, WH; Kearns, WT; McMullen, KP; Stieber, VW; Urbanic, JJ, 2008)	0.35
" Many adverse reactions and false positive reactions related to radiopharmaceuticals take place every day in hospitals, but most of them are not reported."	( Undesirable events with radiopharmaceuticals. Santos-Oliveira, R, 2009)	0.35
" Most adverse effects are due to infusion-related reactions, and severe respiratory complications are rare."	( [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Escalon, MP; Kalkanis, D; Lossos, IS; Paes, F; Serafini, A; Stefanovic, A, 2009)	0.35
" The aim of this study was to analyze the acute single toxic effects dose of two nonradiochemical labeled compounds in rats."	( Acute toxicity of two Alzheimer's disease radiopharmaceuticals: FDDNP and IMPY. Chang, KW; Chen, CC; Lee, SY; Wang, HE, 2009)	0.35
" Grade 3-4 toxic effects included neutropenia (n=7), raised alanine aminotransferase concentrations (n=5), peripheral neuropathy (n=5), and hypertension (n=5)."	( Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Abrams, TA; Allen, JN; Bhargava, P; Blaszkowsky, LS; Chan, JA; Clark, JW; Enzinger, PC; Fuchs, CS; Horgan, K; Jain, SR; Kambadakone, AR; Kwak, EL; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Sahani, DV; Sheehan, S; Stuart, K; Zheng, H; Zhu, AX, 2010)	0.36
" Our results suggest that auto-cell transplantation therapy using MSC-derived Schwann cells is safe and effective for accelerating the regeneration of transected axons and for functional recovery of injured nerves."	( Long-term observation of auto-cell transplantation in non-human primate reveals safety and efficiency of bone marrow stromal cell-derived Schwann cells in peripheral nerve regeneration. Dezawa, M; Hayashi, T; Iida, H; Itokazu, Y; Kitada, M; Kohama, M; Koshino, K; Matsue, D; Ose, T; Tabata, Y; Takamoto, T; Teramoto, N; Wakao, S; Watabe, H, 2010)	0.36
"To determine safe surgical margins for soft tissue sarcoma, it is essential to perform a general evaluation of the extent of tumor, responses to auxiliary therapy, and other factors preoperatively using multiple types of diagnostic imaging."	( Clinical implications of determination of safe surgical margins by using a combination of CT and 18FDG-positron emission tomography in soft tissue sarcoma. Arishima, Y; Komiya, S; Nagano, S; Tanimoto, A; Terahara, M; Yokouchi, M; Yoshioka, T; Zemmyo, M, 2011)	0.37
"Three patients (125 mg cohort) had dose-limiting toxic effects (grade 3 nausea/vomiting, diarrhea)."	( Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Anak, Ö; Baselga, J; Birle, D; Chen, LC; Hackl, W; Krop, I; Markman, B; Melendez Cuero, M; Mita, M; Shapiro, GI; Siu, L; Stutvoet, S; Tabernero, J, 2012)	0.38
" Hence, the current challenge is to develop a new therapeutic strategy maintaining excellent patient outcome while reducing potentially life-threatening late adverse effects."	( Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Gallamini, A; Kostakoglu, L, 2012)	0.38
" It has a favorable toxicity profile but may induce unexpected adverse effects, such as an infiammatory reaction in the bladder."	( Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease. Brangi, M; Cartenì, G; Chiurazzi, B; Laterza, MM; Riccardi, F, )	0.13
"3-40 mg/kg) resulted in no dose-limiting toxicities (DLTs); adverse events (AEs) included fatigue, hypotension, abdominal pain, dyspnea, and nausea."	( Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Bilic, S; Burris, HA; de Vries, EG; Gietema, JA; Goldbrunner, M; Infante, JR; Oldenhuis, CN; Parker, K; Scott, JW; Sharma, S; Yang, L, 2014)	0.4
"Short-course pre-operative administration of cetuximab is safe and shows a high rate of (18)FDG-PET response."	( Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Cappoen, N; Duprez, T; Gillain, A; Hamoir, M; Hanin, FX; Lhommel, R; Lonneux, M; Machiels, JP; Magremanne, M; Michoux, N; Reychler, H; Rommel, D; Schmitz, S; Weynand, B, 2013)	0.39
"In 37 patients receiving dalantercept, the most common treatment-related adverse events were peripheral edema, fatigue, and anemia."	( Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Agarwal, N; Attie, KM; Bendell, JC; Blobe, GC; Condon, CH; Gordon, MS; Hurwitz, HI; Jones, SF; McClure, T; Mendelson, DS; Pearsall, AE; Sharma, S; Sherman, ML; Wilson, D; Yang, Y, 2014)	0.4
" Most of the patients on erlotinib show cutaneous adverse effects."	( Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging. Bal, C; Gupta, RK; Kumar, K; Kumar, R; Singh, H, 2015)	0.42
" There were no incidences of anaphylaxis or Grade 4/5 adverse events."	( Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety. Hasebe, T; Hirokawa, E; Kuji, I; Matsuura, K; Osaki, A; Saeki, T; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S; Yamane, T, 2015)	0.42
"Ipilimumab is a promising novel immunotherapy agent and is associated with a variety of immune-related adverse events (irAE)."	( Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Bailey, ND; Hodi, FS; Keraliya, A; Nishino, M; Ott, PA; Ramaiya, NH; Tirumani, SH, 2015)	0.42
" Sequential lobar treatment and absence of prior angiosuppressive therapy were both associated with a lower rate of serious adverse events."	( Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients. Bartenstein, P; Fendler, WP; Haug, AR; Jakobs, TF; Lechner, H; Lehner, S; Michl, M; Paprottka, KJ; Paprottka, PM; Todica, A, 2016)	0.43
"Radioembolization for breast cancer liver metastases shows encouraging local response rates with low incidence of serious adverse events, especially in those patients with sequential lobar treatment or without prior angiosuppressive therapy."	( Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients. Bartenstein, P; Fendler, WP; Haug, AR; Jakobs, TF; Lechner, H; Lehner, S; Michl, M; Paprottka, KJ; Paprottka, PM; Todica, A, 2016)	0.43
"Cumulative cardiotoxicity is a well-established adverse effect of Adriamycin therapy."	( Substantial Increase in Myocardial FDG Uptake on Interim PET/CT May Be an Early Sign of Adriamycin-Induced Cardiotoxicity. Gorla, AK; Mittal, BR; Parmar, M; Prakash, G; Sood, A, 2016)	0.43
" There is an ongoing debate as to whether progressive ataxia reflects a delayed therapeutic failure due to disease progression or an adverse effect related to repeated increases of stimulation intensity."	( Progressive gait ataxia following deep brain stimulation for essential tremor: adverse effect or lack of efficacy? Åström, M; Brumberg, J; Buck, AK; Isaias, IU; Lanotte, M; Lehrke, R; Lopiano, L; Marotta, G; Musacchio, T; Pozzi, NG; Reich, MM; Roothans, J; Volkmann, J, 2016)	0.43
" Adverse events within 30 days of MWA were considered procedure-related complications."	( Safety and efficacy of microwave ablation for medically inoperable colorectal pulmonary metastases: Single-centre experience. Ferguson, CD; Luis, CR; Steinke, K, 2017)	0.46
"Microwave ablation is safe and efficacious in the local control of colorectal pulmonary metastases."	( Safety and efficacy of microwave ablation for medically inoperable colorectal pulmonary metastases: Single-centre experience. Ferguson, CD; Luis, CR; Steinke, K, 2017)	0.46
" We analyzed the adverse events related to NACRT and surgical complications following surgery."	( Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer. Imai, K; Kawakita, Y; Konno, H; Liu, J; Minamiya, Y; Mizusawa, KT; Motoyama, S; Nagaki, Y; Saito, H; Sasaki, T; Sato, Y; Wakita, A, 2017)	0.46
"Transthoracic esophagectomy with Japanese-style extended 3-field lymph node dissection after NACRT is a safe and powerful treatment."	( Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer. Imai, K; Kawakita, Y; Konno, H; Liu, J; Minamiya, Y; Mizusawa, KT; Motoyama, S; Nagaki, Y; Saito, H; Sasaki, T; Sato, Y; Wakita, A, 2017)	0.46
" These study findings confirm that the novel radiotracer would be safe for use in human PET imaging."	( Dosimetry and Toxicity Studies of the Novel Sulfonamide Derivative of Sulforhodamine 101([18F]SRF101) at a Preclinical Level. Bardiès, M; Engler, H; Kreimerman, I; Mora-Ramirez, E; Reyes, L; Savio, E, 2019)	0.51
" Further studies are necessary to determine if the F-FDG PET/CT could early predict adverse effects of mTOR inhibitors."	( Everolimus-induced pulmonary toxicity: Findings on 18F-FDG PET/CT imaging. Bruna-Muraille, C; Dejust, S; Eymard, JC; Morland, D; Papathanassiou, D; Savoye, AM; Yazbek, G, 2018)	0.48
"To investigate whether the evaluation of tumors, lymphoid cell-rich organs, and immune-related adverse events (IRAE) with F-FDG PET/CT can predict the efficacy and outcome of immunotherapy."	( Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. Baratto, L; Hatami, N; Mittra, E; Nobashi, T; Reddy, SA; Srinivas, S; Toriihara, A; Yohannan, TK, 2019)	0.51
"CD19-targeting chimeric antigen receptor (CAR)-T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) but has been associated with serious adverse effects, such as cytokine release syndrome (CRS)."	( Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma. Chang, AH; Chen, D; Hu, Y; Huang, H; Wang, J; Wei, G; Wu, W; Wu, Z; Xiao, L; Yang, S; Zhang, Y; Zhao, K; Zhao, X, 2019)	0.51
"To investigate the frequency and imaging features of radiographically evident abdominal immune-related adverse events (irAEs) in patients with metastatic non-small-cell lung cancer (NSCLC) treated with PD-1 inhibitors."	( Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Adeni, AE; Alessandrino, F; Awad, MM; Nishino, M; Sahu, S; Shinagare, AB; Tirumani, SH, 2019)	0.51
"Blocking the PD-1 pathway induces immune-related adverse events (irAEs) which often involve the thyroid gland (thyroid irAEs)."	( Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. Fujii, T; Hishizawa, M; Inagaki, N; Kawaguchi-Sakita, N; Kim, YH; Kitamura, M; Kitawaki, T; Matsumoto, S; Nomura, M; Otsuka, A; Saito, R; Sakamori, Y; Sone, M; Taura, D; Yamasaki, T; Yamauchi, I; Yasoda, A, 2019)	0.51
" Fat necrosis, an immune-related adverse event, can be FDG-avid and mimic malignancy on PET/CT scan."	( Nivolumab-Induced Subcutaneous Fat Necrosis: Another FDG-Avid Immune-Related Adverse Event. Bhargava, P; Flynt, L; Marcal, L, 2020)	0.56
"Both doses were safe and tolerated."	( Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients. Anderson, H; Becker, A; Bothwell, R; Brooks, W; Burns, JM; Choi, IY; Clutton, J; Harris, RA; Lee, P; Mahnken, JD; Mosconi, L; Pleen, J; Reed, G; Sherry, E; Swerdlow, RH; Vidoni, ED; Wilkins, HM; Zhang, N, 2021)	0.62
"1000 mg OAA, taken twice daily for 1 month, is safe in AD patients and engages brain energy metabolism."	( Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients. Anderson, H; Becker, A; Bothwell, R; Brooks, W; Burns, JM; Choi, IY; Clutton, J; Harris, RA; Lee, P; Mahnken, JD; Mosconi, L; Pleen, J; Reed, G; Sherry, E; Swerdlow, RH; Vidoni, ED; Wilkins, HM; Zhang, N, 2021)	0.62
"BIMRT may be a safe and effective treatment for patients with peritoneal metastases, especially for patients who cannot undergo surgery."	( Safety and Efficacy of the Metabolic Profiling of the BIMRT Utilizing 18F FDG PET-CT. Dang, YZ; Huang, SG; Li, J; Wang, GD; Zhang, DX; Zhao, HL, )	0.13
"Immune checkpoint inhibitor and chimeric antigen receptor T-cell therapies are associated with a unique spectrum of complications termed immune-related adverse events (irAEs)."	( Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. Anderson, MA; Bradley, W; Kilcoyne, A; Kurra, V; Lee, SI; Mojtahed, A, 2021)	0.62
"Lung toxicity is a rare but serious side effect of sirolimus, a mammalian target of rapamycin inhibitor used as an immunosuppressive agent in solid-organ transplant recipients."	( Role of Fluorodeoxyglucose Positron Emission Tomogram Scan in Sirolimus-Induced Lung Toxicity: A Rare Case Report. Albaiz, F; Alothman, B; Alrasheedi, S; Saleemi, A; Saleemi, S; Shah, YZ, 2020)	0.56
"In this pilot study, patients with refractory CS treated with infliximab, on top of standard of care, had a reduction in inflammation on FDG-PET/CT and an improvement in LV function, without serious adverse events."	( Effectiveness and safety of infliximab in cardiac Sarcoidosis. Akdim, F; Azzahhafi, J; Bakker, ALM; Grutters, JC; Keijsers, RGM; Mathijssen, H; Post, MC; Swaans, MJ; Veltkamp, M, 2021)	0.62
" A variety of adverse effects from chemotherapy, targeted therapy, immunotherapy, and radiation therapy are commonly encountered in oncologic patients."	( Side Effects of Oncologic Treatment in the Chest: Manifestations at FDG PET/CT. Bhalla, S; Felder, GJ; Ganeshan, D; Itani, M; Lang, JA, )	0.13

Excerpt	Reference	Relevance
" The MRI data were acquired with a turbo fast low-angle shot sequence and analyzed using a pharmacokinetic model."	( Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Brix, G; Doll, J; Haberkorn, U; Hawighorst, H; Henze, M; Junkermann, H; Knopp, MV; Lucht, R, 2001)	0.31
" The development of a PET proliferation probe would be a useful pharmacodynamic tool."	( Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. Harris, A; Jones, T; Price, P; Wells, P; West, C, 2004)	0.32
"The microBC is a compact automated counter allowing real-time measurement of blood radioactivity for pharmacokinetic studies in animals as small as mice."	( A new tool for molecular imaging: the microvolumetric beta blood counter. Archambault, M; Bentourkia, M; Cadorette, J; Convert, L; Lecomte, R; Morin-Brassard, G, 2007)	0.34
" Inhibition of glucose metabolism measured by (18)F-FDG PET was postulated to serve as a pharmacodynamic marker in everolimus-treated non-small cell lung cancer (NSCLC) patients."	( Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. Bangard, C; Boellaard, R; Dietlein, M; Dimitrijevic, S; Eschner, W; Giaccone, G; Gross, SH; Hayes, W; Hoekstra, OS; Hoetjes, N; Kobe, C; Lammertsma, AA; Nogová, L; Pellas, T; Schmidt, K; Thomas, RK; Wolf, J; Zander, T, 2009)	0.35
"To evaluate 2-deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography imaging ((18)FDG-PET) as a predictive, noninvasive, pharmacodynamic (PD) biomarker of response following administration of a small-molecule insulin-like growth factor-1 receptor and insulin receptor (IGF-1R/IR) inhibitor, OSI-906."	( 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Bugaj, JE; Gokhale, PC; Guleryuz, S; Manning, HC; Mantis, C; McKinley, ET; Wild, R; Zhao, P, 2011)	0.37
" PF-03814735 was rapidly absorbed and demonstrated linear pharmacokinetics up to 100mg QD; mean terminal half-life ranged from 14."	( Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Burris, HA; Dumez, H; English, PA; Fowst, C; Gerletti, P; Infante, JR; Jakubczak, JL; Jones, SF; Pierce, KJ; Schöffski, P; Van Mieghem, E; Xu, H, 2011)	0.37
" This work aims to evaluate F-fluorodeoxyglucose-positron emission tomography (FDG-PET) as a pharmacodynamic (PD) biomarker for linifanib treatment utilizing the Calu-6 model of human non-small cell lung (NSCLC) cancer in SCID-beige mice."	( FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model. Albert, DH; Day, M; Fox, GB; Hickson, JA; Luo, Y; Mudd, SR; Refici-Buhr, M; Reuter, DR; Tapang, P; Voorbach, MJ, 2012)	0.38
" We describe a chemotherapy-refractory patient whose clinical condition necessitated rapid identification of an effective agent in whom we used (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomographic scanning 48 hours after an initial dose of panitumumab to document a pharmacodynamic response to the antibody."	( Early FDG/PET scanning as a pharmacodynamic marker of anti-EGFR antibody activity in colorectal cancer. Alesi, E; Krystal, GW; Tatum, JL, 2012)	0.38
" Pharmacokinetic MRI parameters such as the volume transfer constant (K(trans)), the extravascular-extracellular volume fraction (ν(e)), and the blood volume fraction (ν(p)) calculated with the Gd-DTPA AIF and the Gd-DTPA AIF converted from (18)F-FDG AIF normalized with or without blood sample were not statistically different."	( Conversion of arterial input functions for dual pharmacokinetic modeling using Gd-DTPA/MRI and 18F-FDG/PET. Bentourkia, M; Blanchette, M; Croteau, E; Lebel, R; Lecomte, R; Lepage, M; Poulin, E; Tremblay, L, 2013)	0.39
" In addition to determining the MTD, we evaluated pharmacokinetics of BIIB021 and pharmacodynamic effects of BIIB021 [Hsp70, HER2 extracellular domain (HER2-ECD)]."	( A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Banerji, U; Castro, J; Lamanna, N; Mita, M; O'Brien, S; Saif, MW; Stogard, C; Takimoto, C; Von Hoff, D, 2014)	0.4
" Cmax occurred at approximately 90 minutes and t1/2 was approximately 1 hour across dosing cohorts of 25 to 800 mg BIIB021 twice weekly."	( A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Banerji, U; Castro, J; Lamanna, N; Mita, M; O'Brien, S; Saif, MW; Stogard, C; Takimoto, C; Von Hoff, D, 2014)	0.4
" [(18)F]Fluorodeoxyglucose positron emission tomography (FDG-PET) was performed as a pharmacodynamic marker of mTOR inhibition, and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was performed as an indicator of tumor perfusion changes, at 3 time points."	( Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Avadhani, AN; Ciunci, CA; Divgi, CR; Englander, S; Flaherty, KT; Giantonio, BJ; Harlacker, K; Kang, HC; O'Dwyer, PJ; Perini, RF; Redlinger, M; Rosen, MA; Schnall, M; Song, HK; Sun, W; Troxel, A, 2014)	0.4
" Correlative pharmacodynamic markers included tumor metabolic activity and tumor blood flow, which decreased from baseline in 63% and 82% of evaluable patients, respectively, and telangiectasia in eight patients."	( Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Agarwal, N; Attie, KM; Bendell, JC; Blobe, GC; Condon, CH; Gordon, MS; Hurwitz, HI; Jones, SF; McClure, T; Mendelson, DS; Pearsall, AE; Sharma, S; Sherman, ML; Wilson, D; Yang, Y, 2014)	0.4
" This Perspective discusses the use of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) for pharmacodynamic evaluation in a very early phase of treatment to predict clinical outcomes in patients with advanced non-small-cell lung cancer."	( Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction. Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K, 2014)	0.4
" In pharmacokinetic image analysis, the blood concentration of the imaging compound as a function of time, [i."	( Optimization of the reference region method for dual pharmacokinetic modeling using Gd-DTPA/MRI and (18) F-FDG/PET. Bentourkia, M; Blanchette, M; Croteau, É; Lebel, R; Lecomte, R; Lepage, M; Poulin, É; Tremblay, L, 2015)	0.42
"An AIF derived from an RR in MRI can be accurately converted into a (18) F-FDG AIF and used in PET pharmacokinetic modeling."	( Optimization of the reference region method for dual pharmacokinetic modeling using Gd-DTPA/MRI and (18) F-FDG/PET. Bentourkia, M; Blanchette, M; Croteau, É; Lebel, R; Lecomte, R; Lepage, M; Poulin, É; Tremblay, L, 2015)	0.42
" We studied the pharmacodynamic effects of everolimus in resectable non-small cell lung cancer (NSCLC) to inform further development of these agents in lung cancer."	( A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. Auffermann, WF; Bechara, R; Behera, M; Chen, Z; Deng, X; Force, SD; Fu, H; Fu, RW; Gal, AA; Harvey, RD; Khuri, FR; Kim, S; Mendel, J; Miller, DL; Owonikoko, TK; Pickens, A; Ramalingam, SS; Rogatko, A; Rossi, MR; Saba, NF; Sica, GL; Sun, SY; Tighiouart, M; Torres, WE, 2015)	0.42
" We modeled the pharmacokinetic parameters regarding the nasal cavity and pharynx using mass balance equations, and evaluated the values that were obtained by fitting concentration-time profiles using WinNonlin® software."	( Visualization of drug translocation in the nasal cavity and pharmacokinetic analysis on nasal drug absorption using positron emission tomography in the rat. Cui, Y; Furubayashi, T; Hayashi, T; Hayashinaka, E; Irie, S; Katayama, Y; Nakaoka, T; Okauchi, T; Onoe, K; Ose, T; Sakane, T; Shingaki, T; Tanki, N; Wada, Y; Watanabe, Y; Yamaguchi, M, 2016)	0.43
" 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) is a non-invasive pharmacodynamic imaging biomarker that has become an integral part of drug development."	( The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor. Barjat, H; Ble, FX; Emmas, SA; Hancox, U; Hudson, K; Lawrie, E; Maynard, J; Polanska, UM; Pritchard, A, 2017)	0.46
"Our pre-clinical studies support the use of 18F-FDG PET imaging as a sensitive and non- invasive pharmacodynamic biomarker (understanding the role of PI3K signalling in glucose uptake) for AZD8835 with a decrease in 18F-FDG uptake observed at only two hours post treatment."	( The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor. Barjat, H; Ble, FX; Emmas, SA; Hancox, U; Hudson, K; Lawrie, E; Maynard, J; Polanska, UM; Pritchard, A, 2017)	0.46
" Pharmacokinetic analyses were accompanied by pharmacodynamics assessment of E by FDG-PET."	( Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. Abdulla, DSY; Backes, H; Behringer, D; Buettner, R; Eichstaedt, M; Fischer, RN; Franklin, J; Frechen, S; Fuhr, U; Gardizi, M; Junge, L; Kaminsky, B; Kinzig, M; Kobe, C; Limburg, M; Mattonet, C; Merkelbach-Bruse, S; Michels, S; Nogova, L; Ouyang, D; Persigehl, T; Rokitta, D; Scheffler, M; Schnell, R; Sörgel, F; Sos, ML; Stelzer, C; Suleiman, AA; Taubert, M; Tian, Y; Wolf, J, 2020)	0.56

Excerpt	Reference	Relevance
"[(18)F]FDG-PET was combined with microdialysis."	( Human adipose tissue glucose uptake determined using [(18)F]-fluoro-deoxy-glucose ([(18)F]FDG) and PET in combination with microdialysis. Asola, M; Huupponen, R; Knuuti, J; Lönnroth, P; Marjamäki, P; Nuutila, P; Parkkola, R; Peltoniemi, P; Strindberg, L; Virtanen, KA, 2001)	0.31
"Positron-emitting glucose analogue FDG, combined with microdialysis and tissue analysis, is a feasible method in studying glucose metabolism at the cellular level in animal studies."	( 2-[(18)F]fluoro-2-deoxy-D-glucose combined with microdialysis can be used for the comparison of tissue glucose metabolism in obese and lean rats. Bergman, J; Grönroos, T; Haaparanta, M; Huupponen, R; Nuutila, P; Rouru, J; Solin, O; Virtanen, KA, 2002)	0.31
"To determine the additional value of [(18)F]FDG-PET in combination with computed tomography (CT) over CT used alone, for evaluating ovarian cancer patients after primary treatment."	( Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. Aletti, G; De Cobelli, F; De Marzi, P; Del Maschio, A; Fazio, F; Ferrari, A; Gianolli, L; Landoni, C; Mangili, G; Messa, C; Picchio, M; Sironi, S; Viganò, R; Zangheri, B, 2003)	0.32
"PET used in combination with CT allows to accurately assess tumor response."	( Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. Aletti, G; De Cobelli, F; De Marzi, P; Del Maschio, A; Fazio, F; Ferrari, A; Gianolli, L; Landoni, C; Mangili, G; Messa, C; Picchio, M; Sironi, S; Viganò, R; Zangheri, B, 2003)	0.32
"To evaluate the results of surgical treatment of patients with ischemic heart disease in combination with intraoperative intramyocardial introduction of the human gene VEGF165 (angiostimulin)."	( [New approaches to the treatment of ischemic heart disease: therapeutic angiogenesis in combination with surgical revascularization of the myocardium]. Aslanidi, IP; Bokeriia, LA; Eremeeva, MV; Golukhova, EZ; Kiselev, SL; Kliueva, AF; Lukashkin, MA; Poliakova, ES; Vakhromeeva, MN, 2004)	0.32
"The aim of this study was to define the recommended dose of oxaliplatin when combined with infusional 5-fluorouracil (5-FU) and concurrent pelvic radiotherapy."	( Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. Hicks, RJ; Leong, T; Lim-Joon, D; Loi, S; Mackay, J; Michael, M; Mitchell, P; Mukesh, B; Ngan, SY; Rischin, D; Zalcberg, J, 2005)	0.33
"This study was sought to compare the sensitivity, specificity and accuracy of (1) dual isotope simultaneous acquisition single-photon emission computed tomography (DISA SPECT) myocardial image with (99m)Tc-sestamibi/(18)F-fluorodeoxyglucose ((99m)Tc-MIBI/(18)FDG); (2) low dose dobutamine alone and combined with Isosorbide Dinitrate (ISDN: Isoket) stress two dimensional echocardiography (2DE) to predict regional movement recovery after revascularization (CRV) in patients with old myocardial infarction (OMI) and severe left ventricular dysfunction."	( [Head to head comparison of dobutamine alone and combined with nitrate stress echocardiography and 99mTc-MIBI/18FDG myocardial SPECT image for diagnosis of viable myocardium in patients with severe left ventricular dysfunction]. Chen, JL; Chen, ZJ; Gao, RL; He, ZX; Hu, FH; Shi, RF; Tian, YQ; Wang, YW; Yang, WX; Yang, YJ; Ye, L; You, SJ, 2005)	0.33
"9%) underwent low dose dobutamine 10 microg x kg(-1) x min(-1) (Dob10 microg) and ISDN (286 +/- 31 microg/min) combined with Dob5 microg (ISDN-Dob 5 microg) 2DE and DISA SPECT within one week."	( [Head to head comparison of dobutamine alone and combined with nitrate stress echocardiography and 99mTc-MIBI/18FDG myocardial SPECT image for diagnosis of viable myocardium in patients with severe left ventricular dysfunction]. Chen, JL; Chen, ZJ; Gao, RL; He, ZX; Hu, FH; Shi, RF; Tian, YQ; Wang, YW; Yang, WX; Yang, YJ; Ye, L; You, SJ, 2005)	0.33
" When ISDN combined with Dob5 microg, the sensitivity (91."	( [Head to head comparison of dobutamine alone and combined with nitrate stress echocardiography and 99mTc-MIBI/18FDG myocardial SPECT image for diagnosis of viable myocardium in patients with severe left ventricular dysfunction]. Chen, JL; Chen, ZJ; Gao, RL; He, ZX; Hu, FH; Shi, RF; Tian, YQ; Wang, YW; Yang, WX; Yang, YJ; Ye, L; You, SJ, 2005)	0.33
"Judging tumor residue of hepatocellular carcinoma (HCC) after treatment of transcatheter arterial chemo-embolization (TACE) combined with radiofrequency ablation (RFA) by computed tomography (CT) scan is difficult; while 18-fluorodeoxyglucose-positron emission tomography/CT ((18)FDG-PET/CT) has some advantages in this aspect."	( [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT]. Fan, WJ; Gu, YK; Huang, JH; Lin, YE; Tan, ZB; Wu, PH; Zeng, YX; Zhang, FJ; Zhang, L; Zhao, M, 2005)	0.33
" The results of CT and (18)FDG-PET/CT of the 13 patients 2-3 weeks after treatment of TACE combined with RFA were compared."	( [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT]. Fan, WJ; Gu, YK; Huang, JH; Lin, YE; Tan, ZB; Wu, PH; Zeng, YX; Zhang, FJ; Zhang, L; Zhao, M, 2005)	0.33
"Of the 13 HCC patients that received 1 course of TACE combined with RFA, 11 had tumor residues which were conformed by fine needle biopsy and digital substraction angiography (DSA)."	( [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT]. Fan, WJ; Gu, YK; Huang, JH; Lin, YE; Tan, ZB; Wu, PH; Zeng, YX; Zhang, FJ; Zhang, L; Zhao, M, 2005)	0.33
"(18)FDG-PET/CT is better than CT in judging tumor residue of HCC after treatment of TACE combined with RFA or surgery, and in guiding further treatment of HCC."	( [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT]. Fan, WJ; Gu, YK; Huang, JH; Lin, YE; Tan, ZB; Wu, PH; Zeng, YX; Zhang, FJ; Zhang, L; Zhao, M, 2005)	0.33
"To evaluate the use of positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) to assess early response to pre-operative chemoradiation therapy in combination with external locoregional hyperthermia in patients with oesophageal cancer by correlating the reduction of metabolic activity with histopathologic response."	( Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Boellaard, R; Crezee, H; Hoekstra, OS; Hulshof, MC; Omloo, JM; Sloof, GW; ten Kate, FJ; van Lanschot, JJ; Vervenne, WL; Westerterp, M, 2006)	0.33
"FDG-PET is a promising tool for early response monitoring in patients undergoing chemoradiation therapy in combination with hyperthermia."	( Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Boellaard, R; Crezee, H; Hoekstra, OS; Hulshof, MC; Omloo, JM; Sloof, GW; ten Kate, FJ; van Lanschot, JJ; Vervenne, WL; Westerterp, M, 2006)	0.33
" Clinical data on patients with recurring lymphoma who were treated with second-line chemotherapy (DHAP-VIM-DHAP) followed by autologous stem cell transplantation (ASCT) were collected and combined with the results of FDG-PET performed before and after 2 cycles of reinduction chemotherapy."	( Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Pruim, J; Schot, BW; Sluiter, WJ; Vaalburg, W; van Imhoff, GW; Vellenga, E; Zijlstra, JM, 2007)	0.34
"5-25 mg/kg) was administered every 3 days for 3 weeks alone or in combination with a single dose of 10 Gy or fractionated RT (3 x 5 Gy)."	( VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Burd, R; Cardi, C; Daskalakis, C; Dicker, AP; Holash, J; Thakur, M; Wachsberger, PR; Yancopoulos, GD, 2007)	0.34
"Improved tumor control was seen when RT (either single dose or fractionated doses) was combined with the lowest dose of VEGF Trap (2."	( VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Burd, R; Cardi, C; Daskalakis, C; Dicker, AP; Holash, J; Thakur, M; Wachsberger, PR; Yancopoulos, GD, 2007)	0.34
" PET combined with computed tomography (PET/CT) shows the metabolic activity with precise anatomic localization."	( Detection of aortic graft infection by 18-fluorodeoxyglucose positron emission tomography combined with computed tomography. Björck, M; Savitcheva, I; Sörensen, J; Tegler, G; Wanhainen, A, 2007)	0.34
" This study was conducted to investigate the usefulness of (18)F-FMT PET in combination with fluorine-18-fluorodeoxyglucose ((18)F-FDG) PET for the diagnosis of sarcoidosis in patients with suspected malignancy."	( Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Endo, K; Hisada, T; Ishizuka, T; Kaira, K; Mori, M; Oriuchi, N; Otani, Y; Sunaga, N; Yanagitani, N, 2007)	0.34
" Use of (18)F-FMT PET in combination with (18)F-FDG PET may be the effective method to distinguish sarcoidosis from malignancy."	( Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Endo, K; Hisada, T; Ishizuka, T; Kaira, K; Mori, M; Oriuchi, N; Otani, Y; Sunaga, N; Yanagitani, N, 2007)	0.34
"The purpose of this study was to describe our experiences and analyze the benefits of video-assisted thoracoscopic surgery (VATS) combined with positron emitted tomography (PET)-computed tomography (CT) in the diagnosis of patients with early (Stage 1) sarcoidosis."	( Experiences and benefits of positron emitted tomography-computed tomography (PET-CT) combined with video-assisted thoracoscopic surgery (VATS) in the diagnosis of Stage 1 sarcoidosis. Chen, JY; Luh, SP; Tsao, TC; Wang, YT; Wu, TC, 2007)	0.34
" VATS combined with PET-CT can provide more accurate and earlier diagnosis of patients with unknown intrathoracic lesions, including the sarcoidosis."	( Experiences and benefits of positron emitted tomography-computed tomography (PET-CT) combined with video-assisted thoracoscopic surgery (VATS) in the diagnosis of Stage 1 sarcoidosis. Chen, JY; Luh, SP; Tsao, TC; Wang, YT; Wu, TC, 2007)	0.34
" The aim of this article is to show the first case of focal CHI diagnosed in Spain using PET-CT imaging combined with genetic analysis."	( [18F-fluoro-L-DOPA PET-CT imaging combined with genetic analysis for optimal classification and treatment in a child with severe congenital hyperinsulinism]. Arbizu Lostao, J; Azcona San Julián, C; Carracedo, A; Fernández-Marmiesse, A; Garrastachu Zumarrán, P; Martino Casado, E; Richter Echevarría, JA, 2008)	0.35
" However, 18F-FDG PET/CT in combination with qualitative STIR MRI analysis had a significantly higher capability to detect nodal involvement on an individual-patient basis (96."	( The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax. Ameshima, S; Demura, Y; Fujibayashi, Y; Ishizaki, T; Kimura, H; Miyamori, I; Morikawa, M; Okazawa, H; Sasaki, M; Tsuchida, T, 2009)	0.35
" A microautoradiographic study combined with immunohistochemistry revealed heavy accumulation of 18F-FDG in inflammatory cells containing peroxidase on day 1 and in cells forming granulation tissue (alpha-smooth muscle actin-positive myofibroblasts and ED2-positive macrophages) on days 2-4 in and around ulcers."	( PET and macro- and microautoradiographic studies combined with immunohistochemistry for monitoring rat intestinal ulceration and healing processes. Kataoka, Y; Mizuma, H; Wada, Y; Watanabe, Y; Yamato, M, 2009)	0.35
"To evaluate the clinical usefulness of fluorodeoxyglucose (FDG)-PET maximal SUV in combination with CT features for differentiation of adenocarcinoma with bronchioloalveolar carcinoma (BAC) from other subtypes of non-small cell lung cancer (NSCLC)."	( Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancer Hwang, SC; Lee, KB; Park, KJ; Sheen, SS; Sun, JS; Yoon, JK; Yoon, SN, 2009)	0.35
" A few patients have been reported with semantic dementia (SD) combined with MND."	( Semantic dementia combined with motor neuron disease. Chin, J; Go, SM; Jeong, JH; Kim, SH; Na, DL; Seo, SW; Suh, MK, 2009)	0.35
"To assess the value of F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) combined with CT in critically ill patients suspected of having an infection."	( F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. Bleeker-Rovers, CP; Oyen, WJ; Pickkers, P; Simons, KS; van der Hoeven, JG, 2010)	0.36
" We aimed to define the maximum tolerated dose, toxicity, activity, and pharmacokinetics of oral panobinostat, a pan-deacetylase inhibitor, alone and in combination with docetaxel for the treatment of castration-resistant prostate cancer (CRPC)."	( A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Anand, A; Dzik-Jurasz, A; Hu, J; Rathkopf, D; Ross, RW; Scher, HI; Tanaka, E; Wong, BY; Woo, MM; Yang, W, 2010)	0.36
" In arm II, oral panobinostat (15 mg) was administered on the same schedule in combination with docetaxel 75 mg/m(2) every 21 days."	( A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Anand, A; Dzik-Jurasz, A; Hu, J; Rathkopf, D; Ross, RW; Scher, HI; Tanaka, E; Wong, BY; Woo, MM; Yang, W, 2010)	0.36
" In the diagnostic evaluation, positron emission tomography combined with computed tomography (PET-CT) made a significant contribution--beyond that which would have been possible if only conventional imaging modalities such as magnetic resonance imaging (MRI) and transthoracic echocardiography (TTE) were utilized--and played a major role in follow-up."	( Positron emission tomography combined with computed tomography as an integral component in evaluation of primary cardiac lymphoma. Huang, YT; Lee, JC; Platts, DG; Slaughter, RE, 2010)	0.36
" On the basis of promising preclinical data, the safety and tolerability of therapy with the mTOR inhibitor RAD001 in combination with radiation (RT) and temozolomide (TMZ) was evaluated in this Phase I study."	( North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011)	0.37
"All patients received weekly oral RAD001 in combination with standard chemoradiotherapy, followed by RAD001 in combination with standard adjuvant temozolomide."	( North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011)	0.37
" On the basis of these results, the recommended Phase II dosage currently being tested is RAD001 70 mg/week in combination with standard chemoradiotherapy."	( North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011)	0.37
"RAD001 in combination with RT/TMZ and adjuvant TMZ was reasonably well tolerated."	( North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011)	0.37
"(18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with computed tomography (CT) is a promising new tool for the identification of infectious foci."	( Diagnostic value of positron emission tomography combined with computed tomography for evaluating patients with septic shock of unknown origin. Braune, S; Derlin, T; Kluge, S; Klutmann, S; Mester, J; Nierhaus, A; Wichmann, D, 2012)	0.38
" We investigated whether mental imagery training combined with electromyogram-triggered electric stimulation improved motor function of the paretic upper extremity in patients with chronic stroke and induced cortical changes."	( Cortical changes after mental imagery training combined with electromyography-triggered electrical stimulation in patients with chronic stroke. Choi, JB; Hong, IK; Lee, JH, 2012)	0.38
"Fourteen subjects with chronic stroke (≥12 months) were randomly allocated to receive mental imagery training combined with electromyogram-triggered electric stimulation (n=7) or generalized functional electric stimulation (n=7) on the forearm extensor muscles of the paretic extremity in 2 20-minute daily sessions 5 days a week for 4 weeks."	( Cortical changes after mental imagery training combined with electromyography-triggered electrical stimulation in patients with chronic stroke. Choi, JB; Hong, IK; Lee, JH, 2012)	0.38
"The group receiving mental imagery training combined with electromyogram-triggered electric stimulation exhibited significant improvements in the upper extremity component of the Fugl-Meyer Motor Assessment after intervention (median, 7; interquartile range, 5-8; P<0."	( Cortical changes after mental imagery training combined with electromyography-triggered electrical stimulation in patients with chronic stroke. Choi, JB; Hong, IK; Lee, JH, 2012)	0.38
"Mental imagery training combined with electromyogram-triggered electric stimulation improved motor function of the paretic extremity in patients with chronic stroke."	( Cortical changes after mental imagery training combined with electromyography-triggered electrical stimulation in patients with chronic stroke. Choi, JB; Hong, IK; Lee, JH, 2012)	0.38
"The aim of this study was to assess the diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in combination with ultrasonography-guided fine needle aspiration cytology (US-guided FNAC) for the preoperative diagnosis of axillary lymph node (ALN) metastases in patients with breast cancer."	( Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer. Katayama, T; Kubota, K; Machida, Y; Shibuya, H; Toriihara, A, 2013)	0.39
"The allogenic UCB therapy combined with rhEPO in the present study was safe and suggested potential therapeutic efficacy for patients with TBI."	( Allogenic umbilical cord blood therapy combined with erythropoietin for patients with severe traumatic brain injury: three case reports. Jang, SJ; Kang, MS; Kim, M; Kim, SH; Lee, JH; Min, K; Song, J, 2013)	0.39
"The significance of (18)F-2-deoxy-2-fluoro-glucose positron emission tomography combined with computed tomography imaging (FDG-PET/CT) in the diagnosis of gastric cancer remains controversial."	( Assessment of (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the preoperative management of patients with gastric cancer. Hanazaki, K; Kobayashi, M; Namikawa, T; Nogami, M; Ogawa, Y; Okabayshi, T, 2014)	0.4
" Overall, i-PET was highly and independently predictive of any outcome, and its negative predictive value was improved by combination with IPI."	( Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. André, M; Bosly, A; Bouazza, S; Costantini, S; Lhommel, R; Michaux, L; Mounier, N; Nols, N; Sonet, A; Van Den Neste, E; Vander Borght, T; Vekemans, MC, 2014)	0.4
" The recommended phase 2 dose of oral weekly everolimus is 70 mg in combination with standard cetuximab."	( Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Avadhani, AN; Ciunci, CA; Divgi, CR; Englander, S; Flaherty, KT; Giantonio, BJ; Harlacker, K; Kang, HC; O'Dwyer, PJ; Perini, RF; Redlinger, M; Rosen, MA; Schnall, M; Song, HK; Sun, W; Troxel, A, 2014)	0.4
"Complete insulin suppression combined with markedly increased circulating FFAs does not completely suppress physiological myocardial 18F-FDG uptake and thus conveys no extra diagnostic value compared with extended fasting."	( Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis. Bendstrup, E; Christensen, NL; Gormsen, LC; Nielsen, SS; Tolbod, LP, 2013)	0.39
", in a week-on/week-off schedule, combined with FOLFIRI or FOLFOX."	( Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J, 2014)	0.4
"Axitinib administered in a week-on/week-off schedule combined with FOLFIRI or FOLFOX is supported by (18)FLT-PET data and was well tolerated in patients with gastrointestinal tumours."	( Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J, 2014)	0.4
" We hypothesized that the combination with rationally selected other therapeutic agents may improve response."	( Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. Boerman, OC; Fleuren, ED; Flucke, UE; Franssen, GM; Houghton, PJ; Oyen, WJ; Roeffen, MH; van der Graaf, WT; Versleijen-Jonkers, YM, 2014)	0.4
" This prospective pilot study aimed to assess (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET), combined with whole-body computed tomographic angiography (CTA), in patients with suspected severe sepsis and for whom the prior diagnostic workup had been inconclusive."	( ¹⁸F-fluorodeoxyglucose positron emission tomography combined with whole-body computed tomographic angiography in critically ill patients with suspected severe sepsis with no definite diagnosis. Bollaert, PE; Chevalier-Mathias, E; Gibot, S; Lemarié, J; Mandry, D; Marie, PY; Olivier, P; Roch, V; Tatopoulos, A, 2014)	0.4
" In this study, we investigated the utility of 13N-ammonia and its combination with 18F-FDG in differentiating brain abscess from necrotic high-grade gliomas."	( 13N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess. Chen, Z; Shi, X; Tang, G; Wang, X; Yi, C; Zhang, B; Zhang, X, 2015)	0.42
"13N-ammonia is effective in distinguishing brain abscess from necrotic high-grade gliomas, and its combination with 18F-FDG could further elevate the diagnostic accuracy."	( 13N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess. Chen, Z; Shi, X; Tang, G; Wang, X; Yi, C; Zhang, B; Zhang, X, 2015)	0.42
"To explore the preoperative diagnostic value of ¹⁸F-fluorodexyglucose positron emission tomography combined with contrast enhanced computed tomography (¹⁸F-FDG PET-ceCT) in patients with colorectal cancer liver metastasis."	( [Diagnostic value of ¹⁸F-fluorodexyglucose positron emission tomography combined with contrast enhanced computed tomography in colorectal cancer liver metastasis]. Chen, F; Hu, P; Hu, R; Liao, S; Lyu, Q; Zhang, J; Zhang, Z, 2015)	0.42
"To estimate the diagnostic accuracy of sentinel node biopsy (SNB) combined with preoperative (18) F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) for inguinal lymph node (LN) evaluation in patients with invasive penile squamous cell carcinoma (PSCC) with no clinical evidence of inguinal metastases (cN0) at two tertiary centres with complete clinical follow-up."	( DaPeCa-3: promising results of sentinel node biopsy combined with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph node-negative patients with penile cancer - a national study from Denmark. Alslev, L; Bouchelouche, K; Costa, JC; Høyer, S; Ipsen, P; Jakobsen, JK; Jensen, JB; Krarup, KP; Nerstrøm, H; Sommer, P; Toft, BG, 2016)	0.43
" The primary endpoints were the sensitivity, specificity, and false-negative rate of SNB combined with FDG PET/CT."	( DaPeCa-3: promising results of sentinel node biopsy combined with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph node-negative patients with penile cancer - a national study from Denmark. Alslev, L; Bouchelouche, K; Costa, JC; Høyer, S; Ipsen, P; Jakobsen, JK; Jensen, JB; Krarup, KP; Nerstrøm, H; Sommer, P; Toft, BG, 2016)	0.43
"We examined 254 groins in 129 patients by SNB combined with FDG PET/CT."	( DaPeCa-3: promising results of sentinel node biopsy combined with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph node-negative patients with penile cancer - a national study from Denmark. Alslev, L; Bouchelouche, K; Costa, JC; Høyer, S; Ipsen, P; Jakobsen, JK; Jensen, JB; Krarup, KP; Nerstrøm, H; Sommer, P; Toft, BG, 2016)	0.43
"We describe 10 cases of diffuse large B-cell lymphoma (DLBCL) confined to the bone marrow (BM), spleen, and liver, as evidenced by the uniformly increased uptake of fluorodeoxyglucose (FDG) on positron emission tomography combined with computed tomography (PET/CT)."	( A unique subtype of diffuse large B-cell lymphoma primarily involving the bone marrow, spleen, and liver, defined by fluorodeoxyglucose-positron emission tomography combined with computed tomography. Akasaka, T; Fukutsuka, K; Honjo, G; Iioka, F; Izumi, K; Kamoda, Y; Kitamura, K; Misaki, T; Nagai, Y; Nakagwa, M; Ohno, H; Okumura, A; Toda, Y, 2016)	0.43
" We prospectively evaluated the long-term seizure and cognitive outcomes of MHT combined with multiple subpial transection or lesionectomy (MHT + MST/L)."	( Long-term outcome and neuroradiologic changes after multiple hippocampal transection combined with multiple subpial transection or lesionectomy for temporal lobe epilepsy. Aoki, S; Ibayashi, K; Kamada, K; Kawai, K; Kubota, M; Kunii, N; Matsuo, T; Momose, T; Saito, N; Takahashi, M; Usami, K, 2016)	0.43
" The present case reports an extremely rare case of HLRCC syndrome combined with adrenocortical carcinoma."	( Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome Combined With Adrenocortical Carcinoma on 18F-FDG PET/CT. Chen, H; Fu, H; Guo, X; Wu, H, 2017)	0.46
" Using patients with pulmonary nodules as a study model, we hypothesized that IMI with a folate receptor targeted near-infrared contrast agent (OTL38) can improve malignant pulmonary nodule identification when combined with PET."	( Intraoperative Molecular Imaging Combined With Positron Emission Tomography Improves Surgical Management of Peripheral Malignant Pulmonary Nodules. Baldassari, MP; Barbosa, EM; Connolly, C; Delikatny, EJ; Deshpande, C; Drebin, J; Dunbar, A; Keating, J; Kucharczuk, JC; Kularatne, SA; Low, P; Mizelle, J; Newton, AD; Okusanya, O; Predina, JD; Singhal, S; Xia, L, 2017)	0.46
" We examined F-fluoro-deoxy-glucose positron emission tomography combined with computed tomography (FDG-PET/CT)'s value in ruling out cancer or infection in patients with AAV."	( 18F-fluoro-deoxy-glucose positron emission tomography combined with computed tomography can reliably rule-out infection and cancer in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis suspected of disease relapse. Frary, EC; Gerke, O; Hess, S; Laustrup, H, 2017)	0.46
"The aim of the study was to investigate the value of F-fluorodeoxyglucose positron-emission tomography combined with computed tomography (F-FDG-PET/CT) in diagnosing native valve endocarditis (NVE)."	( 18F-fluorodeoxyglucose positron-emission tomography combined with computed tomography as a diagnostic tool in native valve endocarditis. Aarntzen, EHJG; Berrevoets, MAH; Bleeker-Rovers, CP; de Geus-Oei, LF; de Vries, J; Kouijzer, IJE; Oyen, WJG; van Dijk, APJ, 2018)	0.48
"To investigate and discuss the clinical value of positron emission tomography-computed tomography (PET-CT) combined with ultrasound in detection of primary tumors in patients with malignant ascites (MA)."	( Clinical Value of Positron Emission Tomography-Computed Tomography Combined with Ultrasound in Detection of Primary Tumors in Patients with Malignant Ascites. Gou, B; Liu, G; Liu, J; Liu, X; Wang, Y; You, L; Zhu, X, 2019)	0.51
"7%), and PET-CT combined with abdominal B-ultrasound had the highest sensitivity and accuracy in diagnosing the primary foci of MA (98."	( Clinical Value of Positron Emission Tomography-Computed Tomography Combined with Ultrasound in Detection of Primary Tumors in Patients with Malignant Ascites. Gou, B; Liu, G; Liu, J; Liu, X; Wang, Y; You, L; Zhu, X, 2019)	0.51
"The PET-CT combined with ultrasound is conducive to improving the diagnostic efficiency for primary tumors in patients with MA."	( Clinical Value of Positron Emission Tomography-Computed Tomography Combined with Ultrasound in Detection of Primary Tumors in Patients with Malignant Ascites. Gou, B; Liu, G; Liu, J; Liu, X; Wang, Y; You, L; Zhu, X, 2019)	0.51
" He received 3 cycles of radiopeptide therapy using [Lu]Lutetium-DOTATATE combined with temozolomide."	( Dual Imaging With 68Ga-DOTATOC and 18F-FDG PET for Planning and Follow-up of PRRT in Combination With Temozolomide Treatment in a Patient With a Metastatic Neuroendocrine Tumor. Ahmadzadehfar, H; Hain, S; Hartmann, L; Hirzebruch, S; Wei, X, 2019)	0.51
"The study is to evaluate biodistribution, dosimetry, safety, and clinical usefulness of F-AlF-NOTA-octreotide (F-OC) PET/CT in combination with F-FDG PET/CT for detection of neuroendocrine neoplasms (NENs)."	( Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms. Chen, D; Hu, S; Li, J; Li, Y; Li, Z; Liu, Z; Long, T; Tang, Y; Yang, N; Zhou, M, 2019)	0.51
"We report a case of a patient with chronic inflammatory rheumatism, psoriasis and Hashimoto thyroiditis and subsequent appearance of static and dynamic ataxia and episodic memory deficit who was diagnosed as PLE combined with small cell lung cancer (SCLC)."	( The role of 18F-FDG PET/CT in management of paraneoplastic limbic encephalitis combined with small cell lung cancer: A case report. Capoccetti, F; Castagnoli, H; Fattori, S; Manni, C; Marchesani, F; Rossi, G, 2019)	0.51
"To investigate the diagnostic value of ultrasound combined with computed tomography (CT) in pancreatic cancer."	( Ultrasound combined with computed tomography in pancreatic cancer. Huang, X; Li, X; Liu, L; Ma, L; Yang, X; Zhao, X, )	0.13
" A hundred and one patients with ultrasonic diagnosis were enrolled into the ultrasound group, 98 patients with CT diagnosis were enrolled into CT group, and 113 patients undergoing ultrasound combined with CT diagnosis were enrolled into combined group."	( Ultrasound combined with computed tomography in pancreatic cancer. Huang, X; Li, X; Liu, L; Ma, L; Yang, X; Zhao, X, )	0.13
"Ultrasound combined with CT can make up for the deficiency of each other and effectively improve the predictive value in the diagnosis of pancreatic cancer, which can be used as an effective examination method in the diagnosis of this disease."	( Ultrasound combined with computed tomography in pancreatic cancer. Huang, X; Li, X; Liu, L; Ma, L; Yang, X; Zhao, X, )	0.13
" Both plasma Aβ42/40 ratio alone or combined with an FDG-PET-based biomarker of neurodegeneration were assessed as potential AD biomarkers."	( Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Alegret, M; Arbizu, J; Boada, M; Buendía, M; Guillen, F; Hernández, I; Martínez-Lage, P; Monleón, I; Munuera, J; Pérez-Grijalba, V; Pesini, P; Prieto, E; Romero, J; Ruiz, A; San-José, I; Sarasa, L; Sarasa, M; Sotolongo-Grau, O; Tárraga, L, 2019)	0.51
"This exploratory study suggests that FES-PET heterogeneity may potentially identify the subset of ER positive, metastatic breast cancer patients who benefit from letrozole combined with CDK inhibition."	( Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. Boers, J; de Vries, EFJ; Elias, SG; Glaudemans, AWJM; Hospers, GAP; Kwee, TC; Martens, JWM; Schröder, CP; Schuuring, E; Venema, CM, 2020)	0.56
"To explore the clinical application value of 18F-fluorodeoxyglucose (18F-FDG) PET/CT imaging combined with detection of serum tumor molecular markers (carbohydrate antigen 125 (CA 125) and human epididymis protein 4 (HE4)) in the diagnosis of recurrence and metastasis of ovarian cancer."	( The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer. Cui, XW; Gu, L; Li, YS; Sun, J; Wang, SY; Wang, XN; Yin, Q, 2020)	0.56
"Clinical data about 18F-FDG PET/CT imaging and serum CA125 and HE4 of 69 ovarian cancer patients after the first cytoreductive surgery and chemotherapy were retrospectively analyzed, and the clinical application value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer was evaluated."	( The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer. Cui, XW; Gu, L; Li, YS; Sun, J; Wang, SY; Wang, XN; Yin, Q, 2020)	0.56
" In addition, the sensitivity and specificity of 18F-FDG PET/CT combined with detection of serum CA125 and HE4 for the diagnosis were 100."	( The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer. Cui, XW; Gu, L; Li, YS; Sun, J; Wang, SY; Wang, XN; Yin, Q, 2020)	0.56
"18F-FDG PET/CT imaging combined with detection of serum CA125 and HE4 can significantly improve the diagnostic efficiency to recurrence and metastasis of ovarian cancer and is conducive to the early diagnosis of the recurrence and metastasis, which provides a basis for further clinical intervention."	( The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer. Cui, XW; Gu, L; Li, YS; Sun, J; Wang, SY; Wang, XN; Yin, Q, 2020)	0.56
" More and more evidence shows that 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography ( 11C-CFT PET) combined with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) can effectively improve the accuracy of early diagnosis."	( Efficacy of 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography combined with 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of early Parkinson disease: A protocol for systematic review and meta analysis. Feng, Z; Jiang, L; Li, P; Shao, H; Shi, X; Wang, X, 2020)	0.56
"We will integrate the existing randomized controlled trials to evaluate the value of 11C-CFT PET combined with 18F-FDG PET in the diagnosis of early PD."	( Efficacy of 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography combined with 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of early Parkinson disease: A protocol for systematic review and meta analysis. Feng, Z; Jiang, L; Li, P; Shao, H; Shi, X; Wang, X, 2020)	0.56
"Our study may prove that 11C-CFT PET combined with 18F-FDG PET can effectively diagnose early PD."	( Efficacy of 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography combined with 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of early Parkinson disease: A protocol for systematic review and meta analysis. Feng, Z; Jiang, L; Li, P; Shao, H; Shi, X; Wang, X, 2020)	0.56
" Amyloidosis with diffuse abdominal involvement in combination with pulmonary squamous cell carcinoma carcinoma is an exceptionally rare occurrence."	( Lung cancer combined with diffuse peritoneal and mesenteric amyloidosis detected on 18F-FDG PET/CT: A case report. Song, T; Sun, J; Wang, J; Zhao, B, 2021)	0.62
"In patients with fever or inflammation of unknown origin (fever of unknown origin [FUO] or inflammation of unknown origin [IUO], respectively), expert consensus recommends the use of positron emission tomography with fluorine-18-fluorodeoxy glucose combined with computed tomography (FDG-PET/CT) when standard work-up fails to identify diagnostic clues."	( Predictors of Diagnostic Contributions and Spontaneous Remission of Symptoms Associated with Positron Emission Tomography with Fluorine-18-Fluorodeoxy Glucose Combined with Computed Tomography in Classic Fever or Inflammation of Unknown Origin: a Retrospe Iwata, M; Terasawa, T; Toyama, H; Tsuzuki, S; Watanabe, A, 2021)	0.62
"Determine the safety and specificity of a tumor-targeted radiotracer (89Zr-pan) in combination with 18F-FDG PET/CT to improve diagnostic accuracy in head and neck squamous cell carcinoma (HNSCC)."	( 89Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma. Azevedo, EC; Baik, FM; Castillo, J; Chin, FT; Colevas, AD; Duan, H; Ferri, V; Freeman, L; Hom, M; Iagaru, A; Kaplan, MJ; Koran, ME; Lee, YJ; Martin, BA; Raymundo, RC; Rosenthal, EL; Shen, B; Valencia, A; van den Berg, NS; Zhou, Q, 2022)	0.72
" In this study, the watershed algorithm (WA) was used to segment the abdominal images to extract images of pancreatic cancer cells and to compare the value of F-FDG PET/CT combined with MRI in the diagnosis of pancreatic occupying lesions."	( The Clinical Diagnostic Value of F-FDG PET/CT Combined with MRI in Pancreatic Cancer. Liu, X; Lu, L; Ren, Y; Wang, J; Yang, X, 2022)	0.72
" We report here a case diagnosed by positron emission tomography/computed tomography (PET-CT) combined with tumour markers."	( Primary small cell carcinoma of the gallbladder diagnosed by PET/CT combined with tumour markers: A case report. Fu, P; Guo, A; Li, S, 2023)	0.91

Excerpt	Reference	Relevance
"17), whereas [(18)F]FAc has the highest bioavailability (area under concentration of radiotracer vs."	( Biodistribution, pharmacokinetics and PET imaging of [(18)F]FMISO, [(18)F]FDG and [(18)F]FAc in a sarcoma- and inflammation-bearing mouse model. Chang, CH; Chang, CW; Chang, TJ; Chou, TK; Lin, WJ; Liu, RS; Wang, HE; Wang, SJ; Wu, CY, 2009)	0.35
"Hypofractionated radiotherapy of rectal cancer leads to an increased tumor perfusion as reflected by an elevated K(trans), possibly improving the bioavailability of cytotoxic agents in rectal tumors, often administered early after radiotherapy treatment."	( Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings. Aerts, HJ; Backes, WH; Buijsen, J; Janssen, MH; Kierkels, RG; Lambin, P; Lammering, G; Ollers, MC, 2010)	0.36
" In anesthetized rats, the gastric emptying rate of (18)F-FDG decreased dramatically whereas the intestinal absorption rate constant was not significantly different from that in conscious rats."	( PET imaging of the gastrointestinal absorption of orally administered drugs in conscious and anesthetized rats. Cui, Y; Hayashinaka, E; Kataoka, M; Oh, H; Sakuma, S; Suzuki, N; Takahashi, M; Takashima, T; Wada, Y; Watanabe, Y; Yamashita, S, 2011)	0.37
" After oral administration of 11C-labeled telmisartan with or without non-radiolabeled telmisartan, systemic bioavailability and hepatic distribution of radioactivity significantly increased non-linearly with dose."	( [Dynamic analysis of pharmacokinetics of orally administered drugs using positron emission tomography]. Kataoka, M, 2012)	0.38
"We aimed to determine whether BAT can be activated in lean and obese humans after acute administration of an orally bioavailable sympathomimetic."	( Ephedrine activates brown adipose tissue in lean but not obese humans. Bertovic, D; Carey, AL; Cherk, MH; Duffy, SJ; Eikelis, N; Formosa, MF; Kalff, V; Kingwell, BA; Lambert, GW; Van Every, B, 2013)	0.39
" The whole-body average specific absorption rate (SAR) was 4 W/kg for the field of the 915 MHz RFID signal."	( The effects of exposure to 915 MHz radiofrequency identification on cerebral glucose metabolism in rat: a [F-18] FDG micro-PET study. Ahn, YH; An, YS; Choi, HD; Kim, BC; Kim, HS; Kim, N; Lee, YS; Pack, JK; Paik, MJ, 2013)	0.39
"05), which reduces [(18)F]FDG bioavailability for BAT and other tissues."	( Brown adipose tissue activity after a high-calorie meal in humans. Brans, B; Mottaghy, FM; Schrauwen, P; van Baak, MA; van der Lans, AA; van Marken Lichtenbelt, WD; Vosselman, MJ; Wierts, R, 2013)	0.39
" Analysis of the PET imaging data revealed that the pharmacokinetic parameters were independent of the dosing solution volume; however, the viscosity increased the absorption rate constant and decreased the mucociliary clearance rate constant."	( Visualization of drug translocation in the nasal cavity and pharmacokinetic analysis on nasal drug absorption using positron emission tomography in the rat. Cui, Y; Furubayashi, T; Hayashi, T; Hayashinaka, E; Irie, S; Katayama, Y; Nakaoka, T; Okauchi, T; Onoe, K; Ose, T; Sakane, T; Shingaki, T; Tanki, N; Wada, Y; Watanabe, Y; Yamaguchi, M, 2016)	0.43

Excerpt	Relevance	Reference
" Since all patients were scanned while on their current medication regimen, the duration and dosage of the medication of the two patient groups were compared."	( Regional metabolism in microsmic patients with schizophrenia. Clark, C; Hurwitz, T; Kopala, L; Li, D, 1991)	0.28
"The cognitive-enhancing effects of pramiracetam in animal models of learning and memory are characterized by an inverted U-shaped dose-response curve."	( Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Blin, J; Chase, TN; Claus, JJ; Giuffra, M; Ludwig, C; Mohr, E, 1991)	0.28
" We measured the standardized uptake value (SUV), a semiquantative evaluation, ROI activity divided by the dosage per weight of each patient."	( Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas. Kawabe, J; Kitayama, H; Matsuda, M; Nakai, Y; Nasako, Y; Ochi, H; Ohashi, Y; Okamura, T; Sakamoto, H; Sakashita, T, 1998)	0.3
" The dosage form is the injectable solution (2 ml) containing 185 MBq of 18F-FDG at a calibration time."	( [Development of 18F-FDG ([F-18]-2-fluoro-2-deoxy-D-glucose) injection for imaging of tumor reflecting glucose metabolism--results of preclinical studies]. Ino, S; Ito, O; Kanagawa, M; Kato-Azuma, M; Kondo, S; Shimada, T; Shirakami, Y; Suzuki, N, 1999)	0.3
"To determine the dose-response relationship between the probability of tumor control on the basis of pathologic tumor response (pTCP) and the residual metabolic rate of glucose (MRglc) in response to preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer and to define the level of residual MRglc that corresponds to pTCP 50% and pTCP > or = 95%."	( Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Choi, NC; Fidias, P; Fischman, AJ; Lynch, T; Mathisen, D; Niemierko, A; Ryu, JS; Wain, J; Wright, C, 2002)	0.31
"The correlation between the gradient of residual MRglc after chemoradiotherapy and pTCP is an inverse dose-response relationship."	( Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Choi, NC; Fidias, P; Fischman, AJ; Lynch, T; Mathisen, D; Niemierko, A; Ryu, JS; Wain, J; Wright, C, 2002)	0.31
"A novel microfluidic device was designed and developed to miniaturize, multiplex, and automate serial dilution and three-reagent dose-response assays using submicroliter quantities of reagents."	( A prototype microfluidic platform for miniaturization and automation of serial dilution and dose-response assays. Coyne, C; Flynn, T; Koehler, J; Levine, L; Pezzuto, M; Vajjhala, S; Williams, M, 2002)	0.31
" However, in the other patient, critical structure dosage from the nonuniform dose prescription exceeded dose-volume/function limits, and greatly exceeded that from the uniform dose prescription."	( Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Baydush, AH; Bell, M; Craciunescu, O; Das, SK; Dewhirst, MW; Marks, LB; Miften, MM; Munley, MT; Rosenman, JG; Whiddon, CS; Wong, T; Zhou, S, 2004)	0.32
" From these results, the tumor control probability (TCP) was estimated, assuming a clinical dose-response curve with a median toxic dose of 84."	( Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Bentzen, SM; Boersma, L; De Ruysscher, D; Hochstenbag, M; Lambin, P; Lamers, R; Lutgens, L; Nijsten, S; van Der Wel, A; Wanders, R; Wouters, B; Zimny, M, 2005)	0.33
"Controlling the patient's environmental temperature prior to the dosing and during the uptake phase can significantly reduce FDG uptake in brown fat in the neck and paravertebral areas."	( Reduction of brown fat 2-deoxy-2-[F-18]fluoro-D-glucose uptake by controlling environmental temperature prior to positron emission tomography scan. Acio, E; Atkins, F; Butler, C; Esposito, G; Garcia, CA; Kulkarni, K; Majd, M; Van Nostrand, D, )	0.13
" We imaged 18 normal volunteers in a dose-escalation study with 3 endotoxin dosing groups (n = 6 in each group): 1 ng/kg, 2 ng/kg, and 4 ng/kg."	( FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. Chen, DL; Mintun, MA; Rosenbluth, DB; Schuster, DP, 2006)	0.33
" The mean lamotrigine dosage was 211."	( Regional effects of lamotrigine on cerebral glucose metabolism in idiopathic generalized epilepsy. Hong, SB; Joo, EY; Tae, WS, 2006)	0.33
" Deviation of the dose-response curve from a linear model was tested."	( Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Ajani, J; Guerrero, T; Hart, J; Johnson, V; Khan, M; Komaki, R; Liao, Z; Luo, D; Pan, T; Stevens, C, 2007)	0.34
"Because C75 causes an effect that is shorter in duration than expected, modification of the current weekly dosing regimen should be considered."	( FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer. Alvey, S; Gabrielson, E; Gabrielson, K; Hagemann, RL; Kuhajda, FP; Lee, JS; Orita, H; Pomper, MG, 2007)	0.34
" CT and FDG-related dosage data were gathered from the literature and then extrapolated to the scan parameters at a model PET center."	( Cancer screening with whole-body PET/CT for healthy asymptomatic people in Japan: re-evaluation of its test validity and radiation exposure. Ghotbi, N; Iwanaga, M; Ogawa, Y; Ohtsuru, A; Yamashita, S, )	0.13
" In addition, we aimed to determine optimum dosing and to determine if there are positron emission tomography (PET)-attenuation effects on 2-deoxy-2[F-18]fluoro-D-glucose (FDG) values due to Fenestra LC."	( MicroCT liver contrast agent enhancement over time, dose, and mouse strain. Stout, DB; Suckow, CE, )	0.13
"The previously published European Association of Nuclear Medicine (EANM) paediatric dosage card recommends 70 MBq F-18 or F-18 Fluoro-2-Deoxyglucose (F-18-FDG) as the "minimum recommended activity"."	( The new EANM paediatric dosage card: additional notes with respect to F-18. Biassoni, L; Franzius, C; Lassmann, M; Monsieurs, M, 2008)	0.35
"Mean patient dosage of (18)F-FDG was 699 +/- 181 MBq (range 451-984)."	( Comprehensive evaluation of occupational radiation exposure to intraoperative and perioperative personnel from 18F-FDG radioguided surgical procedures. Hall, NC; Hinkle, GH; Knopp, MV; Marsh, SG; Martin, EW; Povoski, SP; Sarikaya, I; White, WC, 2008)	0.35
" This protocol is based on standardisation of: (1) patient preparation; (2) matching of scan statistics by prescribing dosage as function of patient weight, scan time per bed position, percentage of bed overlap and image acquisition mode (2D or 3D); (3) matching of image resolution by prescribing reconstruction settings for each type of scanner; (4) matching of data analysis procedure by defining volume of interest methods and SUV calculations and; (5) finally, a multi-centre QC procedure is defined using a 20-cm diameter phantom for verification of scanner calibration and the NEMA NU 2 2001 Image Quality phantom for verification of activity concentration recoveries (i."	( The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Arends, B; Boellaard, R; Comans, EF; Hoekstra, CJ; Hoekstra, OS; Oyen, WJ; Paans, AM; Pruim, J; Verzijlbergen, FJ; Visser, EP; Willemsen, AT; Zijlstra, J, 2008)	0.35
" This case was deemed in operable, and one-shot bolus of 5-FU was administered through the tumor feeding arteries: the left 3rd, 4th lumbar, and ilio -- lumbar arteries at a dosage of 250 mg/body from each artery."	( Arterial infusion chemotherapy in patient with repeated recurrent tumor of cecal cancer: report of a case. Anazawa, S; Eto, K; Ogawa, M; Takao, Y; Ushigome, T; Watanabe, M; Yamagata, T; Yanaga, K, 2008)	0.35
" An activation index (AI) was calculated from microPET data o quantify the changes in local metabolic activities normalized to variations in FDG dosage between animals."	( MicroPET study of brain neuronal metabolism under electrical and mechanical stimulation of the rat tail. Chen, YY; Chien, CN; Chou, TW; Jaw, FS; Lee, TW; Shih, YY, 2009)	0.35
" Consequences are under dosing and thereby possibly ineffective treatment."	( Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Beukema, JC; Busz, DM; Langendijk, JA; Muijs, CT; Plukker, JT; Pruim, J; Schreurs, LM; van der Borden, AJ; Van der Jagt, EJ, 2009)	0.35
" However, IMRT requires a particular attention at the target delineation step to avoid inadequate dosage to TVs/OARs."	( [Potential place of FDG-PET for the GTV delineation in head and neck and lung cancers]. Bol, A; Castadot, P; Geets, X; Grégoire, V; Lee, JA, 2009)	0.35
" Importantly, loss or decrease in PTEN expression was found in all murine MPNSTs and a majority of human NF1-associated MPNST lesions, suggesting that PTEN dosage and its controlled signaling pathways are critical for transformation of NFs to MPNST."	( PTEN dosage is essential for neurofibroma development and malignant transformation. Ao, Y; Dang, J; Dry, SM; Eilber, FC; Gregorian, C; Lawson, G; Liu, X; Mellinghoff, IK; Mischel, PS; Nakashima, J; Nghiemphu, PL; Parada, LF; Phelps, M; Smith, KB; Sofroniew, MV; Wu, H, 2009)	0.35
"Corticotropin-releasing factor receptor type 1 (CRF(1)) antagonists have been proposed as therapeutic agents in the treatment of mood and anxiety disorders although clinical evidence supporting their development and understanding of a dose-response relationship has been lacking."	( Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Andrews, RD; Brown, T; de Hoon, J; Mannaert, E; Schmidt, ME; Steckler, T; van der Ark, P; Van Laere, K, 2010)	0.36
" The goal of this study was to investigate the real therapeutic effectiveness of 6 mol% PEG (111)In-vinorelbine liposomes via the elevation of the radiation dosage and reduction in the concentration of chemotherapeutic agents."	( Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. Chow, TH; Hwang, JJ; Lin, WJ; Lin, YY; Liu, RS; Pang, VF; Ting, G; Tseng, YL; Wang, HE; Yang, CS, 2009)	0.35
"PET/CT scans obtained at a median of 2 mo after initial dosing did not demonstrate significant changes in lesion size or (18)F-FDG or (18)F-FLT uptake when focusing on metastatic lesions."	( Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. Allen-Auerbach, MS; Benz, MR; Chmielowski, B; Czernin, J; Gomez-Navarro, J; McCarthy, T; Radu, C; Ribas, A; Seja, E; Williams, JL, 2010)	0.36
"[(18)F]FDG uptake was able to reflect the dose-response relationship for cyclophosphamide."	( Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Balzarini, J; Brepoels, L; De Saint-Hubert, M; Mortelmans, L; Mottaghy, FM; Stroobants, S; Verhoef, G, 2010)	0.36
" This study demonstrated for the first time the use of PET in attaining an IVIVC for a parenterally administered modified release dosage form."	( Predicting the in vivo release from a liposomal formulation by IVIVC and non-invasive positron emission tomography imaging. Bausbacher, N; Buchholz, HG; Hühn, E; Langguth, P; Maus, S; Rösch, F; Schreckenberger, M; Shazly, G; Thews, O, 2010)	0.36
"The first part (Phase IA) consisted of single day BID dosing every three weeks with consecutive dose escalations."	( Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Alvfors, C; Bergman, A; Bergqvist, M; Bergström, S; Dahg, P; Ekman, S; Frödin, JE; Harmenberg, J; Hedlund, A; Ståhl, B, 2011)	0.37
"We conducted a phase II study to assess the efficacy of continuous dosing of sunitinib in patients with flurodeoxyglucose positron emission tomography (FDG-PET)-avid, iodine-refractory well-differentiated thyroid carcinoma (WDTC) and medullary thyroid cancer (MTC) and to assess for early response per FDG-PET."	( Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Bauman, JE; Capell, PT; Carr, LL; Eaton, KD; Goulart, BH; Kell, EM; Mankoff, DA; Martins, RG, 2010)	0.36
" On the basis of these results, the recommended Phase II dosage currently being tested is RAD001 70 mg/week in combination with standard chemoradiotherapy."	( North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011)	0.37
" The goal of this retrospective study was to identify the radiation dose-response relationship of parotid gland glucose metabolism in patients with head and neck squamous cell carcinoma (HNSCC)."	( FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism. Brizel, DM; Hawk, TC; Higgins, KA; Hoang, JK; Roach, MC; Turkington, TG, 2012)	0.38
" Significant dose-response relationship was observed in SUVmax between group 1 and group 2, and the SUV values gradually decreased from d7 to d14 after treatment."	( [Experimental study of CT guided ³²P-CP-PLLA microparticle implantation in the treatment of rabbit VX2 lung tumor]. Huang, P; Liu, L; Pan, D; Wang, L; Xu, Y; Yang, M, 2011)	0.37
" Pharmacodynamic analysis demonstrated inhibition of IGF-1R phosphorylation in tumors in mice dosed with MEDI-573, indicating that the antitumor activity is mediated via inhibition of IGF-1R signaling pathways."	( Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Blakey, DC; Bosslet, K; Cartlidge, SA; Chang, YS; Chesebrough, JW; Coats, S; Gao, J; Incognito, L; Jallal, B; Ricketts, SA; Tabrizi, M; Trail, PA; Veldman-Jones, M, 2011)	0.37
" Each study included in the present review was described in a narrative way, and major components of each study were reported (ie, research design, patient characteristics, types of drugs and radiopharmaceuticals, dosing information and adverse reactions)."	( Pitfalls with radiopharmaceuticals. Machado, M; Santos-Oliveira, R, 2011)	0.37
"Pediatric (18)F-FDG dosing and acquisition durations are generally based on coarse extrapolation from adult guidelines."	( Evaluation of optimal acquisition duration or injected activity for pediatric 18F-FDG PET/CT. Alessio, AM; Manchanda, V; Mohr, BC; Parisi, MT; Phillips, GS; Sammer, M, 2011)	0.37
" Serum ACE level was reduced in all cases, and daily steroid dosage was reduced."	( Refractory multisystem sarcoidosis responding to infliximab therapy. Carruthers, D; Croft, AP; Giovanni, G; Gordon, C; Khair, O; Situnayake, D; Sivaguru, A, 2012)	0.38
" Clinical indices of disease activity, inflammatory markers, and 18Ffluorodeoxyglucose positron emission/computerised tomography findings normalised, while the prednisone dosage could be tapered."	( Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers. Boiardi, L; Catanoso, MG; Dardani, L; Magnani, L; Meliconi, R; Pipitone, N; Pulsatelli, L; Salvarani, C; Versari, A, )	0.13
" Under the condition of adding 5-FU at various concentrations for 24 hours, the uptake rate of (18)F-FDG was negatively correlated with 5-FU dosage (r = -0."	( Early evaluation for treatment efficacy of 5-fluorouracil and hyperthermia on HCT-116 colon cancer cells by fluorine-18-fluorodeoxyglucose uptake. Chen, SJ; Deng, SM; Wang, ZX; Zhang, B, 2012)	0.38
"To quantify the post-radiotherapy 2-[(18)F]-fluoro-2-deoxyglucose (FDG) pulmonary uptake dose-response in lung cancer patients and determine its relationship with radiation pneumonitis symptoms."	( [18F]-FDG uptake dose-response correlates with radiation pneumonitis in lung cancer patients. Al Hallack, MN; Castillo, R; Guerrero, T; Lichter, J; Martinez, J; McCurdy, MR; Zouain, N, 2012)	0.38
"The metabolic radiation pneumonitis dose-response was evaluated from post-treatment FDG-PET/CT imaging."	( [18F]-FDG uptake dose-response correlates with radiation pneumonitis in lung cancer patients. Al Hallack, MN; Castillo, R; Guerrero, T; Lichter, J; Martinez, J; McCurdy, MR; Zouain, N, 2012)	0.38
" Zolpidem was then given in dosage of 10 mg three times per day."	( Zolpidem improves neuropsychiatric symptoms and motor dysfunction in a patient with Parkinson's disease after deep brain stimulation. Chiou, SM; Hsu, YT; Huang, HY; Kao, CH; Tsai, CH; Tsai, MC; Wu, YC, 2012)	0.38
" (A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging; NCT00633022)."	( Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. Cai, G; Cheriyan, J; Choudhury, RP; Collier, DJ; Davies, LC; Davis, B; Elkhawad, M; Fayad, ZA; Gleeson, FV; Lepore, JJ; Marber, MS; Rudd, JH; Sarov-Blat, L; Sprecher, DL; Tawakol, A; Wells, R; Wilkinson, IB; Willette, RN, 2012)	0.38
" Levetiracetam monotherapy at a dosage of 40 mg/kg/day improved the clinical findings, and seizures were controlled at the end of the first month of treatment."	( Acquired epileptiform opercular syndrome: F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings and efficacy of levetiracetam therapy. Akın, R; Arslan, M; Ince, S; Ünay, B; Vurucu, S; Yiş, U, 2012)	0.38
" A linear dose-response relationship was demonstrated for radioactivity concentrations typical of experiments with rodents."	( Blood compatible microfluidic system for pharmacokinetic studies in small animals. Aimez, V; Baril, FG; Boisselle, V; Charette, PG; Convert, L; Fontaine, R; Lecomte, R; Pratte, JF, 2012)	0.38
"Glucose metabolic changes in CM patients taking different dosage of analgesic during headache-free periods and clear distinctions in several brain regions were observed."	( Overuse of paracetamol caffeine aspirin powders affects cerebral glucose metabolism in chronic migraine patients. Di, W; Fang, Y; Luo, N; Miao, J; Qi, W; Shi, X; Tao, Y; Xiao, Z; Yi, C; Zhang, A; Zhang, X; Zhu, Y, 2013)	0.39
"Two mitogen-activated protein kinase kinase (MAPK2, also known as MEK) inhibitors were assessed with (18)F-FDG PET in separate phase I clinical studies, clearly illustrating the potential of metabolic imaging for dose, dosing regimen, and compound selection in early-phase trials and utility for predicting nonresponding patients."	( Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials. Carlier, T; Chua, S; Gleeson, F; Hugonnet, F; Kraeber-Bodéré, F; Lumbroso, J; Naegelen, VM; Nagarajah, J; Shochat, E; Stokkel, M; Tessier, J; Trampal, C, 2012)	0.38
" The local dose-response relation was used in the LKB model to calculate the EUD."	( Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer. Belderbos, J; Kwint, M; Lebesque, J; Nijkamp, J; Rossi, M; Sonke, JJ; Uyterlinde, W; van den Heuvel, M; Vogel, W, 2013)	0.39
" Although sunitinib treatment lowered the patient's blood glucose concentrations further and induced repeated symptomatic hypoglycemic episodes, he was able to tolerate the treatment well after changing the timing of sunitinib dosing and adjusting his diet."	( Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Chen, J; Cong, L; Cui, Y; Han, J; Luan, Y; Sha, D; Shen, R; Wang, C; Wang, W; Zhang, Z, 2013)	0.39
" All cross-sectional diagnostic imaging examinations performed for disease assessment after completion of chemotherapy were reviewed and cumulative radiation dosage from these examinations and the frequency of relapse detection by these examinations were recorded."	( Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Allen, CE; Bollard, CM; Dreyer, Z; Eissa, HM; Goradia, P; Guillerman, RP; Kamdar, K; McClain, KL; Simko, S; Steuber, P, 2014)	0.4
"The MTD was 700 mg twice weekly when BIIB021 was dosed for 3 weeks out of each 4-week course."	( A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Banerji, U; Castro, J; Lamanna, N; Mita, M; O'Brien, S; Saif, MW; Stogard, C; Takimoto, C; Von Hoff, D, 2014)	0.4
" The significant dose-response relationship points to the clinical utility of patient-specific absorbed dose calculations for radionuclide therapy."	( Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma. Barron, B; Eaton, BR; Fox, T; Galt, JR; Kim, HS; Kim, S; Landry, J; Liu, Y; Schreibmann, E; Schuster, DM, 2014)	0.4
"We evaluated week-on/week-off axitinib dosing plus chemotherapy in patients with gastrointestinal tumours, including tumour thymidine uptake by fluorine-18 3'-deoxy-3'-fluorothymidine positron emission tomography ((18)FLT-PET)."	( Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J, 2014)	0.4
") axitinib 7 mg (n=3) or 10 mg (n=18) for 7 days followed by a 7-day dosing interruption; serial (18)FLT-PET scans were performed before day 1 and on days 7, 10, and 14."	( Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J, 2014)	0.4
" To compensate for the heterogeneity among multi-institutional patient cohorts and corresponding treatment techniques, local control data of the cohorts were fit to a single dose-response curve with a clinically representative steepness (γ50=2), thereby defining an 'outcome-equivalent dose' (OED) for each institutional cohort."	( Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. Deasy, JO; Jeong, J; Lee, NY; Oh, JH; Setton, JS, 2014)	0.4
"We introduced a novel outcome-equivalent dose analysis method to estimate the dose-response modifying effect of FDG uptake variation."	( Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. Deasy, JO; Jeong, J; Lee, NY; Oh, JH; Setton, JS, 2014)	0.4
" The patient was in need of high dosage of inotrops during the following days."	( Detection of necrosis of the gastric fundus after blunt abdominal trauma by PET-CT. Gabriel, M; Hofer, A; Kratochwill, H; Pentsch, A, 2015)	0.42
"TAK-733 was administered orally by gavage to nude xenograft rats for 2 weeks, at dosage levels of 0 (0."	( Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using ¹⁸F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549. Ishino, S; Miyake, H; Mori, I; Vincent, P, 2015)	0.42
" BMI showed a dose-response association with increased odds (1."	( Aleksunes, LM; Amer, H; Ashare, RL; Avula, RT; Badgaiyan, RD; Bakera, B; Beanlands, R; Bircsak, KM; Blake, J; Blum, K; Braverman, ER; Chakkera, HA; Chandy, G; Chang, CJ; Chang, YH; Chen, CL; Chen, LW; Chiu, CH; Chow, JC; Claupein, W; Contreras-Dominguez, V; D'Aiuto, F; Darbar, U; DaSilva, JN; Davies, RA; deKemp, R; Demotrovics, Z; Denic, A; Dennie, C; Döhler, J; Donath, S; Donos, N; Du, Y; Dunne, R; Dushaj, K; Ehrhart, E; Evans, GC; Gawrońska, H; Giordano, J; Gold, MS; Gruber, S; Hartung, K; Huang, CW; Hubert, S; Johnson, CA; Kolesnichenko, I; Lee, HY; Lerman, LO; Li, M; Lowenthal, DH; Madigan, MA; Makary, T; Mc Ardle, B; Mc Klein, R; McShane, MJ; Mielniczuk, LM; Müller, T; Newton, JM; Nibali, L; Ohira, H; Okoth, EA; Ongarora, BG; Oscar-Berman, M; Palmer, PH; Pekrun, C; Pena, E; Petrie, A; Piepho, HP; Pugliese, C; Rakmanee, T; Renaud, JM; Ritter, DW; Rule, AD; Sakuma, KL; Schoenthaler, SJ; Schulz, R; Smith, KM; Souprountchouk, V; Stewart, DJ; Strasser, AA; Suvan, JE; Thomas, LF; Thompson, B; Tsaur, S; Vicente, MG; Waite, RL; Wang, Q; Wang, X; Wang, YH; Watson, JG; Weiß, K; Wen, X; Xiao, J; Zhou, Z, )	0.13
"5 %) underwent PSA dosage and biopsy to determine the nature of the incidental uptake."	( Multicentre study of 18F-FDG-PET/CT prostate incidental uptake. Bertagna, F; Bertoli, M; Biasiotto, G; Bosio, G; Dib, B; Fracassi, F; Giovanella, L; Giubbini, R; Piccardo, A; Treglia, G, 2015)	0.42
"The 2010 North American Consensus Guidelines (NACG) for pediatric administered doses and the European Association of Nuclear Medicine (EANM) Dosage Card guidelines recommend lower activities than those administered at our institution."	( Dose Optimization of the Administered Activity in Pediatric Bone Scintigraphy: Validation of the North American Consensus Guidelines. Ayres, KL; Delbeke, D; Hodges, PK; Martin, WH; Price, R; Spottswood, SE; Wang, L, 2015)	0.42
" Data were subsampled to represent different administered activities corresponding to the activities recommended by the NACG and the EANM Dosage Card."	( Dose Optimization of the Administered Activity in Pediatric Bone Scintigraphy: Validation of the North American Consensus Guidelines. Ayres, KL; Delbeke, D; Hodges, PK; Martin, WH; Price, R; Spottswood, SE; Wang, L, 2015)	0.42
"5 mg continuous daily dosing of sunitinib."	( FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Agarwal, N; Beardmore, B; Boucher, K; Butterfield, RI; Hoffman, JM; Horn, KP; Kadrmas, DJ; Morton, KA; Yap, JT, 2015)	0.42
" This study's primary objective examined the relationship between GSK2141795, an oral, pan-AKT inhibitor, and (18)F-FDG PET markers of glucose metabolism in tumor tissue to determine whether (18)F-FDG PET could be used to guide personalized dosing of GSK2141795."	( Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. Agarwal, R; Babar, S; Blagden, S; Carme, S; Chen, M; Curry, E; Dina, R; El-Bahrawy, MA; Gabra, H; Gungor, H; Krachey, E; Madison, S; Morris, SR; Pickford, E; Rama, N; Saleem, A; Salinas, C; Santiago-Walker, A; Smith, DA; Stronach, EA, 2015)	0.42
" No dose-response relationship was observed between GSK2141795 pharmacokinetics and (18)F-FDG PET pharmacodynamic measures; however, an exposure-response relationship was seen between maximum drug concentrations and maximal decrease in (18)F-FDG uptake in the best-responding tumor."	( Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. Agarwal, R; Babar, S; Blagden, S; Carme, S; Chen, M; Curry, E; Dina, R; El-Bahrawy, MA; Gabra, H; Gungor, H; Krachey, E; Madison, S; Morris, SR; Pickford, E; Rama, N; Saleem, A; Salinas, C; Santiago-Walker, A; Smith, DA; Stronach, EA, 2015)	0.42
" The dosing solution of [(18)F]FDG was varied in volume (ranging from 5 to 25 μl) and viscosity (using 0% to 3% concentrations of hydroxypropylcellulose)."	( Visualization of drug translocation in the nasal cavity and pharmacokinetic analysis on nasal drug absorption using positron emission tomography in the rat. Cui, Y; Furubayashi, T; Hayashi, T; Hayashinaka, E; Irie, S; Katayama, Y; Nakaoka, T; Okauchi, T; Onoe, K; Ose, T; Sakane, T; Shingaki, T; Tanki, N; Wada, Y; Watanabe, Y; Yamaguchi, M, 2016)	0.43
" We asked whether there is a dose-response relationship between the number of blast-related mild TBIs and uptake of (18)F-fluorodeoxyglucose (FDG), a commonly used indicator of neuronal activity, in the brains of blast-exposed veterans with mild TBI."	( Repetitive blast exposure in mice and combat veterans causes persistent cerebellar dysfunction. Cook, DG; Cross, DJ; Huber, BR; Kraemer, BC; Li, G; Meabon, JS; Meeker, KD; Minoshima, S; Pagulayan, KF; Peskind, ER; Petrie, EC; Raskind, MA; Richards, TL, 2016)	0.43
" We included the 372 subjects (85 normal subjects, 212 patients with mild cognitive impairment, and 75 patients with AD) with a CSF biomarker dosage (Aβ1-42, t-tau, and p-tau) and brain FDG-PET."	( What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects? Andriuta, D; Devendeville, A; Godefroy, O; Meyer, ME; Moullart, V; Schraen, S, 2016)	0.43
" To minimize the acute effects of MPH on FDG uptake, microPET/CT scans were scheduled on Mondays before their first daily dosing of the week (approximately 68h since their last treatment)."	( MicroPET/CT assessment of FDG uptake in brain after long-term methylphenidate treatment in nonhuman primates. Apana, SM; Berridge, MS; Callicott, R; Liu, S; Newport, GD; Paule, MG; Slikker, W; Thompson, J; Wang, C; Zhang, X, )	0.13
" Normalized uptake may provide patient-specific dose-response information not discernible from dose."	( (18)F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy. Briere, TM; Court, LE; Gomez, DR; Liao, Z; Martel, MK; Mohan, R; Niedzielski, JS; Stingo, F; Yang, J, 2016)	0.43
" Imaging in two subjects was performed ~4 hr after PET/CT imaging to simulate lower injected F(18-) FDG dose by taking advantage of the natural radioactive decay of the tracer (F(18) half-life of 110 min), with an estimated imaging dosage of 25% of the standard."	( Concept of an upright wearable positron emission tomography imager in humans. Bauer, CE; Brefczynski-Lewis, J; Jaliparthi, G; Lewis, JW; Majewski, S; Mandich, MB; Marano, G; Martone, P; Raylman, RR; Stolin, A, 2016)	0.43
" Based on this information we derived SUV driven dose-response functions and used these to optimize ideal dose redistributions under the constraint of equal average dose to the tumor volumes as for a conventional treatment."	( Dose painting by numbers based on retrospectively determined recurrence probabilities. Ahnesjö, A; Grönlund, E; Johansson, S; Montelius, A, 2017)	0.46
" Levothyroxine dosing required doubling in three patients with a known history of hypothyroidism."	( Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. Bornschlegl, S; Delivanis, DA; Dietz, AB; Gustafson, MP; Kottschade, L; Merten, MM; Ryder, M; Withers, S, 2017)	0.46
" Incidence of PIs, radiological features, patients' characteristics, underlying NHL type, rituximab/chemotherapy dosing schedules, and symptoms were recorded."	( 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics. Bairey, O; Berger, T; Cohen, YC; Eshel, L; Raanani, P; Shpilberg, O; Stern, D, 2017)	0.46
" 18F-FDG PET/CT results during treatment induced anti-fungal drugs dosage increase and/or new drugs addition in 8/54 cases (15%) and contributed to the reduction of anti-fungal drugs dosage or treatment withdraws in 17 cases (31%)."	( 18F-FDG PET/CT for invasive fungal infection in immunocompromised patients. Argemi, X; Bund, C; Herbrecht, R; Imperiale, A; Kessler, R; Leroy-Freschini, B; Treglia, G, 2018)	0.48
" We further demonstrate the importance of precise drug volume dosing to neural structures to elicit behavioral effects reliably."	( Focal, remote-controlled, chronic chemical modulation of brain microstructures. Cima, MJ; Cotler, M; Dagdeviren, C; Graybiel, AM; Joe, P; Langer, R; Nunez-Lopez, C; Ramadi, KB; Rousseau, E; Spencer, KC, 2018)	0.48
"3years, 48% of patients were successfully weaned from prednisone completely, and 20% were weaned to a maintenance dosage of 5-10mg/d."	( Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis. Fowler, M; Guo, HH; Iagaru, A; Mittra, E; Ning, N; Witteles, R, 2019)	0.51
" This article describes the current state-of-the-art of the use of FDG-PET/CT for patient selection, prognosis, treatment evaluation, and as a research tool into absorbed dose-response relationships in radioembolization."	( The Unique Role of Fluorodeoxyglucose-PET in Radioembolization. Bastiaannet, R; de Jong, HWAM; Lam, MGEH; Lodge, MA, 2019)	0.51
" These measures were equivalent to those obtained after 6 days of daily dosing by tofacitinib."	( Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo Abria, C; Chaudhari, AJ; Harmany, ZT; Kundu-Raychaudhuri, S; Raychaudhuri, S; Raychaudhuri, SP; Smith, CM, 2019)	0.51
" These measures were equivalent to those obtained after 6 days of daily dosing by tofacitinib."	( Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo Abria, C; Chaudhari, AJ; Harmany, ZT; Kundu-Raychaudhuri, S; Raychaudhuri, S; Raychaudhuri, SP; Smith, CM, 2019)	0.51
" New technologies for automated dosing and infusion delivery are available, however these incorporate both a multidose vial and a multi-patient infusion set."	( Use of a radiopharmaceutical multidose dispenser for positron emission tomography: Risk assessment and mitigation measures for infection prevention. Barton, H; Cheng, A; Karanfilovska, D; Martin, R; Yap, KS, 2020)	0.56
" However, there is a high rate of locoregional failure in patients with locally advanced non-small cell lung cancer (NSCLC), probably due to the fact that standard dosing may not be effective in all patients."	( Radiotherapy Planning and Molecular Imaging in Lung Cancer. Casali, M; Ciammella, P; Filice, A; Fioroni, F; Galaverni, M; Iotti, C; Versari, A, 2020)	0.56
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."	( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)	0.72
" However, to reliably implement this technique, the effect of uncertainties in quantitative PET/CT imaging feedback on tumor voxel dose-response assessment and DPbN needs to be determined and reduced."	( Effect of uncertainties in quantitative Chen, S; Krauss, DJ; Maniawski, P; Qin, A; Wilson, GD; Yan, D, 2020)	0.56
"Effect of uncertainties in quantitative FDG-PET/CT imaging feedback on intratumoral dose-response quantification was not negligible."	( Effect of uncertainties in quantitative Chen, S; Krauss, DJ; Maniawski, P; Qin, A; Wilson, GD; Yan, D, 2020)	0.56
" Abatement of arteritis symptoms along with reduction of glucocorticoid dosage was achieved in 12 patients, resulting in a remission induction rate of 70."	( Evaluation of tocilizumab for intractable Takayasu arteritis and Isobe, M; Maejima, Y; Saji, M; Tateishi, U, 2021)	0.62
" Responder analysis definitions were based on; dosage of immunosuppressive drugs, improvement in functional class, left ventricular ejection fraction (LVEF) and SUVmax."	( Effectiveness and safety of infliximab in cardiac Sarcoidosis. Akdim, F; Azzahhafi, J; Bakker, ALM; Grutters, JC; Keijsers, RGM; Mathijssen, H; Post, MC; Swaans, MJ; Veltkamp, M, 2021)	0.62
"In analogy to the existing EANM dosage card, new parameters for the EANM paediatric dosage card were developed (class B, baseline value: 10."	( The effect of modern PET technology and techniques on the EANM paediatric dosage card. Dickson, J; Eberlein, U; Lassmann, M, 2022)	0.72
"With this, recommendations for paediatric dosing are given for systems that have not been considered previously."	( The effect of modern PET technology and techniques on the EANM paediatric dosage card. Dickson, J; Eberlein, U; Lassmann, M, 2022)	0.72
" A dose-response curve was generated by binning each voxel in the heart into 10 Gy dose-bins and analyzing the SUVmean changes in each dose-bin."	( Cardiac metabolic changes on Castillo, E; Castillo, R; Goodman, KA; Jones, B; Miften, M; Olsen, J; Schefter, T; Vinogradskiy, Y; Zakem, SJ, 2023)	0.91
" A titration dosing regimen of thionamide anti-thyroid drug (ATD) was used to establish euthyroidism over 12-24 weeks."	( Brown adipose tissue influences adiponectin and thyroid hormone changes during Graves' disease therapy. Goh, HJ; Ho, WE; Leow, MKS; Sun, L; Tint, MT, 2022)	0.72
" However, statin dosage was significantly associated with Aβ deposition in 2 years (r = -0."	( Does statin use affect amyloid beta deposition and brain metabolism? Balabandian, M; Nabizadeh, F; Valizadeh, P, 2023)	0.91

Class	Description
2-deoxy-2-fluoro-aldehydo-D-glucose
2-deoxy-2-((18)F)fluoro-D-glucose
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Assay ID	Title	Year	Journal	Article
AID609650	Cellular uptake in mouse S180 cells after 30 mins	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Synthesis and biological evaluation of novel F-18 labeled pyrazolo[1,5-a]pyrimidine derivatives: potential PET imaging agents for tumor detection.
AID609652	Cellular uptake in mouse S180 cells after 60 mins	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Synthesis and biological evaluation of novel F-18 labeled pyrazolo[1,5-a]pyrimidine derivatives: potential PET imaging agents for tumor detection.
AID335928	Decrease in urinary excretion of thromboxane B2 in adenine rich diet fed LWH:Wistar rat at 10 mg/g, ip administered from day 7 to day 12 of adenine ingestion
AID335930	Increase in urinary excretion of prostaglandin E2 in adenine rich diet fed LWH:Wistar rat at 10 mg/g, ip administered from day 7 to day 12 of adenine ingestion
AID335929	Protection against renal failure in adenine rich diet fed LWH:Wistar rat up to 20 mg/g, ip administered once daily from day 7 to day 12 of adenine ingestion
AID335927	Effect on urinary excretion of prostaglandin in adenine rich diet fed LWH:Wistar rat assessed as urine TXB2 level per 24 hrs at 10 mg/g, ip administered from day 7 to day 12 of adenine ingestion
AID335925	Effect on urinary excretion of prostaglandin in adenine rich diet fed LWH:Wistar rat assessed as urine prostaglandin E2 level per 24 hrs at 10 mg/g, ip administered from day 7 to day 12 of adenine ingestion
AID335926	Effect on urinary excretion of prostaglandin in adenine rich diet fed LWH:Wistar rat assessed as urine 6-keto-PGF1-alpha level per 24 hrs at 10 mg/g, ip administered from day 7 to day 12 of adenine ingestion
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	461 (1.41)	18.7374
1990's	2183 (6.70)	18.2507
2000's	8459 (25.95)	29.6817
2010's	15697 (48.16)	24.3611
2020's	5796 (17.78)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2,160 (6.21%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	3,791 (10.90%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	7,933 (22.81%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	246 (0.71%)	0.25%
Observational	0 (0.00%)	0.25%
Other	20,641 (59.36%)	84.16%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (407)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder [NCT01222676]	Phase 2	45 participants (Anticipated)	Interventional	2010-10-31	Recruiting
Impact of Local Tissue Inflammation on Intramyocardial Conduction Pathways Post Percutaneous Valve : Evaluation by Positron Emission Tomography on Exploratory Cohort [NCT05308888]	Phase 2	100 participants (Anticipated)	Interventional	2022-05-01	Not yet recruiting
Endoprosthesis Treatment Effects on Human Abdominal Aorta Aneurysms(AAA)Metabolic Activity [NCT01253252]		45 participants (Actual)	Interventional	2009-08-31	Completed
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma [NCT05976763]	Phase 3	421 participants (Anticipated)	Interventional	2023-09-08	Recruiting
PET fUnCtionaL Imaging to Evaluate Cardiac Radiation Damage (EUCLID) [NCT05775939]		20 participants (Anticipated)	Interventional	2023-01-20	Recruiting
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors [NCT05286801]	Phase 1/Phase 2	86 participants (Anticipated)	Interventional	2022-11-17	Recruiting
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer [NCT02595879]	Phase 1	22 participants (Actual)	Interventional	2019-09-18	Active, not recruiting
A Pilot Prospective Study of the RefleXion [18F]- FDG PET-CT Subsystem Imaging Performance in Patients With Various Malignancies [NCT05844306]		20 participants (Anticipated)	Interventional	2023-03-15	Recruiting
A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC) [NCT01283178]	Phase 1	3 participants (Actual)	Interventional	2011-07-31	Terminated(stopped due to The study was terminated. The data analysis was futile with only 3 accruals. PI opted to terminate with IRB and withdraw FDA IND.)
A Phase I Study of Preoperative Chemoradiation With Oxaliplatin, 5-Fluorouracil, Erlotinib and Radiation Followed by Resection and Consolidative Erlotinib for Patients With Locally Advanced Cancer of the Esophagus and Gastroesophageal Junction [NCT01561014]	Phase 1	9 participants (Actual)	Interventional	2007-04-30	Completed
Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma [NCT01038778]	Phase 1/Phase 2	47 participants (Actual)	Interventional	2009-10-29	Active, not recruiting
Comparaison Entre la Performance du 18F-FDG PET/CT et de la Scintigraphie Osseuse/Gallium ou de la Scintigraphie Osseuse/Globules Blancs marqués /Souffre colloïdal Dans le Diagnostic d'Une ostéomyélite du Pied ou de la Cheville [NCT03712046]		2 participants (Actual)	Interventional	2019-01-15	Terminated(stopped due to Poor patient recruitment)
Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation [NCT01254591]		500 participants (Anticipated)	Interventional	2006-11-30	Recruiting
The Role of Positron Emission Tomography (PET) Imaging in the Evaluation of Response to Sorafenib Treatment in Advanced Hepatocellular Carcinoma. [NCT01157013]		40 participants (Actual)	Interventional	2009-01-31	Completed
A Study to Assess the Impact of Moderate/Significant Infiltrations on the Standardized Uptake Values of Target Lesions [NCT03320564]		2 participants (Actual)	Interventional	2018-08-27	Terminated(stopped due to Recruitment slow due to improved extravasation rate.)
Role of Dedicated Breast PET in the Characterisation of Indeterminate Breast Lesions on MRI Requiring a Second-look Ultrasound - a Feasibility Study [NCT03198442]		12 participants (Actual)	Interventional	2016-10-05	Completed
Phase I Dose-Escalation Study of BCMA/CS1 Bispecific Chimeric Antigen Receptor (CAR)-T Cells for Relapsed/Refractory Multiple Myeloma [NCT05950113]	Phase 1	30 participants (Anticipated)	Interventional	2024-03-28	Not yet recruiting
18F-DCFPyL PET/CT in Hepatocellular Carcinoma [NCT05009979]	Phase 2	50 participants (Anticipated)	Interventional	2023-01-18	Recruiting
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study [NCT02754037]		120 participants (Anticipated)	Observational	2016-04-30	Active, not recruiting
EVALUATION OF THE DIAGNOSTIC VALUE OF PET (18F-FDG) IN CHRONIC GRAFT VERSUS HOST DISEASE (cGVH) [NCT02352064]		26 participants (Anticipated)	Interventional	2015-01-31	Recruiting
An Adaptive Design Open Label Pilot Study in Rheumatoid Arthritis Patients to Assess Inflammation Using Molecular Imaging Techniques [NCT02350426]	Phase 1	10 participants (Actual)	Interventional	2015-08-12	Terminated(stopped due to A decision to stop the study was made by the site and GSK project team based on pre-defined stopping criteria in the protocol)
18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules [NCT03824535]	Phase 2	50 participants (Anticipated)	Interventional	2019-02-04	Recruiting
Open Label Randomized Trial of Early Assessment of Therapy Response Using 18FDG-PET/CT in Patients With Marginally Resectable Stage IIIA (N2) Non-Small Cell Lung Cancer (NSCLC) Treated With Induction Concurrent Chemoradiation Followed by Resection and Adj [NCT01314677]		0 participants (Actual)	Interventional	2011-04-30	Withdrawn(stopped due to No subjects have been accrued to this trial. The PI will no longer be at COH and requests a study withdrawal/closure.)
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade [NCT02070406]	Phase 1	4 participants (Actual)	Interventional	2014-07-17	Terminated(stopped due to low accrual)
Study of the Cerebral Metabolism in Patients With Refractory Chronic Cluster Headache Treated by Occipital Nerve Stimulation [NCT02081482]		20 participants (Actual)	Interventional	2014-03-31	Active, not recruiting
Brown Adipose Tissue Activity Young and Older Individuals [NCT02130154]		16 participants (Actual)	Observational	2013-05-31	Completed
A Phase III, Multi-center, Single-blind, Cross-over Study to Evaluate the Efficacy and Safety of 18Ffluorocholine (18F-FCH) Comparing With 18F-fluorodeoxyglucose (18F-FDG) for Detecting Hepatocellular Carcinoma [NCT02074202]	Phase 3	150 participants (Anticipated)	Interventional	2014-02-28	Not yet recruiting
Comparison of PET/CT vs. PET/MRI [NCT03125629]	Phase 2	53 participants (Actual)	Interventional	2014-05-27	Completed
Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction [NCT04417998]	Phase 4	70 participants (Anticipated)	Interventional	2020-06-03	Enrolling by invitation
Cohort Study Evaluating 18FDG PET for Early Identification of Tumor Exhaust for Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Bronchopulmonary Carcinoma or Melanoma [NCT03584334]		100 participants (Anticipated)	Interventional	2019-04-04	Recruiting
Per-operating Use of a Probe for Detection of β+ [NCT02666599]		60 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Molecular Imaging in Infective Endocarditis Using Hybrid Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR) and Computed Tomography (PET/CT) [NCT03626571]		60 participants (Anticipated)	Observational	2018-05-01	Recruiting
Early Metabolic Response Evaluation With 18-FDG PET-CT in Esophageal Cancer Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy [NCT01269970]		0 participants	Observational	2004-01-31	Completed
Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients [NCT01171300]		94 participants (Actual)	Interventional	2010-10-31	Active, not recruiting
Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas [NCT00381797]	Phase 2	97 participants (Actual)	Interventional	2006-08-31	Completed
Diagnostic Performance of PET/MRI Versus Standard of Care Imaging (PET/CT and/or CT and/or PET) in Preoperative Women With Presumed Early-stage High Grade Endometrial Carcinoma [NCT05390021]		33 participants (Anticipated)	Interventional	2023-03-30	Not yet recruiting
Risk of Developing Dementia and Associated Factors in Patients With Normal Brain FDG PET [NCT04804722]		100 participants (Actual)	Observational	2022-01-20	Completed
Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx Using Metabolic Signature From Interim 18FDG-PET/CT [NCT04667585]		120 participants (Anticipated)	Interventional	2021-04-12	Recruiting
Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer [NCT02285192]	Phase 1	42 participants (Actual)	Interventional	2014-11-30	Active, not recruiting
A Pilot Study to Evaluate the Utility of Interim Digital PET/CT in Predicting Outcomes for Locally Advanced Oropharyngeal Cancer [NCT04140513]		25 participants (Anticipated)	Interventional	2020-10-09	Suspended(stopped due to PI decision)
Open-label, Multicenter Study of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY86-9596 Following a Single Intravenous Administration of 200 or 300 MBq (Corresponding to ≤ 18 µg Mass Dose) for Evaluation of Radiation [NCT01089998]	Phase 1	35 participants (Actual)	Interventional	2010-05-31	Completed
Brown Adipose Tissue Activity and Energy Metabolism in Cachexia Induced by Cancer or Chronic Disease [NCT02500004]		16 participants (Actual)	Interventional	2015-06-30	Completed
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET [NCT03432741]	Phase 1	39 participants (Anticipated)	Interventional	2018-03-27	Suspended(stopped due to funding - sponsor filing of Chapter 11 bankruptcy)
Alterations in the Brain's Connectome in Severe Traumatic Brain Injury [NCT02424656]		35 participants (Actual)	Observational	2014-09-30	Completed
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms [NCT05709171]	Phase 2	200 participants (Anticipated)	Interventional	2023-01-17	Enrolling by invitation
PET/CT Characterization of Treatment Resistance of AR-targeted Therapies in mCRPC [NCT05647564]		20 participants (Anticipated)	Interventional	2023-03-06	Recruiting
Phase IIa Clinical Trial: Feasibility Study on Non-Invasive Simultaneous Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy and 18F-FDG PET (hyperPET) for Metabolic Imaging in Patients With Cancer [NCT05396118]	Phase 2	15 participants (Anticipated)	Interventional	2022-05-18	Enrolling by invitation
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations [NCT04293562]	Phase 3	1,400 participants (Anticipated)	Interventional	2020-07-21	Recruiting
Pilot Study of a Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution [NCT04016818]	Early Phase 1	20 participants (Anticipated)	Interventional	2023-01-31	Not yet recruiting
A Prospective Study on Comparison 18F-FAPI and 18F-FDG PET/CT in the Evaluation of Patients With Various Types of Cancer [NCT05485792]		200 participants (Anticipated)	Interventional	2022-08-01	Not yet recruiting
"Combined One Stop Shop NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients: A Pilot Study" [NCT02429804]	Phase 1	4 participants (Actual)	Interventional	2015-04-30	Terminated(stopped due to Accrual factor)
A Pilot Study of 18F-FDG PET-CT Kinetic Analysis in Head and Neck Squamous Cell Carcinoma (HNSCC) [NCT02678884]		20 participants (Anticipated)	Interventional	2014-10-31	Recruiting
[18 F]-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) in Cardiac Sarcoidosis [NCT01764191]		0 participants	Expanded Access		Approved for marketing
Contribution of 18F-FDG PET-CT in the Diagnosis and the Detection of Peripheral Emboli of Infectious Endocarditis on Native Valves [NCT03695861]		31 participants (Actual)	Interventional	2018-11-10	Completed
Development of Radiation Free Whole Body MR Imaging Technique for Staging of Children With Cancer. [NCT01542879]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2012-02-29	Recruiting
Could Positon Emission Tomography With Radiolabelled 3'-Deoxy-3'-(18)F-Fluoro-L-Thymidine be a Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patients ? [NCT02069418]	Phase 2	80 participants (Anticipated)	Interventional	2014-02-28	Active, not recruiting
Evaluation of Resectable Cervical Carcinoma With PET/MRI [NCT04219904]	Early Phase 1	25 participants (Anticipated)	Interventional	2018-09-07	Active, not recruiting
Pilot Study of Gene Expression and FDG-PET/MR Biomarkers for Evaluation of Response to Neoadjuvant Therapy for Locally Advanced Rectal Cancer [NCT02112162]	Phase 1	2 participants (Actual)	Interventional	2014-06-30	Terminated(stopped due to Loss of funding)
18F-FAPI PET/CT and 18F-FDG PET/CT in Patients With Pancreatic Adenocarcinoma : A Prospective, Single-Center, Comparative Study [NCT05884463]		62 participants (Actual)	Interventional	2021-04-01	Completed
PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis [NCT02955966]		51 participants (Actual)	Interventional	2017-06-02	Completed
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Gynecological Tumors. [NCT06159907]		380 participants (Anticipated)	Observational	2021-10-27	Recruiting
Exploratory Evaluation of Simultaneous Cardiac PET/MR, Metabolomic Markers and Circulating DNA as Possible Prognostic Markers in Identifying Patients Developing Transient or Permanent Cardiopulmonary Dysfunctions After Radiotherapy [NCT04901884]		40 participants (Anticipated)	Interventional	2021-06-01	Recruiting
Arterial Imaging of Inflammation and Resolution After Endovascular Surgery [NCT03590769]	Phase 1	9 participants (Actual)	Interventional	2017-06-01	Completed
Diagnostic Accuracy of Positron Emission Tomography/ Computed Tomography With 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients With Colorectal Cancer [NCT03572595]		45 participants (Anticipated)	Observational	2018-07-01	Not yet recruiting
Positron Emission Tomography Assessment of Acute Lung Transplant Rejection [NCT02204202]		28 participants (Actual)	Observational	2014-02-28	Terminated(stopped due to PI left institution)
Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography /Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma [NCT03051568]		80 participants (Anticipated)	Interventional	2017-03-01	Not yet recruiting
18FDG-PET/MRI Imaging in Predicting Pathological Response to Neo-adjuvant Chemo-Radiotherapy in Rectal Cancer [NCT06057831]	Phase 2	40 participants (Anticipated)	Interventional	2024-05-31	Not yet recruiting
Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors [NCT05322512]		20 participants (Anticipated)	Interventional	2024-05-01	Not yet recruiting
Characterization in 18F-FDG PET-CT of Brain and Lung Lesions in Young Subjects With Sequelae Psycho-cognitive Disorders in the Aftermath of Severe Covid-19 [NCT04764721]		25 participants (Actual)	Interventional	2021-11-17	Completed
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer [NCT03181867]	Phase 2	330 participants (Anticipated)	Interventional	2017-08-03	Enrolling by invitation
Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung Cancer [NCT04553601]		150 participants (Anticipated)	Interventional	2019-10-01	Recruiting
Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy; a Randomized Controlled Trial [NCT03740126]		750 participants (Actual)	Interventional	2018-10-25	Active, not recruiting
Characterizing Histiocytosis With 68Ga-FAPI PET/CT [NCT05803629]		100 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
Biological Interconnection of Brain Neurobiological Activity With Atherosclerotic Plaque Vulnerability and the Prognostic Value [NCT05545618]		300 participants (Anticipated)	Observational	2015-01-01	Recruiting
Tumor Perfusion and Hypoxia Evaluation and Comparation in 18F-FDG PET/CT [NCT03373994]		40 participants (Anticipated)	Observational	2016-11-01	Recruiting
Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease [NCT01236508]	Phase 4	50 participants (Anticipated)	Interventional	2010-11-30	Terminated(stopped due to difficulties recruiting this population for study population)
Activation of Brown Adipose Tissue in Lean and Obese Men [NCT02173834]		20 participants (Actual)	Interventional	2013-03-31	Completed
The Role of Nuclear Imaging in Heart Failure: Correlation With Cardiac Function and Metabolism, Biomarkers and Clinical Prognosis [NCT02697669]		200 participants (Anticipated)	Observational	2012-08-31	Recruiting
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas [NCT00043979]	Phase 2	60 participants (Actual)	Interventional	2002-09-19	Completed
A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs [NCT00662506]	Phase 1/Phase 2	46 participants (Actual)	Interventional	2008-04-30	Completed
Comparison of FDG and FAPI in Patients With Various Types of Cancer [NCT04416165]		3,000 participants (Anticipated)	Interventional	2019-10-20	Recruiting
Effect of 18-FDG PET/CT Imaging on Clinical Decision Making During the Acute Phase of Infective Endocarditis: a Multicenter Prospective Impact Study [NCT02287792]		150 participants (Actual)	Interventional	2015-04-17	Completed
A Cancer Research UK Phase I Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Aurora B Inhibitor GSK1070916A in Patients With Advanced Solid Tumors [NCT01118611]	Phase 1	38 participants (Actual)	Interventional	2010-03-31	Completed
PET Imaging of Hemophilic Arthropathy Correlates With Clinical, Radiographic and Sonographic Assessments [NCT03485170]		20 participants (Actual)	Interventional	2018-01-22	Completed
Investigating the Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging [NCT01172041]		10 participants (Actual)	Observational	2010-07-31	Completed
Comparison of F-18 FDG PET CT and PET MRI With C-11 Acetate PET CT and PET MRI in the Diagnosis of Active Multiple Myeloma Disease: a Pilot Study [NCT03262389]	Phase 2	10 participants (Actual)	Interventional	2017-09-19	Completed
18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology [NCT01180751]	Phase 3	1,000 participants (Anticipated)	Interventional	2010-07-31	Enrolling by invitation
[NCT02510872]		19 participants (Actual)	Interventional	2011-12-31	Completed
[NCT01322477]		25 participants	Observational		Not yet recruiting
Development of Activity MRI (aMRI): Direct Comparison to PET in Human Subjects [NCT05937776]		20 participants (Anticipated)	Observational	2023-12-11	Not yet recruiting
Ideal Imaging Time Point Assessment for Spinal Cord Lesions of Unknown Etiology With FDG PET-MRI [NCT04219969]		20 participants (Anticipated)	Interventional	2018-09-21	Active, not recruiting
A Sub-study of 18F-DCFPyL Positron Emission Tomography / Computed Tomography (PET/CT) for Assessment of Recurrent Prostate Cancer Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients [NCT04017104]		60 participants (Anticipated)	Observational	2019-11-01	Recruiting
Comparison of FLT and FDG PET in the Evaluation of Response to Cetuximab, Cisplatin and Radiation Therapy in Advanced Head and Neck Malignancies or Response to Standard Chemo-radiotherapy in Esophageal Malignancies [NCT00757549]	Early Phase 1	30 participants (Anticipated)	Interventional	2008-09-30	Completed
A Pilot Study of FDG-PET Variability to Establish Biology-Guided Treatment Planning Feasibility for Stereotactic Body Radiation Therapy [NCT03493789]	Phase 1	19 participants (Actual)	Interventional	2018-04-13	Completed
68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG [NCT05873777]		30 participants (Anticipated)	Interventional	2023-04-09	Recruiting
Relationship Between Histopathological Features, Mutation Status, 18F-FDG PET/CT Radiomic Imaging Parameters as Well as Clinical Outcome in Patients With Treatment-naïve Non-small Cell Lung Cancer [NCT04276025]		2,000 participants (Actual)	Observational	2016-07-31	Completed
A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG) [NCT02130492]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2014-05-31	Suspended(stopped due to Temporarily interrupted due to lack of funding: will re-open in the near future)
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases [NCT00375830]	Phase 2	114 participants (Actual)	Interventional	2006-01-31	Completed
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients [NCT03602911]	Phase 2	30 participants (Anticipated)	Interventional	2019-02-01	Recruiting
Improving Breast Cancer Staging With 18F-FDG PET/CT Imaging (The IMBRECAS PET Study) [NCT05730608]		300 participants (Anticipated)	Interventional	2023-02-16	Recruiting
Diagnostic Potential of PET/MRI in Cardiac Sarcoidosis: A Pilot Study Combining Advanced MRI and 18F-FDG and 18F-GE180 PET of the Myocardium [NCT03561025]		33 participants (Actual)	Interventional	2018-10-01	Completed
Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma [NCT03891914]	Phase 3	30 participants (Anticipated)	Interventional	2019-11-12	Recruiting
18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor [NCT06126705]	Early Phase 1	60 participants (Anticipated)	Interventional	2023-07-18	Recruiting
18F-FDG PET Scan and MRI Diffusion : Correlation Study of the Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma [NCT03121456]		74 participants (Anticipated)	Interventional	2017-10-13	Active, not recruiting
Evaluation of Right Ventricular Function and Metabolism Following Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension- Images of Rio [NCT02094001]	Phase 2	6 participants (Actual)	Interventional	2014-05-31	Completed
Pilot Study of PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient Before and After Neoadjuvant Chemotherapy [NCT03295695]	Early Phase 1	0 participants (Actual)	Interventional	2020-12-31	Withdrawn(stopped due to closure of radiolaboratory)
A Prospective Exploration in the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms [NCT03288597]		146 participants (Anticipated)	Observational [Patient Registry]	2017-09-01	Recruiting
Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma [NCT05892393]	Phase 1	20 participants (Anticipated)	Interventional	2023-06-16	Recruiting
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer [NCT02059889]		0 participants (Actual)	Interventional	2014-07-31	Withdrawn(stopped due to slow accrual)
Biokinetics Study for F-18 FDG for Dose Reduction in Pediatric Molecular Imaging [NCT03107325]	Phase 4	0 participants (Actual)	Interventional	2019-02-01	Withdrawn(stopped due to No subjects who met the study criteria agreed to participate in two years prior to the COVID-19 crisis.)
Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With NK/T-cell Lymphoma [NCT03051542]		60 participants (Anticipated)	Interventional	2017-03-01	Not yet recruiting
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients [NCT05549024]	Early Phase 1	90 participants (Anticipated)	Interventional	2022-08-16	Recruiting
A Pilot Study of 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients [NCT05543954]	Early Phase 1	60 participants (Anticipated)	Interventional	2022-09-03	Recruiting
The Novel 18F-labeled MAO-B PET/CT Imaging on Parkinsonism Patients of Chinese Population: a Prospective Study [NCT06010290]		80 participants (Anticipated)	Observational	2022-11-30	Recruiting
A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma [NCT02125786]	Phase 2	70 participants (Anticipated)	Interventional	2014-05-07	Active, not recruiting
Radioguided Detection of Lymph Node Metastasis in Non-Small Cell Lung Cancer [NCT00732563]		100 participants (Actual)	Interventional	2008-07-16	Completed
Prospective Study Evaluating the Combination of Positron Emission Tomography (PET) With 18F-FDG and 18 F-Fluorocholine for Optimization of Staging and Treatment Modification in Patients With Hepatocellular Carcinoma [NCT04391348]		230 participants (Actual)	Interventional	2020-07-17	Completed
PET/MR, PET/CT and Whole Body MR in Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT02390635]	Phase 1	55 participants (Anticipated)	Interventional	2016-05-02	Recruiting
Quantitative Dynamic PET and MRI and Breast Cancer Therapy [NCT01931709]		35 participants (Actual)	Interventional	2011-11-30	Terminated(stopped due to Terminated due to end of funding)
A Multicenter Trial to Measure Early Patterns of Change in [18F]-Fluorodeoxyglucose Uptake by PET/CT in Relapsed Ovarian Cancer Patients [NCT00959582]	Phase 1	42 participants (Actual)	Interventional	2009-09-30	Completed
MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix [NCT01992861]		51 participants (Actual)	Observational	2014-02-14	Terminated
Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study [NCT02208544]		132 participants (Actual)	Interventional	2015-07-16	Completed
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI [NCT00537056]		17 participants (Actual)	Interventional	2007-10-31	Completed
Pilot Study Evaluating a Combined and Integrated Technological Approach of F-18-FDG-Directed Perioperative PET/CT Imaging and Intraoperative Handheld Gamma Prove Detection of Known and Occult Disease in Patients Undergoing Surgery for Solid Malignancies [NCT00816335]	Early Phase 1	65 participants (Actual)	Interventional	2008-10-31	Completed
Evaluation of the Sensitivity and Reproducibility of 18F-fluorodeoxyglucose Positron Emission Tomography Coupled With Magnetic Resonance Imaging for the Assessment of Respiratory Muscle Activity and Relationships With Multiparametric Respiratory Muscle Ul [NCT05234099]		16 participants (Anticipated)	Interventional	2022-05-05	Recruiting
A Phase II, Single-center STudy on the vAlue of Non-invasive Dual-Pet（18F-FES PET and 68Ga-HER2-Affibody PET）InformatiOn IN Subtype of Metastatic Breast Cancer(MBC) [NCT04758416]		50 participants (Anticipated)	Observational	2020-12-31	Recruiting
Phase II Trial: uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer [NCT02805608]	Phase 2	40 participants (Anticipated)	Interventional	2016-09-30	Active, not recruiting
FDG-PET Based Chemotherapy Selection for Metastatic Non-Small Cell Lung Cancer [NCT00564733]	Phase 2	55 participants (Actual)	Interventional	2007-10-31	Completed
EXPLORER Total Body PET/CT Imaging for Myofascial Pain [NCT05876858]	Early Phase 1	53 participants (Anticipated)	Interventional	2023-06-13	Recruiting
A Single Case Study of Hypermetabolism [NCT04805268]		1 participants (Actual)	Interventional	2020-12-14	Completed
A Pilot Bioimaging Trial of Cancer Cachexia [NCT04127981]		40 participants (Anticipated)	Interventional	2019-03-28	Recruiting
Diagnostic Assessment of 18F-fluciclovine and 18F-FDG - PET/MRI of Primary Central Nervous System Lymphoma [NCT03188354]		10 participants (Anticipated)	Interventional	2017-11-01	Recruiting
An Open-label, Non-randomized Study to Monitor for Adverse Drug Reactions Among Patients Administered Fedoruk-manufactured [F-18]-FDG Injection [NCT02811185]	Phase 4	1,012 participants (Actual)	Interventional	2016-06-30	Completed
Prospective Evaluation of PET-CT Scan in Patients With Non-operable or Non-resectable NSCLC Treated by Radical 3-Dimensional Conformal Radiation Therapy [NCT00958321]	Phase 2	40 participants (Anticipated)	Interventional	2007-03-31	Terminated(stopped due to Low levels of recruitment)
Research on the Lymphoma Staging and Therapeutic Evaluation of 18F-FDG PET/CT Comparing With Whole Body MRI IVIM Functional Imaging [NCT02733887]		66 participants (Anticipated)	Interventional	2016-02-29	Recruiting
A Multicenter Phase 2 Study Comparing 99m Tc EC-DG SPECT/CT With 18F FDG PET/CT in the Evaluation of Patients With Non-small Cell Lung Cancer (NSCLC) [NCT00865319]	Phase 2	22 participants (Actual)	Interventional	2009-06-30	Completed
Evaluation of Brain Functional Changes With 18F-FDG PET and Cognitive Processes After Brain Radiotherapy for Cavernous Sinus Meningiomas and Non-secreting ACTH Adenomas [NCT06180226]		20 participants (Actual)	Observational	2008-04-21	Completed
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma [NCT05675410]	Phase 3	1,875 participants (Anticipated)	Interventional	2023-05-11	Recruiting
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC [NCT03811015]	Phase 3	636 participants (Anticipated)	Interventional	2019-08-16	Recruiting
Contribution of PET/MRI in Locally Advanced Cervical Cancer [NCT06083103]		50 participants (Anticipated)	Observational	2023-10-02	Not yet recruiting
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation [NCT04459273]	Phase 1	30 participants (Anticipated)	Interventional	2020-08-27	Recruiting
PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46 in Patients With Non-Prostate Cancers: An Exploratory Biodistribution Study With Histopathology Validation [NCT04147494]	Early Phase 1	30 participants (Anticipated)	Interventional	2019-11-05	Recruiting
"Phase II Study of Sunitinib (SU011248) in Patients With Small Cell Lung Cancer Who Are Either Chemo-naïve (Extensive Disease) or Have a Sensitive Relapse" [NCT00953459]	Phase 2	9 participants (Actual)	Interventional	2009-02-28	Terminated(stopped due to poorly recruiting)
Creating Metabolic Vulnerabilities in Patients With EGFR Activated Recurrent Glioblastoma by Inhibiting EGFR With Osimertinib [NCT03732352]	Phase 2	12 participants (Actual)	Interventional	2018-11-28	Active, not recruiting
Assessing Hypoxia by 18F-EF5 PET Scanning and Glycolysis by 18FFDG PET Scanning in Subjects With Non-Small Cell Lung Cancer [NCT01017133]	Phase 1	56 participants (Anticipated)	Interventional	2009-05-31	Completed
The Diagnostic Value of 18F-2-fluoro-2-deoxy-D-glucose Fluorodeoxyglucose-Positron-Emission-Tomography/Magnetic-Resonance Imaging (PET/MRI) for Cervical Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma [NCT04117139]		142 participants (Anticipated)	Interventional	2019-10-01	Recruiting
Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery: A Multicenter, Prospective, Randomized Study [NCT02637479]		40 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Non-invasive Diagnosis and Management of Subclinical Rejection in Kidney Transplant Patients Using 18F-fluorodeoxy Glucose Positron Emission Tomography (18FDG-PET/CT) [NCT04702022]		50 participants (Anticipated)	Interventional	2021-01-04	Recruiting
Diagnostic and Prognostic Significance of Combined PET/MRI in Inflammatory Cardiomyopathies and Sarcoidosis [NCT03356756]		60 participants (Anticipated)	Observational	2016-06-27	Recruiting
A Pilot Study of 18F Fluorothymidine (FLT) PET/CT in Lymphoma [NCT00775268]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2008-09-29	Terminated
Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer [NCT01031875]	Phase 2	41 participants (Anticipated)	Interventional	2009-12-31	Completed
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors [NCT05436093]		15 participants (Anticipated)	Interventional	2022-06-23	Recruiting
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma [NCT01146054]	Phase 2	59 participants (Actual)	Interventional	2009-10-31	Completed
Phase II Single-Arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess the Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Cell Lung Cancer [NCT00963807]	Phase 2	26 participants (Actual)	Interventional	2009-09-30	Completed
Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endomet [NCT00416455]	Phase 1/Phase 2	384 participants (Actual)	Interventional	2007-09-30	Completed
Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer: Prospective Observational Study [NCT05260606]		100 participants (Anticipated)	Observational [Patient Registry]	2022-05-09	Recruiting
Single-tracer Multiparametric PET Imaging [NCT06014515]	Early Phase 1	60 participants (Anticipated)	Interventional	2024-01-31	Recruiting
A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma [NCT01286272]	Phase 2	135 participants (Actual)	Interventional	2011-04-08	Active, not recruiting
Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study [NCT00006421]		200 participants (Actual)	Observational	2000-10-25	Completed
A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine [NCT02226276]		10 participants (Actual)	Interventional	2015-01-07	Active, not recruiting
Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis [NCT04943211]	Phase 3	150 participants (Anticipated)	Interventional	2021-04-01	Recruiting
Pilot Study of Ex-Vivo Molecular Polyp Imaging Using 18-F Fluorodeoxyglucose (FGD) Positron Emission Tomography (PET) in the Determination of Protein and Gene Expression Signatures of Premalignant Polyps [NCT00550628]		8 participants (Actual)	Observational	2007-09-30	Completed
Evaluation of Metabolic Changes in FDG PET/CT Imaging After mRNA-based COVID-19 Vaccination [NCT05270967]		129 participants (Actual)	Observational	2021-07-29	Completed
A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC) [NCT00864110]	Phase 1	4 participants (Actual)	Interventional	2010-04-30	Completed
PET-imaging of Unruptured Intracranial Aneurysm Inflammation [NCT04715503]		20 participants (Anticipated)	Interventional	2021-01-14	Recruiting
A Phase 2 Study of Triapine® (NSC #663249) and Cisplatin in Combination With Pelvic Radiation for Treatment of Stage IB2-IVa Cervical Cancer or Stage II-IV Vaginal Cancer [NCT00941070]	Phase 2	26 participants (Actual)	Interventional	2009-07-31	Completed
PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor [NCT05803746]		20 participants (Anticipated)	Interventional	2022-07-15	Recruiting
A Study to See if a New Type of Imaging Can Help Our Understanding of the Course of Non-small Cell Lung Cancer in Patients Undergoing Treatment With Radiotherapy or Chemoradiotherapy [NCT00765986]		30 participants (Anticipated)	Observational	2008-10-31	Recruiting
Contribution of Positron Emission Tomography in Biological Targeting by Conformational Radiotherapy and Intensity-modulated Radiotherapy of Ear, Nose and Throat Tumors [NCT00809016]		40 participants (Anticipated)	Interventional	2007-05-31	Completed
A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy [NCT00729157]	Phase 2	41 participants (Actual)	Interventional	2008-08-31	Completed
A Pilot Study of Dual Time Point FDG PET MR Imaging Optimization for the Evaluation of Brain Metastasis [NCT05054998]	Phase 4	20 participants (Anticipated)	Interventional	2018-08-03	Recruiting
Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging With Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC [NCT02607423]	Phase 2	0 participants (Actual)	Interventional	2015-11-19	Withdrawn(stopped due to The study failed to meet its accrual targets.)
Early Changes in 18F-fluorodeoxyglucose Positron Emissions Tomography (18F-FDG-PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI) [NCT02043002]		67 participants (Actual)	Interventional	2013-04-30	Completed
Study of Positron Emission Tomography With 18-fluorodeoxyglucose in Detecting Cancer in Patients With Idiopathic Venous Thromboembolism [NCT00964275]		400 participants (Actual)	Interventional	2009-03-31	Completed
Epileptogenic Focus Localization for Children With Epilepsy Using 18F-FDG PET Molecular Imaging [NCT04725162]		234 participants (Actual)	Observational	2014-07-01	Completed
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study [NCT02938546]	Phase 3	200 participants (Anticipated)	Interventional	2016-11-30	Not yet recruiting
Phase I Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) With Patients With Head and Neck Tumor [NCT00406289]	Phase 1	24 participants (Anticipated)	Interventional	2006-11-30	Completed
A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients [NCT00983697]		292 participants (Anticipated)	Interventional	2010-04-01	Active, not recruiting
Early Positron Emission Tomography as a Predictor of Response in Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer [NCT00227539]	Phase 2	25 participants (Actual)	Interventional	2005-07-31	Completed
Molecular Imaging of Cerebral Amyloid Plaques Using PET With Fluoro Tracker for Early Diagnosis of Alzheimer's Disease [NCT01325259]	Phase 2	54 participants (Actual)	Interventional	2009-04-30	Completed
Use of Integrated PET/CT as a First Line Staging and Re-staging Technique in Oncologic Patient. [NCT06168877]		30 participants (Actual)	Observational	2009-10-21	Completed
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Varying Risk Factors for Alzheimer's Disease and Subjects on a Diet Intervention [NCT03130036]		60 participants (Anticipated)	Interventional	2015-06-09	Enrolling by invitation
An Evaluation of Preoperative Chemotherapy With Irinotecan and Cisplatin for Advanced, But Resectable Gastric Cancer: A Coordinated Multidisciplinary, Multicenter Study Linking Functional Imaging, Genomic Expression Profiles and Histopathology [NCT00062374]	Phase 2	55 participants (Actual)	Interventional	2003-06-30	Completed
Multicenter Prospective Pilot Study Investigating Pathophysiology, Diagnostic and Therapeutic Strategies of Hepatosplenic Candidiasis [NCT01916057]		100 participants (Actual)	Interventional	2013-11-19	Completed
Autologous Blood or Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma Based on Early [18F] FDG-PET Scanning [NCT00238368]	Phase 2	59 participants (Actual)	Interventional	2004-02-29	Completed
FDG PET/MR Imaging of Peripheral Pain Generators in Persistent Post-Surgical Pain (PPSP) [NCT06171659]		128 participants (Anticipated)	Observational	2023-12-31	Recruiting
The Beneficial Value of 18F FDG PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients: the NVALT31-PET Study [NCT06082492]		690 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
RELATIONSHIP BETWEEN THORACIC AORTIC STRUCTURE ASSESSED BY PET/CT SCAN AND ARTERIAL STIFFNESS IN ELDERLY PATIENTS: FICTEP STUDY [NCT01963221]		30 participants (Actual)	Interventional	2010-01-31	Completed
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC [NCT04214262]	Phase 3	480 participants (Anticipated)	Interventional	2020-08-13	Recruiting
Phase I Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer [NCT02213497]	Phase 1	30 participants (Anticipated)	Interventional	2014-04-30	Active, not recruiting
Evaluation of 18F-2-fluoro-2-deoxy-D-glucose Produced by a New Manufacturer, for Safety, Through the Identification of Adverse Events, and Efficacy, Through the Evaluation of Its Ability, When Utilized in Performance of a Positron Emission Tomography Comp [NCT04615156]	Phase 3	10,000 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
Positron Emission Tomography Using 11C Topotecan in Predicting Response to Treatment in Patients With Brain Metastases Due to Ovarian, Small Cell Lung, or Other Cancer [NCT00253461]	Early Phase 1	7 participants (Actual)	Interventional	2004-12-31	Terminated(stopped due to Drugs unavailable:unable to make radioactive topotecan)
Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging [NCT02003456]	Early Phase 1	30 participants (Actual)	Interventional	2013-12-31	Completed
Clinical Applications of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracer 68Ga-DOTA-F2 PET/CT Imaging for Malignant Tumors [NCT05637034]		30 participants (Anticipated)	Interventional	2022-09-15	Recruiting
A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer [NCT06179303]	Phase 2	60 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma [NCT06103838]	Phase 2	55 participants (Anticipated)	Interventional	2024-01-03	Not yet recruiting
Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma [NCT01132807]	Phase 2	164 participants (Actual)	Interventional	2010-05-31	Completed
Dissection of Aorta: Descending Part, Imaging [NCT01648881]		89 participants (Actual)	Observational	2011-05-31	Completed
68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies [NCT05506566]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2022-05-01	Recruiting
Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults (30-49yo) [NCT01609335]	Phase 1	41 participants (Actual)	Interventional	2012-07-31	Completed
Early Assessment of Response to Dual Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma Using 18F-FLT PET/CT and PET/MR [NCT02891616]	Phase 1	4 participants (Actual)	Interventional	2016-10-10	Terminated(stopped due to Low accrual rate)
A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Soft Tissue Sarcoma [NCT01169350]	Phase 2	8 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to funding source ended earlier than anticipated)
Effects of Chemotherapy on Brain Structure and Function [NCT00755313]		81 participants (Actual)	Observational	2007-05-31	Completed
Vorinostat to Augment Response to Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer [NCT06145633]	Phase 2	15 participants (Anticipated)	Interventional	2024-04-01	Not yet recruiting
Creation of a Database of PET Digital Brain Exams, Adapted to a Population Aged 50 Years and Over, to Help in the Interpretation of Fluoro Desoxy Glucose (FDG) Labelled With Fluor 18 (18F-FDG) PET/CT (Computer Tomography) Exam [NCT04163276]		80 participants (Actual)	Observational	2008-01-02	Completed
A Prospective Study of the Diagnostic Accuracy of the Augmented Whole-body Scanning Via Magnifying PET (AWSM-PET) Technique Versus the Standard-of-care (SOC) FDG PET/CT for Malignant Lesion Detection [NCT05513027]		35 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Longitudinal Assessment of Amyloid Positron Emission Tomography (PET), Fludeoxyglucose F18 (FDG) PET, Tau PET, Magnetic Resonance Imaging (MRI), and Blood Spot Ribonucleic Acid (RNA) in Down Syndrome Individuals With and Without Alzheimer's Dementia and N [NCT02759887]		19 participants (Actual)	Interventional	2016-11-30	Completed
FDG and FDOPA PET Demonstration of Functional Brain Abnormalities [NCT04315584]	Early Phase 1	5 participants (Anticipated)	Interventional	2020-03-15	Recruiting
Evaluation of Somatostatin Receptor Imaging Using PET/MRI as a Novel Approach to Detecting Pathology in Pulmonary TB [NCT02845570]	Phase 1	8 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Reproducibility of 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR [NCT02717572]	Phase 1	19 participants (Actual)	Interventional	2016-03-01	Completed
Prospective Longitudinal Observation Trial of Clinical and Molecular Features of Pancreatic Neuroendocrine Tumours [NCT03741517]		40 participants (Anticipated)	Observational [Patient Registry]	2019-01-30	Recruiting
Longitudinal Measurement of Synaptic Density to Monitor Progression of Huntington's Disease. [NCT04701580]		33 participants (Actual)	Interventional	2020-01-14	Completed
Combined 68Ga-DOTATATE and 18F-FDG PET/CT Imaging in Patients With Well-differentiated, G2-G3, Gastroenteropancreatic (GEP)-Neuroendocrine Tumors (NETs) - A Pilot Study [NCT04804371]		40 participants (Anticipated)	Interventional	2021-03-04	Active, not recruiting
NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial With Either Rituximab or Mosunetuzumab [NCT05886036]	Phase 2	70 participants (Anticipated)	Interventional	2024-07-27	Recruiting
A Prospective Study on Predicting the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer. [NCT05140746]		40 participants (Anticipated)	Interventional	2020-09-10	Recruiting
Dual Time Point FDG PET Imaging Optimization for the Evaluation of Glioblastoma [NCT02885272]	Early Phase 1	21 participants (Actual)	Interventional	2016-10-28	Completed
A Pilot Study of 18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients After Treatment for a Pulmonary Exacerbation [NCT00684346]	Phase 3	20 participants (Actual)	Interventional	2008-04-30	Completed
Comparison of 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT and Ultrasound in Staging of Patients With Malignant Melanoma: An Analysis in a Single Patient Population [NCT04253574]		258 participants (Actual)	Observational	2014-09-01	Completed
Creation of a Probabilistic Atlas of Normal Cerebral Uptake of 18F-FDG in PET/MRI. [NCT05355857]		39 participants (Actual)	Interventional	2022-08-10	Completed
Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection [NCT00373711]		0 participants (Actual)	Observational	2007-05-31	Withdrawn(stopped due to Abandoned)
Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial [NCT05710328]	Phase 2	235 participants (Anticipated)	Interventional	2023-05-10	Recruiting
Use of [18F]FDG PET/MRI in the Diagnosis of Pain Generators and/or Sites of Inflammation and to Monitor Treatment Effects in Patients With Chronic Pain [NCT03195270]	Phase 1	88 participants (Actual)	Interventional	2014-11-24	Completed
Simultaneous Fluorodeoxyglucose and Magnetic Resonance Imaging (18F-FDG PET/MR) Study of Metabolic and Structural Changes in Visual Snow Syndrome Compared to Healthy Controls [NCT05569733]		22 participants (Actual)	Observational	2017-01-02	Completed
A Phase I Study Evaluating the Efficacy and Toxicity of Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer [NCT01494012]	Phase 1	1 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to low accrual)
Monitoring Targeted Lung Cancer Treatments With FDG-PET/CT [NCT00450567]		36 participants (Actual)	Observational	2004-12-31	Completed
The H10 EORTC/GELA/IIL Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Supradiaphragmatic Stage I/II Hodgkin's Lymphoma [NCT00433433]	Phase 3	1,952 participants (Actual)	Interventional	2006-10-31	Active, not recruiting
Phase I/II Study on Induction Chemotherapy Followed by Chemoradiation With or Without Lapatinib, a Dual EGFR/ErbB2 Kinase Inhibitor, in Patients With Locally Advanced Larynx and Hypopharynx Squamous Cell Carcinoma [NCT00498953]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2007-05-31	Completed
Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT [NCT02902757]		50 participants (Anticipated)	Interventional	2015-08-25	Recruiting
d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis [NCT03549598]	Phase 4	15 participants (Actual)	Interventional	2018-07-20	Completed
Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography /Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma [NCT02931201]		100 participants (Anticipated)	Interventional	2016-10-31	Recruiting
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma [NCT02928861]		100 participants (Anticipated)	Interventional	2016-10-31	Recruiting
Improved Visualization of Glioblastoma Using Delayed 18F-FDG PET/CT. [NCT02919332]		0 participants (Actual)	Observational	2016-06-08	Withdrawn(stopped due to No participants were enrolled)
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma [NCT05321316]		20 participants (Anticipated)	Interventional	2022-05-31	Recruiting
Clinical Evaluation of PET-MRI Versus PET-CT in Pediatric Oncology Patients [NCT02287636]		13 participants (Actual)	Interventional	2013-04-30	Completed
A Pilot Study of Novel Imaging Modalities in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM) [NCT01237054]	Phase 2	31 participants (Actual)	Interventional	2010-10-17	Completed
Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy [NCT02149173]		29 participants (Actual)	Interventional	2010-09-15	Terminated(stopped due to Terminated due to low accrual)
Evaluation of 18F-FDG PET/CT in Diagnosis and Response Assessment of Patients With IgG4-Related Disease [NCT01665196]	Early Phase 1	100 participants (Anticipated)	Interventional	2012-09-30	Recruiting
Glucidic Metabolism, Ossification and Arterial Calcification During PseudoXanthoma Elasticum (PXE) [NCT03070860]		23 participants (Actual)	Interventional	2016-11-30	Completed
Distribution of Eosinophils in Asthma After Reslizumab (DEAR). A 7-Week, Placebo-Controlled, Double-Blinded, Parallel-Group, Imaging Study Using Positron Emission Tomography/Computer Tomography (PET/CT) to Characterize the Effect of Intravenous Reslizumab [NCT02937168]	Phase 4	5 participants (Actual)	Interventional	2017-05-08	Terminated(stopped due to The study was terminated early due to challenges in recruitment. The decision to terminate the study was not related to any safety issues or concerns.)
A Pilot Study to Compare 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) Scanning in Addition to CT Scanning With CT Scanning Alone in the Pre-Operative Evaluation of Patients With Stage III and IV Melanoma [NCT00004152]	Phase 2	0 participants	Interventional	1999-02-28	Completed
18F-FDG PET/CT in Diagnostic Patients of Disorder of Consciousness [NCT02999490]		20 participants (Actual)	Interventional	2016-03-31	Completed
Optimized Arterial Spin Labeling MRI for Cognitive Decline [NCT01727622]		102 participants (Actual)	Observational	2012-08-31	Completed
Investigation of the Use of Positron Emission Tomography With 18F-FDG PET/CT for the Diagnosis of Synovitis in the Temporomandibular Joint [NCT01471418]	Phase 2	0 participants (Actual)	Interventional	2011-12-31	Withdrawn(stopped due to 29-Apr-14 UPENN IRB granted approval to close study due to lack of funding)
A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma [NCT01476410]	Phase 2	48 participants (Actual)	Interventional	2011-11-30	Active, not recruiting
Positron Emitter I-124-Iododeoxyuridine to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer: Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose, as a Tracer for Glycolysis [NCT00109785]	Phase 1	8 participants (Actual)	Interventional	1997-03-31	Completed
Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy [NCT01663753]		146 participants (Actual)	Interventional	2012-03-31	Completed
68Ga-FAPI-04 PET Imaging in Early Response Evaluation of Rectal Cancer Patients Treated With Immunotherapy: A Single-center Clinical Study [NCT05999227]		20 participants (Anticipated)	Interventional	2023-06-20	Recruiting
Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-targeted Therapy [NCT04692103]	Phase 2	2 participants (Actual)	Interventional	2021-07-10	Active, not recruiting
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma [NCT00086801]	Phase 2	104 participants (Actual)	Interventional	2004-05-31	Completed
Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma [NCT00095693]	Phase 2	25 participants (Actual)	Interventional	2004-10-31	Terminated
First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents [NCT00433459]	Phase 3	2,134 participants (Actual)	Interventional	2007-01-31	Completed
Prognostic Significance of Early Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F] FDG) in Intermediate and High Grade Non-Hodgkin's Lymphoma [NCT00110006]		0 participants (Actual)	Interventional	2004-12-31	Withdrawn(stopped due to No accrual)
A Pilot Study on the Efficacy of Advanced 18F-FDG PET-MRI in Spine Stereotactic Radiosurgery [NCT05174026]		10 participants (Actual)	Interventional	2018-11-30	Active, not recruiting
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE [NCT04316117]	Phase 2	138 participants (Actual)	Interventional	2020-09-15	Active, not recruiting
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer [NCT03952585]	Phase 2/Phase 3	590 participants (Anticipated)	Interventional	2019-10-09	Suspended(stopped due to End of Initial Phase of Multi-phase protocol)
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT [NCT03604315]	Phase 1	120 participants (Anticipated)	Interventional	2018-12-18	Recruiting
International Multicenter Trial on the Prognostic Value of Arterial 18F-FDG PET Imaging in Patients With History of Myocardial Infarction [NCT05138718]		2,041 participants (Anticipated)	Observational [Patient Registry]	2021-12-01	Recruiting
A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging [NCT01004718]		10 participants (Actual)	Interventional	2009-05-31	Completed
Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy. [NCT01129206]	Phase 2	6 participants (Actual)	Interventional	2010-07-31	Completed
A Pilot Comparison of 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients [NCT05432947]		42 participants (Actual)	Interventional	2022-04-14	Completed
A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL) [NCT01359592]	Phase 2	159 participants (Actual)	Interventional	2011-09-30	Active, not recruiting
Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac Sarcoidosis [NCT03048097]	Early Phase 1	15 participants (Actual)	Interventional	2017-02-01	Completed
Direct Imaging of Ischemia With 18F-FDG PET Imaging Combined With Coronary Anatomy From CT Coronary Angiography [NCT01520025]	Phase 4	18 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Continued recruitment of study participants was not feasible)
Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis : Neuropsychological, Imaging and Neuropathological Study [NCT01530438]		90 participants (Anticipated)	Interventional	2009-04-30	Recruiting
Phase I Trial of The Combination of Vismodegib and Sirolimus [NCT01537107]	Phase 1	31 participants (Actual)	Interventional	2012-03-05	Completed
A Prospective Study of the Predictive and Prognostic Value of Multimodalitic Imaging in the N-stage of Lung Cancer [NCT05840094]		100 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
Prospective Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Multimodality Management of Locally Advanced Primary Rectal Cancer [NCT00004891]		149 participants (Actual)	Interventional	1999-09-30	Completed
A Pilot Study To Assess The Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) In The Pre-Operative Evaluation Of Patients With Primary And Recurrent Breast Carcinoma [NCT00039286]	Phase 1	118 participants (Actual)	Interventional	2001-10-31	Completed
Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities [NCT00001568]	Phase 2	200 participants	Interventional	1997-02-28	Completed
Study on the Prediction of Groin Lymphonodal Status Through 18FDG-PET/CT Combined With Sentinel Lymph Node Biopsy in Bulky a/o Multifocal a/o Pretreated Vulvar Cancer, N0 at Conventional Imaging (GRO-SNaPET Study) [NCT02969278]		50 participants (Anticipated)	Interventional	2013-07-31	Recruiting
Detection of Hepatocellular Carcinoma by Positron Emission Tomography With C-Acetate-11 and F-fluorodeoxyglucose-18 [NCT00081094]		31 participants (Actual)	Interventional	2003-09-30	Completed
Positron Emission Tomography Pre- and Post-treatment Assessment For Locally Advanced Non-Small Cell Lung Carcinoma [NCT00083083]	Phase 2	250 participants (Anticipated)	Interventional	2005-03-31	Active, not recruiting
[18F]FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-Small Cell Lung Cancer [NCT00424138]		96 participants (Actual)	Interventional	2007-03-30	Terminated(stopped due to Recruitment obstacles; data to be combined with other resources for analysis)
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis [NCT01806675]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2013-03-04	Completed
Energy Expenditure and Brown Adipose Tissue in Amyotrophic Lateral Sclerosis [NCT03150290]		10 participants (Actual)	Interventional	2017-10-26	Completed
64Cu-DOTATATE PET-CT-skanning to Diagnose Macrophage Infiltration in the Heart Valves of Patients With Infective Endocarditis. [NCT05432427]		65 participants (Anticipated)	Interventional	2022-04-28	Recruiting
The Use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to Assess the Effects of Anti-neoplastic Therapy on Tumor Associated Vasculature [NCT00019565]	Phase 1	53 participants (Actual)	Interventional	1998-10-31	Completed
A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls. [NCT01890343]	Phase 2	34 participants (Actual)	Interventional	2009-09-30	Completed
A Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of Flavopiridol in Patients With Refractory Solid Tumors and Hematologic Malignancies [NCT00070239]	Phase 1	100 participants (Actual)	Interventional	2003-08-31	Terminated
Comparison of Positron Nuclide Labeled DOTA-FAPI PET and FDG PET Study in Colocrectal Cancer [NCT04750772]		60 participants (Anticipated)	Interventional	2019-10-16	Recruiting
A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image [NCT00146458]	Phase 3	200 participants	Interventional	2002-01-31	Active, not recruiting
A Study Of 18 FDG PET In The Prediction Of Relapse In Patients With A Clinical Stage I Non-Seminomatous Germ Cell Tumor [NCT00045045]		0 participants	Interventional	2002-05-31	Completed
[NCT00200668]		0 participants (Actual)	Interventional	2005-03-31	Terminated
A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer [NCT00559377]	Phase 2	16 participants (Actual)	Interventional	2007-11-30	Completed
Assessment of Diagnostic Accuracy of 18FDG-PET-CT in Patients With Suspicion of Pacing or Defibrillation Lead Infection: a Prospective Multi-center Study [NCT02251262]		235 participants (Actual)	Interventional	2015-06-22	Completed
The Utility of FDG-PET and PET/CT in the Evaluation of Patients With Suspected Cholecystitis [NCT00590395]		19 participants (Actual)	Interventional	2007-07-31	Completed
Pilot Project for Creation of the DLBCL Response Prediction Model: Combining Early Interim Functional Imaging, Detection of a Tumor-Specific Clonotype and Metabolic Profiling of Blood of in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma t [NCT02405078]	Early Phase 1	35 participants (Actual)	Interventional	2015-10-13	Completed
Assessment of the Heterogeneity of Estrogen Receptor Expression in Patients With Estrogen Receptor Positive Breast Cancer Using F-18 Fluoroestradiol and High Resolution Positron Emission Mammography [NCT03266562]		0 participants (Actual)	Interventional	2018-09-01	Withdrawn(stopped due to unable to recruit patients due to competing studies)
A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer [NCT00735917]	Phase 2	19 participants (Actual)	Interventional	2008-10-31	Completed
Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma [NCT04367948]		200 participants (Anticipated)	Interventional	2020-05-01	Not yet recruiting
Characterization of Radiolabeled Tracer Uptake Pattern in Noninfected Transcatheter Aortic Valves. The COUNT Study. A Prospective, Observational Study. [NCT03683355]		30 participants (Anticipated)	Observational	2018-11-09	Active, not recruiting
CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients [NCT04512118]		22 participants (Actual)	Observational	2020-03-15	Completed
Evaluation of PET-MRI in Initial Staging of High Grade Rectal Cancer Patients and in the Follow up of Colorectal Cancer Patients. [NCT01807117]		15 participants (Actual)	Interventional	2013-04-30	Completed
18F-FDG PET/CT in the Diagnosis of Tuberculous Pericarditis [NCT05458089]		11 participants (Actual)	Observational	2015-01-01	Completed
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer [NCT03173924]	Phase 2	180 participants (Anticipated)	Interventional	2017-06-06	Enrolling by invitation
Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT01507428]	Phase 2	138 participants (Actual)	Interventional	2012-02-22	Active, not recruiting
PiB PET Scanning in Speech and Language Based Dementias [NCT01623284]	Phase 1	168 participants (Actual)	Interventional	2010-03-31	Completed
A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer [NCT01652196]	Phase 2	56 participants (Actual)	Interventional	2012-11-14	Active, not recruiting
LCCC 1209: Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) for Staging of Muscle-Invasive Bladder Cancer [NCT01655745]		22 participants (Actual)	Interventional	2012-07-24	Completed
Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes [NCT01664936]		27 participants (Actual)	Observational	2012-08-08	Completed
LCCC 1213: Defining Molecular and Functional Imaging Correlates of Renal Cell Carcinoma Biological Features [NCT01665703]		17 participants (Actual)	Interventional	2012-08-31	Completed
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy [NCT01666353]	Early Phase 1	20 participants (Actual)	Interventional	2012-04-16	Completed
Dual-Time Point (DTP) FDG PET CT for the Post-Treatment Assessment of Head and Neck Tumors Following Definitive Chemoradiation Therapy [NCT03575949]		50 participants (Anticipated)	Interventional	2018-06-15	Recruiting
SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study [NCT05501665]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2023-05-09	Recruiting
Reliability Of The Human Brain Connectome [NCT02193425]	Early Phase 1	112 participants (Actual)	Interventional	2015-06-08	Completed
FDG PET/CT: Reducing False Positive Mediastinal Uptake by Premedicating With Methylprednisolone [NCT01789892]		0 participants (Actual)	Interventional	2011-06-30	Withdrawn(stopped due to no patient accrual)
The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ) [NCT01824056]	Phase 2	120 participants (Actual)	Interventional	2010-08-31	Completed
A Pilot Study of the Utility of 18F-FLT-PET and Diffusion-Weighted MRI for Surgical Planning, Radiotherapy Target Delineation, and Treatment Response Evaluation in Ewing Sarcoma Patients [NCT01825902]	Early Phase 1	1 participants (Actual)	Interventional	2013-03-31	Completed
A Single-blind Study to Evaluate the Efficacy and Safety of 18F-Fluorodeoxygalactose (18F-FDGal) Compared to 18F-Fluorodeoxyglucose (18F-FDG) to Detect Hepatocellular Carcinoma Via PET/CT in Patients With Cirrhosis or Chronic Liver Disease [NCT02899325]		0 participants (Actual)	Observational	2019-10-31	Withdrawn(stopped due to PIs will not pursue trial due to staff and time constraints)
A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B [NCT01720602]		15 participants (Actual)	Interventional	2012-11-30	Completed
A Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide in Chemo-Naïve Patients With Progressive Prostate Cancer Who Have Failed Androgen Deprivation Therapy (Castration-resistant Prostate Cancer Patients) [NCT02814968]	Phase 2	66 participants (Actual)	Interventional	2015-02-28	Completed
Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT) [NCT02773238]	Phase 2	56 participants (Actual)	Interventional	2016-05-20	Completed
Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study [NCT05806697]		240 participants (Anticipated)	Interventional	2023-04-17	Not yet recruiting
Positron Emission Tomography for the Diagnosis of Immune Checkpoint Inhibitor-Related Myocarditis [NCT05062395]		13 participants (Actual)	Observational	2021-03-30	Completed
Intra-operative Lymph Node Evaluation Using a Hand Held PET Gamma Probe in Endometrial Cancer Surgery - A Pilot Study [NCT01467219]		12 participants (Actual)	Interventional	2012-01-31	Completed
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia [NCT04311515]	Phase 2	4 participants (Actual)	Interventional	2020-06-30	Terminated(stopped due to Samus Therapeutics company closure)
Assessment of the Minimal Residual Disease in Diffuse Large B-Cell Lymphomas (DLBCL) From Cell-free Circulating DNA by Next Generation Sequencing (NGS) [NCT02339805]		30 participants (Actual)	Interventional	2014-11-01	Completed
A Pilot Study of Sirolimus (Rapamycin, Rapamune[Registered Trademark]) in Subjects With Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN [NCT00971789]	Phase 2	18 participants (Actual)	Interventional	2008-07-31	Completed
FDG-PET/CT as a Biomarker for Treatment Response in Advanced Melanoma [NCT02236546]		3 participants (Actual)	Interventional	2012-05-31	Terminated(stopped due to loss of funding)
[F18]EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Carcinoma of the Cervix [NCT00978874]		15 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to The PI is no longer with our institution)
A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer [NCT00602043]	Phase 2	20 participants (Actual)	Interventional	2008-09-30	Completed
Multi-tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents [NCT01243333]		26 participants (Actual)	Interventional	2011-02-02	Terminated
Novel Imaging Modalities For Plexiform Neurofibromas [NCT00060008]		18 participants (Actual)	Interventional	2002-04-30	Terminated(stopped due to Study was closed early due to poor accrual.)
The Utility of Positron Emission Tomography (PET) in Staging of Patients With Potentially Operable Non-Small Cell Lung Carcinoma [NCT00004138]		303 participants (Actual)	Interventional	1999-09-30	Completed
Longitudinal Early-onset Alzheimer's Disease Study Protocol [NCT03507257]		700 participants (Anticipated)	Observational	2018-04-30	Recruiting
Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma [NCT04759235]		118 participants (Anticipated)	Observational	2020-01-01	Recruiting
11C-Methionine and 2-18F-Fluoro-2-Deoxy-D-Glucose PET Imaging in Patients With Progressive Prostate Cancer [NCT00002981]		173 participants (Actual)	Interventional	1997-01-31	Completed
Evolution of Lung 18FDG Uptake in Patients With Idiopathic Pulmonary Fibrosis and Receiving Pirfenidone [NCT03692481]		50 participants (Anticipated)	Interventional	2020-02-04	Recruiting
A 2 Phase Comparison of Pre-operative CT AND PET Images in the Intraoperative Detection of Disease to a Hand-held Probe, and to an Intraoperative CT Scan in Patients Undergoing Surgery for Metastatic Colorectal Cancer. [NCT01821105]	Phase 2	21 participants (Actual)	Interventional	2004-03-31	Completed
PET Imaging of Lung Cancer and Indeterminate Pulmonary Nodules With 18F-FSPG [NCT02448225]	Phase 2	46 participants (Actual)	Interventional	2015-06-16	Completed
Does Ultra Short-term Steroid Therapy Increase the Accuracy of FDG-PET/CT in Evaluation of Pulmonary Nodules? [NCT00906503]	Phase 1	9 participants (Actual)	Interventional	2009-04-30	Completed
Value of PET/ CT in the 68Ga-NODAGA-RGD for the Evaluation of the Tumoral Neoangiogenesis [NCT02666547]	Phase 1	120 participants (Anticipated)	Interventional	2014-03-31	Recruiting
T Cell Effector and Regulatory Mechanisms in Asthma [NCT01612936]	Phase 1	168 participants (Actual)	Interventional	2012-09-30	Completed
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies [NCT01697527]	Phase 2	6 participants (Actual)	Interventional	2012-11-02	Active, not recruiting
PET/CT Evaluation of Subjects Treated on Surgery Branch Adoptive Cell Therapy Protocols [NCT00316901]	Phase 2	70 participants (Anticipated)	Interventional	2006-04-30	Completed
Evaluation of a Low-Carbohydrate Diet to Highlight Easily Infective Endocarditis by 18F-FDG PET [NCT03465098]		26 participants (Actual)	Interventional	2018-03-19	Completed
Noninvasive Assessment of Abdominal Aortic Aneurysm (AAA) Wall Structural Integrity and Inflammation as Predictors of Expansion and/or Rupture [NCT03231397]	Phase 4	2 participants (Actual)	Interventional	2017-08-01	Terminated(stopped due to We were unable to recruit more subjects who met the inclusion/exclusion criteria and we have closed the study.)
Whole-Body 18F-Fluorodeoxyglucose Positron Emission Tomography to Measure the Response to Induction Chemotherapy of Potentially Resectable Lung and Esophageal Carcinomas [NCT00002930]	Phase 2/Phase 3	75 participants (Anticipated)	Interventional	1996-12-31	Completed
Biological Interconnection Between Stress-associated Neurobiological Activity and Atherosclerotic Plaque Instability: A Prospective Cohort Study With OCT-FLIM Dual-modal Intravascular Imaging and Serial 18F-FDG-PET/CT Assessment [NCT04853511]		200 participants (Anticipated)	Observational [Patient Registry]	2022-02-14	Recruiting
The Utility of Positron Emission Tomography (PET) in Staging of Patients With Potentially Operable Carcinoma of the Thoracic Esophagus [NCT00004867]		235 participants (Actual)	Interventional	1999-11-30	Completed
Natural History of Metabolic Abnormalities in Children With Epilepsy [NCT00001325]		80 participants	Observational	1992-04-30	Completed
Comparative Study of 18F-FAPI and 18F-FDG PET/CT for Gastrointestinal Cancer [NCT05788874]		50 participants (Anticipated)	Observational	2023-05-31	Not yet recruiting
Stress and Atherosclerotic Plaque Macrophages: A Systems Biology Approach - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients [NCT03279393]	Early Phase 1	190 participants (Actual)	Interventional	2017-11-28	Completed
PET Imaging of Breast Cancer Using Oncogene Expression [NCT02810873]		19 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to Study terminated by PI)
PET/CT-Guided Liver Tumor Ablation: Intraprocedural Assessment of Results Using Ammonia Perfusion PET [NCT02018107]		33 participants (Actual)	Interventional	2014-01-31	Completed
Copper Cu 64-ATSM and PET/CT Scan in Predicting Disease Progression in Patients With Newly-Diagnosed Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Undergoing Chemoradiotherapy Per NCCN Guidelines [NCT00794339]	Phase 2	73 participants (Actual)	Interventional	2009-07-29	Terminated(stopped due to transfer of funding)
A Pilot Study of 18F-Flourodeoxyglucose Positron Emission Tomography in the Diagnosis of Primary and Recurrent Cervical Cancer [NCT00003429]		0 participants	Interventional	1998-05-31	Completed
Phase I Study of Dose Escalation Using Image-guided Radiotherapy to Deliver a Stereotactic Radiosurgical Boost After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer [NCT00368329]	Phase 1	4 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to low accrual)
A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma [NCT05448404]		30 participants (Anticipated)	Interventional	2022-03-08	Recruiting
Evaluation Via PET Scan of Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder [NCT02329626]		20 participants (Actual)	Observational	2016-01-29	Completed
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Sarcoma: An Exploratory Biodistribution Study With Histopathology Validation [NCT04457258]	Early Phase 1	30 participants (Anticipated)	Interventional	2020-09-08	Recruiting
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma [NCT03051555]		60 participants (Anticipated)	Interventional	2017-03-01	Not yet recruiting
Evaluation of the Use of Intra-operative Molecular Imaging With BetaScope and in Vitro Measurement With LightPath Specimen Analyser Devices in Gastrointestinal Tumour Surgery [NCT02446379]		0 participants (Actual)	Observational		Withdrawn(stopped due to Technology licensed to third party. Sponsor did not proceed with study.)
Prediction and Unraveling of Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage Using Early Dynamic 18F-FDG PET/CT Assessment of Cerebral Glucose Uptake (PREDISP) [NCT04356599]		35 participants (Anticipated)	Interventional	2020-07-22	Recruiting
[NCT02394743]		360 participants (Actual)	Observational	2011-03-31	Completed
Study of Metabolic Connectivity in Drug-resistant Temporal Epilepsy [NCT05455047]		90 participants (Actual)	Observational	2022-02-01	Completed
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma: Pilot Study [NCT05422521]		20 participants (Anticipated)	Interventional	2022-08-29	Recruiting
Individualized Precise Radiotherapy With the Guidance of Radiosensitivity: A Study on the Clinical Management Model of Locally Advanced Cervical Cancer [NCT03163979]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2015-07-01	Recruiting
Evaluating the Potential Usefulness of 68Ga-FAP-2286 PET/CT in Patients With Various Types of Cancer and Compared With 18F-FDG PET/CT [NCT05392205]		67 participants (Actual)	Interventional	2022-03-01	Completed
The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG [NCT03138239]		16 participants (Anticipated)	Interventional	2017-07-02	Not yet recruiting
Usefulness of 18F-FDG PET/CT in the Initial Staging and Surveillance of Endometrial Cancer Patients [NCT05056259]		42 participants (Anticipated)	Observational	2022-01-01	Not yet recruiting
Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT [NCT05121779]	Phase 1	80 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG [NCT05543317]		27 participants (Actual)	Interventional	2022-07-01	Completed
Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR-CHOP, for Previously Untreated Diffuse Large B-Cell Lymphoma [NCT05455697]	Phase 1/Phase 2	35 participants (Anticipated)	Interventional	2023-01-26	Recruiting
Clinical Application of 18F-PEG3-FPN PET Imaging in Diagnosis and Staging of Malignant Melanoma [NCT04747561]		50 participants (Anticipated)	Interventional	2021-01-12	Recruiting
A Pilot Prospective Study of the Utility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI), Diffusion Weighted MRI (DWI)and Positron Emission Tomography (PET) Imaging With 18F-Fluorodeoxyglucose (18FDG) in Brachytherapy for Cervix Cancer [NCT01899404]		25 participants (Actual)	Interventional	2012-10-03	Completed
Detection of Functioning Pituitary Microadenoma With Inconclusive MRI Findings: PET/MRI Versus PET/CT [NCT03404414]	Phase 1	100 participants (Anticipated)	Interventional	2013-02-28	Recruiting
The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms [NCT00019604]	Phase 2	44 participants (Actual)	Interventional	1998-08-31	Terminated(stopped due to Principal investigator left the institution.)
Early Assessment of Response to Targeted Breast Cancer Therapy [NCT00362973]		42 participants (Actual)	Observational	2006-05-31	Completed
Imaging of Intracerebral Inflammation in the Progressive Phase of Multiple Sclerosis [NCT02305264]		61 participants (Actual)	Interventional	2012-03-19	Completed
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma [NCT03206060]	Phase 2	90 participants (Anticipated)	Interventional	2017-10-10	Recruiting
A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection [NCT01419067]	Phase 2	112 participants (Actual)	Interventional	2011-08-22	Active, not recruiting
Diagnostic Accuracy of MRI, Diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma [NCT01836484]		162 participants (Actual)	Observational	2012-06-30	Completed
A Pivotal Phase 3 Clinical Trial to Assess the Diagnostic Performance and Safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a Positron Emission Tomography (PET) Imaging Agent, Versus [18F]FDG PET/CT Imaging, for Staging of Patients With Confirmed Marginal Zon [NCT06125028]	Phase 3	148 participants (Anticipated)	Interventional	2023-12-15	Not yet recruiting
A Phase II Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Von Hippel Lindau Disease and Renal Tumors [NCT00088374]	Phase 2	9 participants (Actual)	Interventional	2004-07-31	Completed
Particle-based Partial Tumor Irradiation Targeting Hypoxic Segment and Sparing the Peritumoral Immune Microenvironment for Unresectable Bulky Tumors [NCT04875871]		22 participants (Anticipated)	Interventional	2021-11-11	Recruiting
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma [NCT03051581]		80 participants (Anticipated)	Interventional	2017-03-01	Not yet recruiting
Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/CT in Patients With Gastrointestinal Tumors and Compared With 18F-FDG PET/CT [NCT05430841]		100 participants (Anticipated)	Interventional	2022-06-01	Recruiting
Feasibility and Outcome of Cyberknife® Precision Hypofractionated Radiosurgery for the Curative Management of Non-Small Cell Lung Cancer [NCT00852644]		9 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to poor accrual)
Polymyalgia Rheumatica and Giant Cell Arteritis - Three Challenges - Consequences of the Vasculitis Process, Osteoporosis and Malignancy: A Prospective Cohort Study Protocol [NCT02985424]		80 participants (Anticipated)	Observational	2017-05-31	Not yet recruiting
A Prospective Study to Evaluate 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings [NCT04504110]	Phase 2	30 participants (Anticipated)	Interventional	2020-08-05	Recruiting
The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma [NCT05645484]		100 participants (Anticipated)	Observational	2022-09-02	Recruiting
TocilizuMab discontinuAtion in GIant Cell Arteritis [NCT06037460]	Phase 3	120 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Elucidating Mechanisms of Pain in Adolescent and Adult Fibrous Dysplasia Patients [NCT04125862]		40 participants (Anticipated)	Interventional	2021-01-05	Enrolling by invitation
Is Mediastinal Blood Pool SUV Ratio Valid in Identification of Malignancy in Comparison to Liver SUV Ratio? [NCT05258045]		55 participants (Anticipated)	Observational	2022-06-01	Not yet recruiting
[NCT02481726]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2014-03-31	Completed
Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours [NCT03130205]		30 participants (Anticipated)	Observational	2017-05-01	Recruiting
Evaluation of Regional Myocardial Perfusion, Glucose Utilization and Oxidative Metabolism in Patients With Pulmonary Hypertension Using Combined [11C]Acetate and [18F]Fluorodeoxyglucose (FDG) PET/CT and Cardiovascular MRI [NCT01917136]	Phase 2	21 participants (Actual)	Interventional	2013-08-31	Completed
Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Prosthetic Valve Endocarditis [NCT01916005]		174 participants (Actual)	Interventional	2014-02-05	Completed
Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients [NCT03583528]		800 participants (Anticipated)	Observational	2018-07-11	Recruiting
PET Imaging of Hepatocellular Carcinoma With 18F-FSPG [NCT02379377]	Phase 1	80 participants (Anticipated)	Interventional	2022-02-15	Recruiting
Highlighting the Benefits of Therapeutic Gardens in Alzheimer's Disease by 18F-FDG Cerebral PET /CT [NCT04514328]		0 participants (Actual)	Interventional	2022-08-02	Withdrawn(stopped due to the study never opened for pandemic reasons)
Contribution of PET Scans for the Preoperative Assessment of Symptomatic Endometriosis Lesions: TEP-ENDORUN [NCT04831619]	Phase 3	10 participants (Anticipated)	Interventional	2022-05-31	Not yet recruiting
Phase II Trial of Hypo-fractionated Highly Conformal Radiotherapy for Locally Advanced Pancreatic Carcinomas [NCT05191940]		30 participants (Anticipated)	Interventional	2022-05-16	Recruiting
Role of Positron Emission Tomography/Computed Tomography in Detecting Bone Metastases in Cancer Patients. [NCT04080271]		66 participants (Actual)	Observational	2019-11-01	Completed
Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer [NCT03474341]		200 participants (Anticipated)	Observational	2018-04-09	Recruiting
A Phase II Clinical Trial to Evaluate 18F-Fluoroestradiol Positron Emission Tomography / Computerized Tomography (PET/CT) Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer [NCT00816582]		17 participants (Actual)	Interventional	2010-11-30	Terminated(stopped due to Slow accrual)
Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma [NCT01462630]	Phase 2	29 participants (Actual)	Interventional	2011-11-03	Completed
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma [NCT03226249]	Phase 2	30 participants (Actual)	Interventional	2017-11-09	Active, not recruiting
Integrating Biomarkers From Serum/Plasma and Molecular Images to Predict Occult Distant Metastases in Nasopharyngeal Carcinoma Patients With M0 Disease [NCT04417985]		112 participants (Actual)	Interventional	2011-08-01	Completed
Comparison of the Performance of 18F-FDG PET/CT With That of Labeled Leukocyte Scintigraphy in the Follow-up of Malignant Otitis Externa. [NCT05994768]		18 participants (Actual)	Observational	2020-12-18	Completed
An Evaluation of PET/CT Imaging as a Predictor of Disease Free Survival Following Neo-Adjuvant Chemotherapy for Soft Tissue Sarcoma [NCT00346125]		70 participants (Actual)	Interventional	2006-04-10	Completed
Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging [NCT02494531]		45 participants (Actual)	Interventional	2015-12-12	Completed
Ultra-long Field-Of-View Positron Emission Tomography for Characterization of Indeterminate Lung Nodules: a Pilot Study Exploring Opportunities for Clinical Research [NCT05463913]	Phase 4	20 participants (Anticipated)	Interventional	2022-07-13	Recruiting
A Prospective Study to Evaluate the Inflammation and Fibrosis of Intestinal Stricture in Patients With Crohn's Disease by 18F-FDG and 68Ga-FAPI PET/CT [NCT04502303]	Phase 2	30 participants (Anticipated)	Interventional	2020-09-30	Not yet recruiting
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine [NCT00085293]	Phase 2	12 participants (Actual)	Interventional	2004-05-31	Completed
Early Response Evaluation With 18F-FDG PET/CT and Immunological Profiling of Circulating Immune Cells and Tumor-draining Lymph Nodes in Non-small Cell Lung Cancer Patients Treated With Immunotherapy. [NCT04082988]		9 participants (Actual)	Interventional	2018-01-23	Terminated(stopped due to The study has been closed due to slow enrollment.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00019604 (2) [back to overview]	Response
NCT00019604 (2) [back to overview]	Number of Participants With Adverse Events
NCT00043979 (14) [back to overview]	Early Post Transplantation Relapse
NCT00043979 (14) [back to overview]	Median Progression Free Survival
NCT00043979 (14) [back to overview]	Median Time to Reach a Platelet Count of 50,000/mm(3)
NCT00043979 (14) [back to overview]	Two Year Survival Rate for Patients Undergoing Allo-Hematopoietic Stem Cell Transplant
NCT00043979 (14) [back to overview]	Median Time to Reach Absolute Neutrophil Count of 500/mm(3)
NCT00043979 (14) [back to overview]	Number of Participants Who Experienced Graft Versus Tumor Effect (GVT)
NCT00043979 (14) [back to overview]	Number of Participants With Engraftment
NCT00043979 (14) [back to overview]	Cluster of Differentiation 4 (CD4) Reconstitution
NCT00043979 (14) [back to overview]	Toxicity
NCT00043979 (14) [back to overview]	Best Response Post-Hematopoietic Stem Cell Transplant EOCH (Etoposide, Vincristine, Cyclophosphamide, and Doxorubicin)
NCT00043979 (14) [back to overview]	Median Survival From Date of Progression
NCT00043979 (14) [back to overview]	Number of Participants to Complete Conversion to >95% Donor Chimerism
NCT00043979 (14) [back to overview]	Number of Participants With Acute and Chronic GVHD
NCT00043979 (14) [back to overview]	Post-Hematopoietic Stem Cell Transplant (HSCT) Radiotherapy
NCT00060008 (1) [back to overview]	Tumor Progression as Measured by Tumor Area and Volume at 1 Year.
NCT00062374 (2) [back to overview]	Histological Response Determined by FDG Uptake Correlates
NCT00062374 (2) [back to overview]	Disease Free Survival (DFS)
NCT00085293 (2) [back to overview]	Frequency of Adverse Events According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00085293 (2) [back to overview]	Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration
NCT00088374 (5) [back to overview]	The Number of Participants With Adverse Events
NCT00088374 (5) [back to overview]	Number of Patients in Whom Renal Tumors Could be Identified by Positron Emission Tomography (PET)Based on Fludeoxyglucose 18F (18FDG) Uptake
NCT00088374 (5) [back to overview]	Number of Participants With Flow Dynamics Measured by DCE MRI Within the Renal and Non-renal Tumor
NCT00088374 (5) [back to overview]	Number of Participants With a Renal Tumor Response
NCT00088374 (5) [back to overview]	Number of Participants With a Non-renal Tumor Response
NCT00227539 (3) [back to overview]	Positron Emission Tomography as a Predictor of Response Measured by the Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy
NCT00227539 (3) [back to overview]	Safety of Neoadjuvant Chemotherapy
NCT00227539 (3) [back to overview]	Efficacy of Neoadjuvant Chemotherapy as Measured by Radiologic Response Rate
NCT00375830 (9) [back to overview]	Cohort 1 - 18F-NaF PET/CT vs 18F-FDG PET/CT
NCT00375830 (9) [back to overview]	Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy
NCT00375830 (9) [back to overview]	Cohort 2 - 18F-NaF/18F-FDG PET/CT vs Whole-body MRI for Detection of Extraskeletal Lesions
NCT00375830 (9) [back to overview]	Cohort 2 - 18F-NaF/18F-FDG vs 99mTc-MDP Bone Scintigraphy for Detection of Skeletal Lesions
NCT00375830 (9) [back to overview]	Cohort 2 - 18F-NaF/18F-FDG vs Whole-body MRI for Detection of Skeletal Lesions
NCT00375830 (9) [back to overview]	Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI
NCT00375830 (9) [back to overview]	Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI/99mTc-MDP Bone Scintigraphy
NCT00375830 (9) [back to overview]	Cohort 3 - Total Skeletal Lesions Identified, Tc-99m MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI
NCT00375830 (9) [back to overview]	Cohort 3 - Skeletal Lesions Identified by 99mTc MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI
NCT00381797 (26) [back to overview]	Progression-free Survival Hazard Ratio by VEGF-A Expression
NCT00381797 (26) [back to overview]	Progression-free Survival Hazard Ratio by Carbonic Anhydrase 9 (CA9) Expression
NCT00381797 (26) [back to overview]	Progression-free Survival Hazard Ratio by Hypoxia Inducible Factor-2alpha Expression
NCT00381797 (26) [back to overview]	Correlation of the Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) From Baseline With the Change in Perfusion From Magnetic Resonance Imaging
NCT00381797 (26) [back to overview]	Progression-free Survival Hazard Ratio by VEGF-R2 Expression
NCT00381797 (26) [back to overview]	Sustained Disease Stabilization Rate Associated With Bevacizumab and Irinotecan in Patients With Recurrent or Progressive Low-grade Glioma (Stratum E)
NCT00381797 (26) [back to overview]	Systemic Clearance
NCT00381797 (26) [back to overview]	Terminal Half-life
NCT00381797 (26) [back to overview]	Volume of Distribution
NCT00381797 (26) [back to overview]	Association of Log-transformed Tumor Diffusion Ratio With Progression-free Survival (PFS) Using Hazard Ratio Estimates
NCT00381797 (26) [back to overview]	Association of Log-transformed Tumor Enhancing Volume With Progression-free Survival (PFS) Using Hazard Ratio Estimates
NCT00381797 (26) [back to overview]	Association of Log-transformed Tumor Volume Based on FLAIR With Progression-free Survival (PFS) Using Hazard Ratio Estimates
NCT00381797 (26) [back to overview]	Association of Log-transformed Volume of Cystic Necrosis With Progression-free Survival (PFS) Using Hazard Ratio Estimates
NCT00381797 (26) [back to overview]	Change in Diffusion Ratio Between the Baseline and Day 15 Brain Image
NCT00381797 (26) [back to overview]	Change in Perfusion Ratio Between the Baseline and Day 15 Brain Imaging
NCT00381797 (26) [back to overview]	Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) From Baseline to Day-15
NCT00381797 (26) [back to overview]	Cumulative Incidence of Sustained Objective Responses
NCT00381797 (26) [back to overview]	Descriptive Statistics for the Change of Perfusion in Magnetic Resonance Imaging Concurrently Measured With the Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC)
NCT00381797 (26) [back to overview]	Descriptive Statistics for the Changes in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) Concurrently Measured With the Changes in Perfusion From Magnetic Resonance Imaging
NCT00381797 (26) [back to overview]	Number of Patients With High Carbonic Anhydrase 9 Expression at Baseline
NCT00381797 (26) [back to overview]	Number of Patients With High Hypoxia Inducible Factor-2alpha Expression at Baseline
NCT00381797 (26) [back to overview]	Number of Patients With High VEGF-A Expression at Baseline
NCT00381797 (26) [back to overview]	Number of Patients With High VEGF-R2 Expression at Baseline
NCT00381797 (26) [back to overview]	Number of Study Participants With Grade 3 or 4 Treatment-related Toxicity
NCT00381797 (26) [back to overview]	Objective Response Rate Sustained for ≥ 8 Weeks
NCT00381797 (26) [back to overview]	Progression-free Survival
NCT00416455 (15) [back to overview]	The Diagnostic Specificity of PET/CT for Detection of Lymph Node Metastasis in Pelvis
NCT00416455 (15) [back to overview]	Specificity for Detection of Lymph Node Metastasis in Abdomen by CT Alone
NCT00416455 (15) [back to overview]	The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Pelvis
NCT00416455 (15) [back to overview]	Sensitivity for Detection of Lymph Node Metastasis in Abdomen by CT Alone
NCT00416455 (15) [back to overview]	The Diagnostic Specificity of PET/CT for Detection of Lymph Node Metastasis in Combination of Abdomen and Pelvis
NCT00416455 (15) [back to overview]	Specificity Between for Detection of Lymph Node Metastasis in Pelvis by CT Alone
NCT00416455 (15) [back to overview]	Sensitivity for Detection of Lymph Node Metastasis in Pelvis by CT Alone
NCT00416455 (15) [back to overview]	The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Abdomen
NCT00416455 (15) [back to overview]	Specificity for Detection of Lymph Node Metastasis in Combination of Abdomen and Pelvis by CT Alone
NCT00416455 (15) [back to overview]	Percentage of Participants in Whom PET/CT Detects Biopsy-proven Disease Outside the Abdominal Lymph Nodes
NCT00416455 (15) [back to overview]	Percentage of Participants in Whom PET/CT Detects Biopsy-proven Disease Outside the Pelvic Lymph Node
NCT00416455 (15) [back to overview]	Sensitivity Between for Detection of Lymph Node Metastasis in Combination of Abdomen and Pelvis by CT Alone
NCT00416455 (15) [back to overview]	The Diagnostic Specificity of PET/CT for Detection of Lymph Node Metastasis in Abdomen
NCT00416455 (15) [back to overview]	Cervical Cancer Patients With Adverse Events (Grade 3 or Higher) at Least Possibly Attributed to Extra-peritoneal or Laparoscopic Abdominal and Pelvic Lymphadenectomy
NCT00416455 (15) [back to overview]	The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Combination of Abdomen and Pelvis
NCT00537056 (9) [back to overview]	Tumor Size by Computed Tomography (CT) Scan
NCT00537056 (9) [back to overview]	Initial Tumor Size
NCT00537056 (9) [back to overview]	Histopathology
NCT00537056 (9) [back to overview]	Initial Comprehensive Metabolic Panel
NCT00537056 (9) [back to overview]	Tumor Necrosis
NCT00537056 (9) [back to overview]	Tumor Size by DCE Magnetic Resonance Imaging (MRI) Scan
NCT00537056 (9) [back to overview]	F-18 FDG Tumor Uptake (SUV Max)
NCT00537056 (9) [back to overview]	DCE MRI AUC Peak Flow
NCT00537056 (9) [back to overview]	Adverse Events
NCT00559377 (4) [back to overview]	Disease-free Survival (DFS)
NCT00559377 (4) [back to overview]	Overall Survival (OS)
NCT00559377 (4) [back to overview]	Relationship Between Ki67 and Regional FMISO Uptake in Tumor
NCT00559377 (4) [back to overview]	Relationship Between Hypoxia-related IHC Biomarkers and Regional FMISO Uptake in Tumor
NCT00564733 (1) [back to overview]	Overall Response Rate (Patients That Achieve a CR or PR)
NCT00590395 (1) [back to overview]	Sensitivity and Specificity of FDG PET/CT and Tc99mHIDA in the Evaluation of Subjects Suspected of Cholecystitis
NCT00602043 (3) [back to overview]	Number of Participants With Clinical Benefit
NCT00602043 (3) [back to overview]	Time to Progression
NCT00602043 (3) [back to overview]	Best Overall Response
NCT00729157 (5) [back to overview]	To Determine the Biologic Effect of IV VEGF Trap on FDG Avidity After Four Cycles (Approximately 8 Weeks) of Therapy Through Pre- and Post-treatment FDG-PET Scans in Patients With Recurrent and/or Metastatic D-TC-FCO.
NCT00729157 (5) [back to overview]	The Safety and Toxicity Profile of IV VEGF Trap in Patients With Recurrent and/or Metastatic TC-FCO
NCT00729157 (5) [back to overview]	Effect of Thyroglobulin Concentration on Progression-free Survival
NCT00729157 (5) [back to overview]	Progression-free Survival to Determine the 6-month Progression-free-survival (PFS) Rate
NCT00729157 (5) [back to overview]	Radiographic Response Rate of Aflibercept in Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
NCT00735917 (4) [back to overview]	Six Month Survival
NCT00735917 (4) [back to overview]	Overall Survival
NCT00735917 (4) [back to overview]	Progression-Free Survival
NCT00735917 (4) [back to overview]	Confirmed Tumor Responses (Complete Response [CR] or Partial Response [PR])
NCT00775268 (10) [back to overview]	Time to Progression
NCT00775268 (10) [back to overview]	18F- Fluorothymidine (FLT) Uptake Within the Tumor(s) Between Baseline vs Completion of Therapy Scans
NCT00775268 (10) [back to overview]	18F- Fluorothymidine (FLT) Uptake, Positron-emission Tomography (PET) Standard Uptake Value (SUV)Max in Malignant Residual Tumors Versus Benign Lesions After Therapy
NCT00775268 (10) [back to overview]	18F-fluorodeoxyglucose (18FDG) Standardized Uptake Values (SUV) Estimated Maximum and Tumor: Blood Pool Ratio at 1-hour Post-injection
NCT00775268 (10) [back to overview]	3'-Deoxy-3'-[18F]-Fluorothymidine (FLT) Dynamic Influx Parameter (Ki) Standardized Uptake Values (SUV) Estimated Maximum at 1- and 2-hours Post-injection
NCT00775268 (10) [back to overview]	Tumor Uptake With Fluorothymidine (FLT) - Maximum Standard Uptake Value (SUVmax)
NCT00775268 (10) [back to overview]	Tumor(s) Maximum Standard Uptake Value (SUVmax) at Baseline and at Mid-treatment (Post-2 Cycles) Scan
NCT00775268 (10) [back to overview]	Tumor(s) Maximum Standard Uptake Value (SUVmax) at Baseline Scan and SUVmax After Completion Scan in Responders and Non-responders' Patients
NCT00775268 (10) [back to overview]	Number of Participants With the Presence/Absence of Abnormal 18F- Fluorothymidine (FLT) Uptake, and Positive/Negative Biopsy
NCT00775268 (10) [back to overview]	Number of Participants With Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
NCT00794339 (14) [back to overview]	Primary Tumor Recurrence
NCT00794339 (14) [back to overview]	Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and CA-IX Composite Score as a Marker of Tumor Hypoxia
NCT00794339 (14) [back to overview]	Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and CA-IX Staining Intensity Score: as a Marker of Tumor Hypoxia
NCT00794339 (14) [back to overview]	Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Glucose Transporter 1 (GLUT1) Composite Score as a Marker of Tumor Hypoxia
NCT00794339 (14) [back to overview]	Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Glucose Transporter 1 (GLUT1) Percentage of Tumor Cells Staining Score as a Marker of Tumor Hypoxia
NCT00794339 (14) [back to overview]	Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Glucose Transporter 1 (GLUT1) Staining Intensity Score: as a Marker of Tumor Hypoxia
NCT00794339 (14) [back to overview]	Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Vascular Endothelial Growth Factor (VEGF) Composite Score as a Marker of Tumor Hypoxia
NCT00794339 (14) [back to overview]	Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Vascular Endothelial Growth Factor (VEGF) Staining Intensity Score: as a Marker of Tumor Hypoxia
NCT00794339 (14) [back to overview]	Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and VEGF Percentage of Tumor Cells Staining Score as a Marker of Tumor Hypoxia
NCT00794339 (14) [back to overview]	Relationship Between Copper Cu 64-ATSM Uptake in the Primary Tumor and Progression-free Survival 3 Years After Chemoradiotherapy
NCT00794339 (14) [back to overview]	Lymph Node Metastasis at Baseline
NCT00794339 (14) [back to overview]	Copper Cu 64-ATSM T/M Uptake and Overall Survival
NCT00794339 (14) [back to overview]	Relationship Between Copper Cu 64-ATSM Uptake and Development of Distant Metastasis
NCT00794339 (14) [back to overview]	Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Carbonic Anhydrase IX (CA-IX) Percentage of Tumor Cells Staining Score as a Marker of Tumor Hypoxia
NCT00852644 (2) [back to overview]	Participants Who Did Not Experience a Dose Limiting Toxicity in the Less Than 3 Centimeter Cohort
NCT00852644 (2) [back to overview]	Participants Who Did Not Experience a Dose Limiting Toxicity in the More Than 3 Centimeter Cohort
NCT00906503 (1) [back to overview]	Feasibility of Ultra Short-term Steroid Therapy to Increase the Accuracy of FDG-PET/CT Imaging
NCT00941070 (11) [back to overview]	Progression Free Survival by Smoking Status
NCT00941070 (11) [back to overview]	Progression Free Survival by HPV Subtype
NCT00941070 (11) [back to overview]	Clinical and Objective Response Assignment
NCT00941070 (11) [back to overview]	Clinical and Objective Response Assignment
NCT00941070 (11) [back to overview]	Clinical and Objective Response Assignment
NCT00941070 (11) [back to overview]	Percent of Patients With Incidence of Grade 2 or Higher Gastrointestinal and Genitourinary Toxicity, Assessed Using CTCAE v3.0 Until December 31, 2010 and CTCAE v4.0 Beginning January 1, 2011
NCT00941070 (11) [back to overview]	PET/CT Scan Metabolic Activity
NCT00941070 (11) [back to overview]	Change in Smoking Behavior, Assessed Using the Smoking Questionnaire and Cessation Counseling
NCT00941070 (11) [back to overview]	Progression-free Survival
NCT00941070 (11) [back to overview]	PET/CT Scan Metabolic Activity
NCT00941070 (11) [back to overview]	Fasting F-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) Imaging Complete Metabolic Response, Reported Following National Cancer Institute (NCI) and European Organization for Research and Treatment of Cancer (EORTC) Guidelines.
NCT00963807 (5) [back to overview]	Change in FLT Uptake in Responders and Non-responders
NCT00963807 (5) [back to overview]	Overall Response Rate Reported as a Proportion of the Total Number of Patients Who Received at Least One Cycle of Therapy Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00963807 (5) [back to overview]	Change in FLT Uptake
NCT00963807 (5) [back to overview]	Change in 18F-Fluorodeoxyglucose (FDG) Uptake
NCT00963807 (5) [back to overview]	Change in 18F-Fluorothymidine (FLT) Uptake
NCT00971789 (1) [back to overview]	Number of Participants With Adverse Events
NCT01004718 (1) [back to overview]	Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration
NCT01038778 (8) [back to overview]	Changes in the Level of Specific T Lymphocytes
NCT01038778 (8) [back to overview]	Incidence of Toxicities
NCT01038778 (8) [back to overview]	Dose-limiting Toxicities of Entinostat When Combined With Aldesleukin Within the Phase I
NCT01038778 (8) [back to overview]	Time-to-tumor Progression
NCT01038778 (8) [back to overview]	Incidence of Toxicity (Phase I)
NCT01038778 (8) [back to overview]	Overall Response Rate (Complete Plus Partial) (Phase II)
NCT01038778 (8) [back to overview]	Overall Survival
NCT01038778 (8) [back to overview]	Progression-free Survival
NCT01129206 (4) [back to overview]	Overall Response
NCT01129206 (4) [back to overview]	Overall Survival (OS)
NCT01129206 (4) [back to overview]	Progression-free Survival (PFS)
NCT01129206 (4) [back to overview]	Correlation of FDG PET Response With Response Rate
NCT01132807 (3) [back to overview]	36 Month Progression Free Survival Rate of Patients Receiving 4 Cycles of ABVD Versus Patients Receiving 2 Cycles of ABVD and 2 Cycles of BEACOPP and Radiation.
NCT01132807 (3) [back to overview]	Complete Response Rate
NCT01132807 (3) [back to overview]	Progression-Free Survival (PFS) at 36-Months for Patients Who Received 4 Cycles of ABVD
NCT01146054 (5) [back to overview]	Evaluate Acute Gastrointestinal Toxicity up to 3 Months of Treatment.
NCT01146054 (5) [back to overview]	To Evaluate Progression Free Survival Following Gemcitabine and SBRT for up to 5 Years of Follow up .
NCT01146054 (5) [back to overview]	To Determine the Rate of (Grade 2 or Greater) Gastrointestinal Toxicity Attributable to Gemcitabine and Fractionated SBRT at One Year.
NCT01146054 (5) [back to overview]	To Determine the Overall Survival in Pancreatic Cancer Patients Treated With Gemcitabine and SBRT for up to 5 Years of Follow up.
NCT01146054 (5) [back to overview]	Proportion of Participants Achieving Freedom From Local Progression (FFLP) in Patients Treated With Gemcitabine Followed by Fractionated Stereotactic Body Radiotherapy (SBRT) for up to 5 Years of Follow up.
NCT01169350 (1) [back to overview]	Changes From Baseline Hypoxic Volume (HV)
NCT01237054 (7) [back to overview]	Comparison of Serum Angiogenic Marker Reverse Contrast Transfer Rate (Kep) Between MGUS and SMM/MM Groups
NCT01237054 (7) [back to overview]	Comparison of Serum Angiogenic Markers Ang2 (Angiopoietin), G-CSF (Granulocyte-colony Stimulating Factor), Follistatin, HGF (Hepatocyte Growth Factor), FGF-1, Endothelin 1, and VEGF-A (Vascular Endothelial Growth Factor-A) Between MGUS and SMM/MM Groups
NCT01237054 (7) [back to overview]	Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM.
NCT01237054 (7) [back to overview]	Count of Participants With Positive DCE-MRI Imaging Results
NCT01237054 (7) [back to overview]	Comparison of Reverse Contrast Transfer Rate (Kep) and Forward Contrast Transfer Rate (Ktrans) Among Patients With MGUS, SMM, and MM
NCT01237054 (7) [back to overview]	Comparison of Microvessel Density (MVD) Among Patients With MGUS, SMM, and MM
NCT01237054 (7) [back to overview]	Comparison of Microvessel Density (MVD) Between MGUS and SMM/MM Groups
NCT01286272 (3) [back to overview]	Complete Response Rate
NCT01286272 (3) [back to overview]	Progression-free Survival (PFS)
NCT01286272 (3) [back to overview]	The Number of Patients Who Experienced Grade 3+ Hematologic and Non-hematologic Adverse Events at Least Possibly Related to Treatment
NCT01359592 (4) [back to overview]	Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
NCT01359592 (4) [back to overview]	Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT01359592 (4) [back to overview]	Progression-free Survival (PFS) Within the PET+ and PET- Subgroups of Patients With Newly Diagnosed Limited-stage Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01359592 (4) [back to overview]	Overall Survival of Patients With Newly Diagnosed Limited-stage Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01462630 (5) [back to overview]	Response Rate Defined as Partial Response (PR)
NCT01462630 (5) [back to overview]	Evaluation of Toxicity of Pazopanib Hydrochloride in This Patient Population
NCT01462630 (5) [back to overview]	Overall Survival of Patients Treated With Pazopanib Hydrochloride
NCT01462630 (5) [back to overview]	PFS Rate
NCT01462630 (5) [back to overview]	Response Rate Defined as CR
NCT01720602 (5) [back to overview]	Response Rate According to RECIST
NCT01720602 (5) [back to overview]	Duration of Response
NCT01720602 (5) [back to overview]	Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECIST
NCT01720602 (5) [back to overview]	Progression-free Survival (PFS)
NCT01720602 (5) [back to overview]	Overall Survival
NCT01806675 (4) [back to overview]	Change From Baseline in Maximum Standard Uptake Values (SUVmax)
NCT01806675 (4) [back to overview]	Change in Tumor Size
NCT01806675 (4) [back to overview]	Change From Baseline in Maximum Standard Uptake Values (SUVmax)
NCT01806675 (4) [back to overview]	Tumor Response Rate by EORTC Criteria
NCT01807117 (11) [back to overview]	SUVmax in Which the PET-CT Was Performed Prior to the PET-MRI.
NCT01807117 (11) [back to overview]	True Positive Rate
NCT01807117 (11) [back to overview]	True Negative Rate
NCT01807117 (11) [back to overview]	SUVmax Ratio in Which the PET-MRI Was Performed Prior to the PET-CT
NCT01807117 (11) [back to overview]	SUVmax Ratio in Which the PET-CT Was Performed Prior to the PET-MRI
NCT01807117 (11) [back to overview]	SUVmax in Which the PET-MRI Was Performed Prior to the PET-CT
NCT01807117 (11) [back to overview]	Negative Predictive Values for PET-CT and PET-MRI
NCT01807117 (11) [back to overview]	Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the PET-MRI
NCT01807117 (11) [back to overview]	False Negative Rate
NCT01807117 (11) [back to overview]	Proportion of Lesions Identified by PET-CT That Were Correctly Detected by PET-MRI
NCT01807117 (11) [back to overview]	Positive Predictive Values for PET-CT and PET-MRI
NCT01821105 (3) [back to overview]	All Adverse Events and Complications
NCT01821105 (3) [back to overview]	Tumor Detection
NCT01821105 (3) [back to overview]	Detection of Position Accuracy With Handheld Probe on Anatomical Location.
NCT01890343 (2) [back to overview]	Quantitative Amyloid Image Assessment
NCT01890343 (2) [back to overview]	Qualitative Amyloid Image Assessment
NCT01917136 (1) [back to overview]	Changes in RV Function
NCT01931709 (6) [back to overview]	Percent Change in PET K1 Between Mid-therapy and Pre-therapy FDG PET Scans and Its Association With Pathologic Response
NCT01931709 (6) [back to overview]	Time of Surgery to Overall Survival
NCT01931709 (6) [back to overview]	Time From Surgery to Breast Cancer Recurrence
NCT01931709 (6) [back to overview]	Percent Change in Tumor Metabolism / Perfusion Ratio (MRFDG/K1) Between Mid-therapy and Pre-therapy FDG PET Scans and Its Association With Pathologic Response
NCT01931709 (6) [back to overview]	Number of Participants With Favorable Pathologic Response at Surgery
NCT01931709 (6) [back to overview]	Percent Change in DCE-MRI Peak Percent Enhancement (Peak PE) Between Mid-therapy and Pre-therapy Breast MRI Scans and Its Association With Pathologic Response
NCT02018107 (2) [back to overview]	Does an Inadequate Ablation Margin on PET Predict Local Progression? Compare to MRI?
NCT02018107 (2) [back to overview]	Number and Percentage of Tumors With Complete, Circumferential Ablation Margin Visibility During FDG PET/CT-guided Liver Ablations (AP-PET-1 v. Contrast-enhanced MRI)
NCT02149173 (4) [back to overview]	Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV), Assessed by a One-sample Test of the Percent Change in FES SUV
NCT02149173 (4) [back to overview]	Proportion of Patients Experienced a Threshold in Percentage Change, or Surpassed a Targeted Follow-up F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV)
NCT02149173 (4) [back to overview]	F-18 16 Alpha-fluoroestradiol (FES) Uptake
NCT02149173 (4) [back to overview]	Time to Disease Progression
NCT02226276 (2) [back to overview]	Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response
NCT02226276 (2) [back to overview]	Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response
NCT02448225 (4) [back to overview]	Uptake of 18F-FSPG (Expressed in Maximal Standardized Uptake Value [SUV] Within the Tumor)
NCT02448225 (4) [back to overview]	Ability of 18F-FSPG PET/CT to Discriminate Benign From Malignant Nodules
NCT02448225 (4) [back to overview]	Ability of 18F-FSPG PET/CT to Stage of Lung Cancer (Metastatic or Not)
NCT02448225 (4) [back to overview]	CD44 and xC- Expression Levels in Tissue Samples(0-3)
NCT02810873 (1) [back to overview]	Number of F-18-FDG Positive Lesions That Are Detected by the Copper Cu 64 TP3805 Analog
NCT02937168 (3) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT02937168 (3) [back to overview]	Part 1: Average Global Lung Glycolysis (GLG) at Day 8
NCT02937168 (3) [back to overview]	Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1)
NCT03125629 (2) [back to overview]	PET/CT vs PET/MRI Difference in Standardized Uptake Value Max (SUVmax), by Radiotracer
NCT03125629 (2) [back to overview]	Absolute Accuracy of SUV Max of PET/CT vs PET/MRI
NCT03226249 (3) [back to overview]	Complete Response (CR) With Pembrolizumab Treatment Alone
NCT03226249 (3) [back to overview]	Overall Survival at Treatment Completion
NCT03226249 (3) [back to overview]	Progression Free Survival (PFS) at Treatment Completion
NCT03262389 (2) [back to overview]	Visual Image Analysis of Detected Multiple Myeloma Lesions
NCT03262389 (2) [back to overview]	Mean Multiple Myeloma Lesions Detected
NCT03320564 (1) [back to overview]	Change in SUVpeak of Target Lesions Between Infiltrated and Non-infiltrated Scans
NCT03549598 (2) [back to overview]	13NH3 PET/CT Uptake With Cardia Sarcoidosis (CS)
NCT03549598 (2) [back to overview]	18FDG Uptake With Cardia Sarcoidosis (CS)
NCT04692103 (3) [back to overview]	F-18 16 Alpha-fluoroestradiol (FES) Uptake
NCT04692103 (3) [back to overview]	Proportion of Patients With a Threshold of Percentage Change, or That Surpass a Targeted Follow-up F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV)
NCT04692103 (3) [back to overview]	Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV) - Avg SULmax

Response

Standard response criteria will be used to assess the CT (computed tomography) scan images on a lesion per lesion basis. Complete response is complete disappearance of the index lesion on followup scan when compared to the pretreatment images. Partial response is a decrease of 50% or greater in the product of the perpendicular diameters of the measured lesion following treatment compared to the pretreatment images. Minor response is a decrease between 25% and 49% in the product of the perpendicular diameters of the measured lesion following treatment compared to the pretreatment images. Stable disease is no change in the size of the treated lesion. Progressive disease is an increase of greater than 25% in the product of the perpendicular diameters of the measured lesion following treatment compared to the pretreatment images. (NCT00019604)
Timeframe:

Intervention	Participants (Number)
	Complete Response	Partial Response	Minor Response	Stable Disease	Progressive Disease
Radiofrequency Ablation in Liver Cancer	0	0	0	0	23

Intervention	percentage of participants (Number)
	From date of enrollment	From date of transplantation
Arm 2-Recipients	39.1	34.8

Intervention	Participants (Count of Participants)
	Complete Response (CR)	Progressive Disease (PD)	Partial Response (PR)	Very Good Partial Response (VGPR)
Arm 2-Recipients	2	4	4	2

Intervention	Months (Median)
	Participants who did not receive a transplant(n=7)	Participants who received a transplant (n=23)
Arm 2-Recipients	3.3	19.1

Intervention	participants (Number)
	acute GVHD	chronic GVHD
Recipients -Cyclosporine GVHD Prophylaxis	12	12
Recipients -Tacrolimus/Sirolimus GVHD Prophylaxis	5	5

Intervention	Participants (Count of Participants)
	Chest wall; G2 skin	Abdomen; G4 GI	Pancreas; G4 LFTs, G4 pancreatitis	Pleura, mediastinum; G4 LFTs, G2 mucositis	Chest wall; G4 skin, G3 mucositis	Spine, skull; G2 nausea+vomiting, G2 fatigue	Pelvis; G4 enteritis	Pulmonary (cyberknife)	Brain; B3 mucositis	Whole lung; G3 mucositis, G3 skin, G5 lung	L arm, R shoulder, B/L femur
Arm 2-Recipients	1	1	1	1	1	1	1	1	1	1	1

Intervention	percentage of participants (Number)
	Grade 1, Nausea	Grade 1, Fatigue	Grade 1, Oral Mucositis	Grade 1, Pharyngolaryngeal pain	Grade 1, Decreased white blood cell	Grade 2, Fatigue	Grade 2, Decreased white blood cell	Grade 2, Neutrophil count decreased	Grade 2, Lymphocyte count decreased	Grade 3, Decreased white blood cell	Grade 3, Neutrophil count decreased	Grade 3, Febrile neutropenia	Grade 3, Infections	Grade 3, respiratory disorders	Grade 4, Decreased white blood cell	Grade 5
Treatment	42	33	25	25	25	25	25	16	16	42	25	8	8	8	58	0

Intervention	Participants (Count of Participants)
	18F-NaF > 18F-FDG	18F-NaF = 18F-FDG	18F-NaF < 18F-FDG
Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET Scans	3	0	0

Intervention	Participants (Count of Participants)
	18F-NaF > 99mTc-MDP	18F-NaF = 99mTc-MDP	18F-NaF < 99mTc-MDP
Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET Scans	10	0	0

Intervention	percentage of particpants (Number)
	Sensitivity	Positive predictive value	Accuracy
Cohort 2 - Combined 18F-NaF-CT/18F-FDG-PET Scan	92.9	81.3	76.5
Cohort 2 - Whole Body-MRI Scan	92.9	86.7	82.4

Intervention	percentage of participants (Number)
	Sensitivity	Accuracy
Cohort 2 - 99mTc-MDP Bone Scintigraphy Scan	64.6	65.9
Cohort 2 Combined 18F-NaF-CT/18F-FDG-PET Scan	96.2	89.8

Intervention	lesions (Number)
Cohort 3 - 99mTc-methyl Diphosphonate (MDP) Bone Scan	81
Cohort 3 - 18F-NaF / 18F-FDG PET/MRI	140

Intervention	Ratio (Median)
High-grade Gliomas	-0.34
Brain Stem Tumors	-0.17
Ependymoma	0.11
Low Grade Glioma	-0.11

Intervention	Ratio (Median)
High-grade Gliomas	-0.14
Brain Stem Tumors	-1.98
Low Grade Glioma	-0.42

Intervention	Ratio (Median)
High-grade Gliomas	-0.37
Brain Stem Tumors	-0.21
Medulloblastoma	-0.003
Ependymoma	0.24
Low Grade Glioma	1.70

Intervention	Months (Median)
High-grade Gliomas	4.20
Brain Stem Tumors	2.35
Medulloblastoma	2.48
Ependymoma	2.15

Intervention	percentage of participants (Mean)
Cervical Cancer Patients - Sensitivity of CT	42
Endometrial Cancer Cohort - Sensitivity of CT	50

Intervention	percentage of participants (Mean)
Cervical Cancer Patients-Sensitivity of CT	77
Endometrial Cancer Patients	54

Intervention	Participants (Count of Participants)
	Leukopenia	Thrombocytopenia	Anemia	Other Hematologic	Dermatologic	Gastrointestinal	Infection	Lymphatics	Metabolic	Musculoskeletal	Pain	Vascular
Number of Participants With a Maximum Grade of 3 or Higher Dur	1	1	7	1	1	4	9	5	3	1	2	3

Intervention	SUVmax (Mean)
	Baseline SUVmax	Mean SUVmax, progression-free survival	SUVmax, progression/relapse
F-18 FDG PET/CT and DCE MRI	9.8	-18.9	34.0

Intervention	Participants (Count of Participants)
	+PET/CT72094445			-PET/CT72094445
	+Path	-Path	N/A Path
Suspected Acute Cholecystitis	9
Suspected Acute Cholecystitis	0
Suspected Acute Cholecystitis	1
Suspected Acute Cholecystitis	2
Suspected Acute Cholecystitis	6

fluorodeoxyglucose f18

Description

Cross-References

Synonyms (64)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (2)

Bioassays (8)

Research

Studies (32,596)

Market Indicators

Research Demand Index: 52.35

Study Types

Clinical Trials (407)

Trial Overview

Trial Outcomes

Response

Number of Participants With Adverse Events

Early Post Transplantation Relapse

Median Progression Free Survival

Median Time to Reach a Platelet Count of 50,000/mm(3)

Two Year Survival Rate for Patients Undergoing Allo-Hematopoietic Stem Cell Transplant

Median Time to Reach Absolute Neutrophil Count of 500/mm(3)

Number of Participants Who Experienced Graft Versus Tumor Effect (GVT)

Number of Participants With Engraftment

Cluster of Differentiation 4 (CD4) Reconstitution

Toxicity

Best Response Post-Hematopoietic Stem Cell Transplant EOCH (Etoposide, Vincristine, Cyclophosphamide, and Doxorubicin)

Median Survival From Date of Progression

Number of Participants to Complete Conversion to >95% Donor Chimerism

Number of Participants With Acute and Chronic GVHD

Post-Hematopoietic Stem Cell Transplant (HSCT) Radiotherapy

Tumor Progression as Measured by Tumor Area and Volume at 1 Year.

Histological Response Determined by FDG Uptake Correlates

Disease Free Survival (DFS)

Frequency of Adverse Events According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration

The Number of Participants With Adverse Events

Number of Patients in Whom Renal Tumors Could be Identified by Positron Emission Tomography (PET)Based on Fludeoxyglucose 18F (18FDG) Uptake

Number of Participants With Flow Dynamics Measured by DCE MRI Within the Renal and Non-renal Tumor

Number of Participants With a Renal Tumor Response

Number of Participants With a Non-renal Tumor Response

Positron Emission Tomography as a Predictor of Response Measured by the Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy

Safety of Neoadjuvant Chemotherapy

Efficacy of Neoadjuvant Chemotherapy as Measured by Radiologic Response Rate

Cohort 1 - 18F-NaF PET/CT vs 18F-FDG PET/CT

Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy

Cohort 2 - 18F-NaF/18F-FDG PET/CT vs Whole-body MRI for Detection of Extraskeletal Lesions

Cohort 2 - 18F-NaF/18F-FDG vs 99mTc-MDP Bone Scintigraphy for Detection of Skeletal Lesions

Cohort 2 - 18F-NaF/18F-FDG vs Whole-body MRI for Detection of Skeletal Lesions

Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI

Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI/99mTc-MDP Bone Scintigraphy

Cohort 3 - Total Skeletal Lesions Identified, Tc-99m MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI

Cohort 3 - Skeletal Lesions Identified by 99mTc MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI

Progression-free Survival Hazard Ratio by VEGF-A Expression

Progression-free Survival Hazard Ratio by Carbonic Anhydrase 9 (CA9) Expression

Progression-free Survival Hazard Ratio by Hypoxia Inducible Factor-2alpha Expression

Correlation of the Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) From Baseline With the Change in Perfusion From Magnetic Resonance Imaging

Progression-free Survival Hazard Ratio by VEGF-R2 Expression

Sustained Disease Stabilization Rate Associated With Bevacizumab and Irinotecan in Patients With Recurrent or Progressive Low-grade Glioma (Stratum E)

Systemic Clearance

Terminal Half-life

Volume of Distribution

Association of Log-transformed Tumor Diffusion Ratio With Progression-free Survival (PFS) Using Hazard Ratio Estimates

Association of Log-transformed Tumor Enhancing Volume With Progression-free Survival (PFS) Using Hazard Ratio Estimates

Association of Log-transformed Tumor Volume Based on FLAIR With Progression-free Survival (PFS) Using Hazard Ratio Estimates

Association of Log-transformed Volume of Cystic Necrosis With Progression-free Survival (PFS) Using Hazard Ratio Estimates

Change in Diffusion Ratio Between the Baseline and Day 15 Brain Image

Change in Perfusion Ratio Between the Baseline and Day 15 Brain Imaging

Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) From Baseline to Day-15

Cumulative Incidence of Sustained Objective Responses

Descriptive Statistics for the Change of Perfusion in Magnetic Resonance Imaging Concurrently Measured With the Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC)

Descriptive Statistics for the Changes in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) Concurrently Measured With the Changes in Perfusion From Magnetic Resonance Imaging

Number of Patients With High Carbonic Anhydrase 9 Expression at Baseline

Number of Patients With High Hypoxia Inducible Factor-2alpha Expression at Baseline

Number of Patients With High VEGF-A Expression at Baseline

Intervention	Participants (Count of Participants)
Diagnostic FES: Average FES SUVmean >1.5, no Negative Sites	8
Diagnostic FES: Patients With FES Negative Sites of Disease	0

Intervention	months (Median)
Diagnostic (FES): Average FES SUVmean >1.5, no Negative Sites	4.9
Diagnostic FES: Patients With FES Negative Sites of Disease	2.2

Intervention	participants (Number)
	Progression of Disease	Stable Disease
Treatment (Ziv-aflibercept and Fludeoxyglucose F 18)	7	33

Intervention	SUVmax (Mean)
	Baseline	Completion of therapy scans
Participants Scanned at Baseline & After Chemotherapy	9.15	0.9

Intervention	SUVmax (Mean)
	Malignant Lesions	Benign Lesions
Participants Scanned in the Evaluation of Residual Masses After Therapy	5.5	1.7

Intervention	SUVmax/Tumor blood ratio (Number)
	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12	Patient 13	Patient 14	Patient 15	Patient 16	Patient 17	Patient 18	Patient 19	Patient 20	Patient 21
Participants Scanned in the Evaluation of Residual Masses After Therapy	4.6	8.4	10.1	3.8	6.9	6.7	5.4	4.7	4.6	10.3	4.8	3.8	4.0	6.9	6.4	15.8	11.2	2.1	3.8	3.5	9.1

Intervention	SUVmax (Mean)
	Baseline	2-cycles post treatment
Participants Scanned at Baseline, at 2 Cycles & After ChemotherapyChemotherapy	9.15	1.5

Intervention	Standard Uptake Value (SUV) - units (Median)
	Baseline	After completion of scan
Participants Scanned at Baseline & After Chemotherapy	9.1	1.5

Intervention	Participants (Count of Participants)
	Presence of FLT uptake	Absence of FLT uptake and FLT uptake lower than normal mediastinum	Positive Biopsy	Negative Biopsy	Biopsy not performed
Participants Scanned in the Evaluation of Residual Masses After Therapy	9	12	7	4	10

Intervention	ratio (Mean)
Composite Score: 0	7.58
Composite Score: 1	5.82
Composite Score: 2	8.04
Composite Score: 3	6.50
Composite Score: 4	10.60
Composite Score: 6	8.20